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Laparoscopic Cholecystectomy: the Six
Hemoclip Rule
William J. Wall, MD, FRCSC; Ronald B. Passi, MD, FRCSC
Department o f Surgery, University Hospital. London, Ont.

L

aparoscopic cholecystectomy
has been a tremendous advance
in surgery of the biliary tract. It has
revolutionized the approach to pa
tients who need surgery for gall
stones. Very few operations have
been promoted and endorsed so
enthusiastically and in such a short
time. Because of the wide applica
tion of this technique of cholecys
tectomy, there is concern about the
incidence of injury to the common
duct.1-2 In the past, one or two
patients each year have been re
ferred to our centre for manage
ment of common-duct injury com
plicating open cholecystectomy. In
the last 6 months we have seen five
patients with duct injuries, which
occurred when their gallbladders
were removed by laparoscopy.
In three of the five patients re
ferred to us, more than 12 hemoclips had been placed on or around
the common duct. A transhepatic
cholangiogram from one of the
cases showed complete obstruction
of the common hepatic duct a short
distance below its bifurcation (Fig.
1). A mass of hemoclips was seen
where the common duct would nor
mally be located. Twenty-five clips
were counted on the x-ray film, and

at reoperation to reconstruct the
duct 27 clips were removed.
We propose that a “six hemoclip
rule” be adopted for laparoscopic
cholecystectomy. In the normal la
paroscopic operation only six hemo
clips are required — two clips each
on the down side of the cystic
artery and cystic duct and one each
on the gallbladder side of both
structures. If, after the application
of six clips, it is apparent that more
clips will be needed to complete the

operation, the surgeon should
pause and ask several important
questions: Have the cystic artery
and cystic duct been clearly identi
fied? If not, what structures have
been identified? Is it safe to apply
more clips on the basis of the
anatomy demonstrated so far?
Would the application of more clips
risk injury to the bile duct, indicat
ing the need for conversion to an
open cholecystectomy?
Occasionally a scissored clip or
an accessory vessel may require
placement of one or two more clips
than the usual six. But use of the
six hemoclip rule as a guide may
avoid potentially dangerous situa
tions with a high risk of injury to
the common duct. We suggest that
the six hemoclip rule should be
come a routine part of the educa
tional courses on laparoscopic cho
lecystectomy.

References

FIG. 1. Transhepatic cholangiogram
showing obstruction of common bile
duct with mass of hemoclips (arrow)
where duct would normally be seen.

1. W ay L: Bile duct injury during laparo
scopic cholecystectomy [E]. Ann Surg
1992; 215: 195
2. Davidoff AM, P appas TN, Murray EA et
al: Mechanisms of major biliary injury
during laparoscopic cholecystectomy.
Ibid: 196-202
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Treatment for Nonunion of Humeral
Shaft Fractures
James P. Waddell, MD, FRCSC
Department o f Surgery, St. Michael’s Hospital, Toronto, Ont. Member, Editorial Board,

Canadian Journal of Surgery

rimary treatment of humeral
shaft fractures remains contro
versial. However, it is generally ac
cepted that in isolated fractures of
the humeral shaft not associated
with vascular injury conservative
treatment is the choice.1
Surgical treatment of closed hu
meral shaft fractures tends to be
associated with a higher rate of
delayed and nonunion than does
closed treatment.2
In the article by Wu and Shih in
this issue (pages 661 to 665), the
results of secondary surgery in 35
adults with nonunited fractures of
the humeral shaft are reported. It is
of interest that 70% of the nonun
ions in these 35 patients occurred
after primary surgical treatment.
Wu and Shih have compared two
distinctly different types of surgical
treatment for established nonunion.
Open reduction and internal fixa
tion by plate and screws with sup
plemental bone grafting has been
the standard method of treatment
for humeral shaft nonunion for
many years.1 The results tend to be

P
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predictable and the complications
are well known. The most common
complication is failure of union; the
most troublesome is iatrogenic radi
al nerve injury. The authors com
pare this form of fracture treatment
with intramedullary nailing and
bone grafting. The nail they used
was the Seidel humeral nail.
The results of comparison of
their two groups suggest that the
rate of union is substantially the
same, but the incidence of compli
cations was somewhat higher in the
plating group. This might be ac
counted for, in part, by the authors’
stated preference for using plate
and screws for those nonunions
with significant rotatory instability
— a group in which the Seidel nail
is specifically contraindicated be
cause of a somewhat tenuous grip
on the distal fragment of the hu
merus.
The authors have clearly demon
strated that the smaller surgical
exposure associated with nailing of
humeral shaft nonunions might de
crease the number of radial nerve

JCC, VOL. 35, N ° 6, DECEMBRE 1992

injuries associated with the techni
cally demanding operation of plate
and screw application plus bone
grafting. However, the particular
implant chosen by these surgeons
for intramedullary fixation is recog
nized to have poor rotational con
trol of the distal fragment of the
humerus in some circumstances and
should not be used in patients in
whom rotational instability is a sig
nificant problem.
Regardless of the implant chosen
the objective of anatomic reduction,
rigid fixation and autogenous can
cellous bone grafting must be met
in every case if success is to be
achieved.

References
1. R ockwood C A jr , Green DP (eds): Frac
tures in Adults, 2nd ed, Lippincott, Phila
delphia, 1984:653-674

2. S armiento A, K inman PB, Galvin EG et
al: Functional bracing of fractures of the
shaft of the humerus. J Bone Joint Surg
[Am/ 1977; 59: 596-601
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Routine Nasogastric Decompression After
Abdominal Surgery?
William G. Jamieson, MD, FACS, FRCS, FRCSC; Gaetano DeRose, MD, FACS. FRCSC;
Kenneth A. Harris, MD, FRCSC, FACS*
Division o f Vascular Surgery, Victoria Hospital, University o f Western Ontario, London, Ont.
*Member, Editorial Board, Canadian Journal of Surgery

he nasogastric tube was intro
duced clinically by Levin1 in
1921, and Wangensteen and Paine2
advocated its use for the treatment
of bowel obstruction. Since then
the nasogastric tube has held a
prominent place in the postopera
tive management of patients who
undergo abdominal operations. Arti
cles have appeared sporadically,
both in the European3 and the
North American4-5 literature, docu
menting the safe omission of this
tube after abdominal operations, yet
many surgeons persist in using it
routinely. The classic teaching that
gastric decompression prevents as
piration, abdominal distension,
wound dehiscence and anastomotic
breakdown is being questioned. In
the American College of Surgeon’s
manual on care of the surgical
patient6 it is stated that the routine
use of nasogastric decompression
postoperatively is controversial. In
this issue (pages 625 to 628) MacRae, Fischer and Yakimets from the
University of Alberta describe their
experience with 97 patients who
were managed postoperatively with
out nasogastric intubation. Their
patients had a shorter hospital stay
than normal (ever important in
these days of constraint) and suf
fered no adverse effects. Only nine
patients required insertion of a na
sogastric tube postoperatively, indi

T

cating that unnecessary decompres
sion was avoided in 91% of patients.
Elsewhere in this issue (pages 629
to 632, Cunningham and col
leagues, from Calgary, in a random
ized control trial of 102 patients,
have shown that routine nasogastr
ic decompression is not warranted
after elective surgery with small- or
large-bowel anastomosis. Only 8%
of their patients required subse
quent nasogastric insertion, and the
hospital stay in the group without
nasogastric decompression was sig
nificantly (p < 0.001) shorter. No
difference in morbidity was detected
between groups.
On the vascular service of our
hospital, in operations on the ab
dominal aorta with major retroperi
toneal dissection and extensive
bowel manipulation, nasogastric de
compression has been routine. The
tube is usually removed 3 to 4 days
postoperatively, coinciding with in
creased bowel sounds, decreased
drainage and the passing of flatus.
Thoughtful articles such as the two
contained in this issue of the CJS
have led us to conduct a case
control study of patients who un
derwent aortic surgery. In nine pa
tients no nasogastric tube was
passed intraoperatively. Three of
these required subsequent insertion
of a tube, leading us to believe that
intraoperative decompression is of

benefit. Twenty-six patients who
underwent abdominal aortic aneu
rysm repair or aortobifemoral by
pass grafting had a nasogastric
tube inserted intraoperatively and
removed at the time of endotracheal
extubation (3 to 18 hours postoper
atively). In only 1 of these 26
patients (3.8%) was insertion of a
gastric tube required subsequently.
Like Cunningham and associates
and MacRae, Fischer and Yakimets,
we found that our total hospital
stay was reduced. When compared
with a randomly selected retrospec
tive control group of 26 patients,
matched for operation, the mean
hospital stay was reduced from 15.2
± 5.2 to 12.1 ± 2.5 days, a mean
reduction of 3.1 days. We conclud
ed that intraoperative nasogastric
decompression was of benefit to the
patient (and often the surgeon by
allowing better exposure). The tube
could be safely removed at an early
convenient time, in our case at the
time the endotracheal tube was re
moved.
Many factors have changed since
our teachers developed the “classic
routines” in surgical teaching. Dif
ferent anesthetic agents, better un
derstanding of postoperative pain
management, improved fluid and
electrolyte management and differ
ent concepts of handling of bowel
and adjacent tissues have been de-
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veloped. We must continue to ques
tion, respectfully, the standard
practices to permit continued prog
ress. Nasogastric decompression
will remain necessary and life sav
ing for selected patients. The indi
cations for gastric decompression
must be taught, and tube insertion
should be undertaken when neces
sary.
We add our support to the con
clusions of Cunningham and associ
ates and MacRae, Fischer and Yaki-

mets by advocating early removal
and selective use of nasogastric
tubes in abdominal surgery.
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BOOK REVIEWS
CRITIQUES DE LIVRES

The following books are also re
viewed in this issue: Atlas of Chest
Imaging: Correlated Anatomy With
MRI and CT (page 648); Organ
Transplantation (page 660); Atlas
of Abdominal Surgery (page 660);
Intra-abdominal Infections (page

666 ).

PRINCIPLES AND PRACTICE OF
SURGERY FOR THE COLON, REC
TUM, AND ANUS. Philip H. Gordon
and Santhat Nivatvongs. 1097 pp. IIlust. Quality Medical Publishing, Inc.,
St. Louis, Mo. 1991. $235 (US). ISBN
0 -9 4 2 2 1 9 -1 0 -4

This recently published book is coau
thored by two recognized experts in the
field, who have written many scientific
papers and book chapters as well as a
book on anorectal disorders — a stan
dard text for many trainees in colorectal
surgery. This contains over 900 excel
lent illustrations. Each chapter is well
organized, and the writing is clear and
concise.
The book is comprehensive in that it
covers both anorectal and colorectal
578

diseases. A section on essential consid
erations contains chapters on anatomy,
physiology, diagnosis, preoperative and
postoperative management, local anes
thesia, pharmacology and electrosurgical and laser applications. A unique
section is one on a problem-oriented
approach to colorectal diseases. Besides
a chapter on traumatic injuries, chap
ters in this section deal with complica
tions related to colonic and anorectal
diseases and surgery. Another chapter
deals with unexpected findings at sur
gery. This problem-based approach will
be particularly useful to those in train
ing.
The section on anorectal disorders is
superb. The whole spectrum of anorec
tal disorders is covered, from the com
mon conditions of hemorrhoids, fissure
and fistula to the more esoteric entities
of retrorectal tumours and perianal and
anal tumours. Most chapters include a
discussion of the etiology, epidemiolo
gy, anatomy and physiology of the
condition as well as the clinical manifes
tations and management. The chapters
on hemorrhoids and anorectal abscesses
and fistulas are particularly good. The
chapter on fistula-in-ano contains a de
tailed discussion of the management of
the various types of fistulas. In addition,
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some of the more difficult aspects are
considered, including use of a seton,
how much muscle to divide and primary
versus secondary fistulotomy. The
chapter on hemorrhoids deals with the
various manifestations of the condition
as well as treatment options and the
more common surgical techniques for
performing hemorrhoidectomy. A table
outlining recommended treatment, de
pending on the manifestations, is com
prehensive but succinct.
The chapter on perianal dermatology
is also excellent because of the many
coloured photographs it contains. On
the other hand, the chapter on sexually
transmitted diseases may be less useful.
Although the various gastrointestinal
manifestations seen in acquired im
munodeficiency syndrome (AIDS) are
listed, a discussion of the approach to
diagnosis and management of the AIDS
patient with anorectal disease would
have been useful.
The chapters on colorectal diseases,
covering benign and malignant neo
plasms, ulcerative colitis, Crohn’s dis
ease, volvulus, prolapse, radiation inju
ries and mesenteric vascular diseases,
are good but are less comprehensive,
continued on page 648

In Four Hours, Dr. LeMaitre
And His Valvulotome
Could Forever Change The Way
You Look At Bypass Grafting.
In Situ Grafting Comes Of Age
In the time it takes to perform a single bypass
procedure, you’ll see why Dr. LeMaitre’s Valvulotome
has become the “Instrument of Choice” for vascular
surgeons performing In Situ grafting.
You’ll also understand why a growing number of
surgeons are shifting from reverse grafting to semiclosed In Situ, opting to minimize trauma to the vein
graft, minimize endothelial shearing and maximize
cumulative patency rates.
In about four hours, you’ll see how the LeMaitre
Valvulotome has simplified the performance of bypass
grafting and shortened the In Situ learning curve.
That’s why it’s currently being used in over 1200 hos
pitals including 500 teaching hospitals.
“An Elegant Instrument For An Elegant Technique”
Drawing on the pioneering work of other leaders in
the field, and his 11 years experience performing
In Situ bypass grafting, Dr. LeMaitre has modified and
simplified both the valvulotomy technology and the
procedure. The LeMaitre Valvulotome employs a
unique circular
blade that cuts saphenous valves
instantaneously,
safely and without blade manip
ulation as in
other systems. There is no need
to open the leg,
no guesswork concerning valve
(i)

Now available in two new sizes
2.5 and 3.5 mm.
Also available in 40 cm lengths.

location or lysis, no tearing or disruption of venous
walls. The stainless steel cylinders were designed to
minimize endothelial contact as they travel the length
of the saphenous vein.

Circular
Blade

THE LEMAITRE VALVULOTOME'S streamlined design, with smoothly
tapered head and follower, and recessed circular blade, minimizes
endothelial trauma while ensuring valvulotomy.

You Get The Instrument And The Support
The entire Vascutech team, including Dr. LeMaitre
himself, is committed to providing the information, support
and tools you’ll need to determine for yourself the signifi
cant advantages of this very elegant technique. For more
information about Dr. LeMaitre’s work and his
Valvulotome, just call us at 800-628-9470.

Two New Sizes

Buy One - Get One Free
2.5mm
3.5mm

Submit This Offer
To Your Purchasing Agent By January 15,1993
Offer good in the U.S.A.
and Canada only.

VASCUTECH

Maker of the LeMaitre Valvulotome
790 Turnpike Street / North Andover, MA 01845
(800) 628-9470 ■ (508) 685-6677 Ext. 42
FAX (508) 685-3844

CORRESPONDENCE
CORRESPONDANCE

An Unusual Case
of Hemoperitoneum
Due to Forgotten Blunt
Trauma
To the editors. The article,1 edito
rial2 and letter3 on splenic trauma
in volume 34 of your journal were
very informative. We would like to
share our experience of an unusual
case of hemoperitoneum resulting
from delayed and unsuspected rup
ture of a splenic injury due to
forgotten trauma that had occurred
20 months previously.

Case Report

A 42-year-old man presented with
noncolicky abdominal pain, obstipa
tion and slight abdominal distension
for 5, 3 and 2 days respectively
before admission. He complained of
anorexia, nausea and occasional
retching for 3 days. He was found
to be dehydrated, pale and afebrile.
His pulse rate was 120/min and
the systolic blood pressure was 94
mm Hg. In view of the unexplained
absence of fever and pallor in a
patient admitted with a diagnosis of
peritonitis, a peritoneal tap was
done. This demonstrated blood. On
direct questioning, the patient re
membered experiencing persistent
heaviness in the left upper quadrant
of the abdomen and left lower chest
for 10 days after a fall from his
bicycle 20 months before.
On exploration, 1000 mL of
blood (mixed with serous exudate)
was found in the peritoneal cavity.
There was a tear in the splenic
capsule. Loose capsule was lying
undulating and unattached over a
5-cm diameter depression in the
splenic surface. This depression
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seemed to be the site of a hemato
ma that had ruptured. The spleen
appeared normal. There was no
bleeding on the surface of the
spleen at the time of exploration.
The spleen was left in situ and no
splenorrhaphy or splenectomy was
required. Postoperatively, blood
clotting studies were performed, but
the results of the studies did not
reveal any abnormality. The patient
was well 6 months after operation.

Comment

Delayed rupture of a splenic he
matoma is uncommon.4 Whether
such an unusual problem can be
avoided is difficult to know, but it is
questionable whether a large num
ber of patients, sustaining trivial
injury should be subjected to rou
tine (and repeated) ultrasonography
and nuclear scanning when the
yield of positive findings is un
known.1 We believe caution is war
ranted when the conservative man
agement of splenic trauma is advo
cated.
A.K. Sharma, MS, DNB
R. Surange, MS, DNB
Department of Endocrine Surgery,
Sanjay Gandhi Postgraduate Institute
of Medical Sciences,
PO Box 375,
Lucknow
PIN - 226 001
India
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Goodbye to Routine
To the editors. Two excellent pa
pers appear in this issue, one by
MacRae, Fischer and Yakimets
(pages 625 to 628), the other by
Cunningham and associates (pages
629 to 632), which should convince
us not to use routine nasogastric
suction in most of our abdominal
procedures involving bowel anasto
mosis. The possible exceptions are
when patients have intestinal ob
struction preoperatively and per
haps when treating peritonitis with
an established ileus. There is now
an extensive literature both retro
spective and prospective, random
ized and nonrandomized to support
this principle.
Those of us who have seen other
“routines” of surgery disappear —
carbolic and alcohol in appendiceal
stump treatment, long-term antibi
otic management for “prophylax
is,” prolonged bed rest after abdom
inal surgery, heavy abdominal
dressings, Penrose drains — are no
longer surprised at the passing of
yet another “routine.”
Frankly, it’s comforting to think
that we can justify treating our
patients individually on the merits
of their situations and that some
degree of art and wisdom of experi
ence can be brought to bear on our
practice in this age of high tech
nology. It doesn’t even hurt to save
a little money now and then!
John K. MacFarlane, MD, FRCSC
Department of Surgery,
St. Paul’s Hospital,
Vancouver, BC
V6Z 1Y6

IS THERE A BETTER WAY
TO CONTROL
POST-OPERATIVE PAIN
THAN USING NARCOTICS?

NON-NARCOTIC

NARCOTIC EFFICACY
WITHOUT NARCOTIC DRAWBACKS
Now, Toradol offers a real alternative to narcotics
for the management of pain - an analgesic that
provides the strength of narcotics without the
associated drawbacks.

CLASSIFICATION
Toradol belongs to the non-steroidal anti
inflammatory drug (NSAID) family. However, unlike
conventional NSAIDs, it is a potent analgesic agent
with minimal anti-inflammatory and antipyretic
activity. And it’s the only non-narcotic analgesic
available in both IM injection and tablet form.' 2

EFFICACY
One Toradol 30 mg IM injection has been proven to
be as effective as morphine 12 mg IM and meperidine
100 mg IM,410while one Toradol 10 mg tablet has
been shown to be more effective than 2 tablets of
acetaminophen + codeine #3*:17-’8’22
COMPARABLE PEAK
PAIN RELIEF

LONGER DURATION
OF ANALGESIA

Analgesic efficacy of Toradol 30 mg
IM administered 24-72 hours
postsurgery in 5 single dose studies.
Adapted from reference 10.

Analgesic efficacy of
TORADOL 30 mg IM vs.
morphine 12 mg IM and
meperidine 100 mg IM.'°

TORADOL 30 mg IM

EDMorphine 12 mg IM
B Meperidine 100 mg IM

1

2
3
4
5
HOURS FROM ADMINISTRATION
Measure of pain relief: 0 = none, 1 = poor, 2 = fair, 3 = good, 4 = very good.

EQUIVALENT
ONSET OF
ACTION

SUPERIOR PEAK
PAIN RELIEF

LONGER DURATION
OF ANALGESIA

Randomized, double-blind,
single dose study in patients
following oral surgery.
Adapted from reference 17.
1

2
3
4
5
HOURS FROM ADMINISTRATION
Measure of pain relief: 0 = none, 1 = poor, 2 = fair, 3 = good, 4 = very good.

Analgesic efficacy of
TORADOL 10 mg Tablet
vs. 2 Tablets of
acetaminophen +
codeine #3i7

G TORADOL 10 mg oral
□ ‘ Acetaminophen 600 mg h
codeine 60 mg oral

A STEP AHEAD OF NARCOTICS3044
TOLERABILITY

CLINICAL APPLICATIONS

Because Toradol is peripherallyacting, its tolerability profile is superior
to morphine, meperidine, and codeinecontaining analgesics, producing less
nausea, vomiting, drowsiness171821 and
constipation.2 Furthermore, Toradol has
no reported incidence of respiratory
depression,"12 and no potential for
narcotic addiction or abuse.3

Toradol has been proven effective in
managing a wide range of pain following
general, orthopedic, gynecological49
and oral surgery1718 as well as pain in the
Emergency Room setting.2922 27
And Toradol is well-suited for the post
operative pain of day-stay surgery, with
faster patient recovery,13 and no need for
monitoring of narcotic-related side-effects
which can delay discharge.32

COST-EFFECTIVE
Importantly, Toradol’s proven efficacy
and tolerability help make it cost-effective
for Canadian hospitals.13 Earlier hospital
discharge and a lower incidence of
complications result in considerable cost
savings - in one well-controlled study,
Toradol IM and tablets saved an average
of approximately $75.00 per patient
compared to meperidine IM followed by
acetaminophen + codeine #3.13
This study also demonstrated that
patients on Toradol were easier to care
for and had greater independence,
requiring significantly less nursing time
and effort.13

General Surgery4 9

Orthopedic Surgery

Gynecological Surgery49

Oral Surgery17

For a better alternative to narcotics in
pain management, consider Toradol IM
and tablets. The non-narcotic analgesic
that is a step ahead of narcotics.

Toradol
NON-NARCOTIC

10mg TABLETS & 30mg IM INJECTIONS

(KETOROLAC TROMETHAMINE)

NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS

3T0RAD0L®
ketorolac tromethamine
tablets/com prim ^s

REVIEW ARTICLE
ARTICLE DE REVUE

Choledochal Cysts: a Retrospective
Review of 28 Patients and a Review
of the Literature
Deepak Katyal, MD; Gordon M. Lees, MD, FRCSC
Retained choledochal cysts have been associated with recurrent cholangitis, portal
hypertension and malignant lesions of the biliary tract. The authors reviewed the
cases of 23 females and 5 males who had congenital cystic dilatation of the biliary
tree; 26 were seen primarily and 2 were referred because of complications from
previous surgery. Patient age at presentation ranged from 6 weeks to 46 years. The
presenting complaints in 25 patients were pain or jaundice, or both; the classic triad
of pain, jaundice and an abdominal mass was present in only 3 patients. Primary cyst
excision was performed in 11 patients. Internal drainage procedures were performed
in 12 patients, external drainage procedures in 3 patients and no direct operative
procedure in 2 patients. Follow-up ranged from 1 to 20 years. Nine of 11 patients
with primary excision were asymptomatic; 2 had recurrent cholangitis and required
treatment for bile duct stricture. Five patients with retained cysts were
asymptomatic. Recurrent cholangitis occurred in seven patients. Six patients
required at least one reoperation, but only two had secondary cyst excision. The
long-term complication rate for patients with retained cysts was 66.7% and for those
with primary excision was 18%.
The findings of this study support the current recommendation of primary
excision of choledochal cysts. Symptomatic patients with retained cysts should have
secondary cyst excision. Asymptomatic patients with retained cysts are at risk for
malignancy and should undergo lifelong periodic radiologic examinations and
liver-function testing.
La persistance de kystes du choledoque a ete associee a la reddive de cholangites, a
l’hypertension porte et a des lesions malignes des voies biliaires. Les auteurs ont
etudie les cas de 23 femmes et 5 hommes qui avaient presente une dilatation
kystique congenitale des voies biliaires; 26 avaient ete vus en premiere intention,
les 2 autres malades ayant ete adresses pour complications d’une chirurgie
precedente. L’age des patients a la consultation variait de 6 semaines a 46
ans. Les symptomes rapportes par 25 patients etaient la douleur ou l’ictere, ou les
deux. La triade classique comprenant douleur, ictere et masse abdominale n’etait
presente que chez 3 patients. L’excision primaire du kyste fut effectuee chez 11
patients. Un drainage interne fut pratique chez 12 malades, un drainage externe
chez 3, et 2 patients n’eurent aucune intervention chirurgicale directe. La duree du
suivi etait de 1 a 20 ans. Neuf des 11 patients qui avaient une excision primaire sont
demeures asymptomatiques; les 2 autres ont souffert de cholangite recidivante
necessitant un traitement pour stenose des canaux biliaires. Cinq patients qui
avaient conserves leurs kystes etaient asymptomatiques. Une cholangite recidivante
est survenue chez sept patients. Six necessiterent au moins une reoperation, mais
seulement deux eurent une excision kystique secondaire. Le taux de complications a
long terme fut de 66,7 % pour les patients qui avaient conserve leurs kystes, par
rapport a un taux de 18 % pour les patient qui avaient subi une excision primaire.
Les resultats de cette etude soutiennent la recommandation actuelle favorisant
l’excision primaire des kystes du choledoque. Les patients symptomatiques qui sont
toujours porteurs de kystes devraient subir une excision secondaire. Les patients
asymptomatiques porteurs de kystes sont a risque de cancerisation et devraient faire
l’objet d’examens radiologiques et de tests hepatiques periodiques, la vie durant.
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cystic dilatation of
C ongenital
the biliary tree was once con

sidered a rare anomaly. However,
acute clinical awareness and im
proved imaging techniques have
shown that this condition occurs
more frequently than initially
thought. Early reviews suggested
that internal drainage procedures
were adequate surgical treatment.
However, long-term follow-up has
shown that complications occur in
up to 40% of cases.1 With improve
ments and modifications in surgical
technique and perioperative care,
cyst excision with biliary-enteric
anastomosis has been widely recog
nized as the treatment of choice
since the late 1970s. Our experi
ence with 28 patients over a
20-year period is presented.
Patients and Methods

Between 1971 and 1990, 28 pa
tients (23 females, 5 males) with
choledochal cysts were operated on
by 20 surgeons in five Edmonton
hospitals. Twenty-six patients had
From the Department o f Surgery, University
o f Alberta. Edmonton, Alta.
Presented at the 14th annual meeting o f the
Canadian Association o f General Surgeons,
held in conjunction with the 60th annual
meeting o f the Royal College o f Physicians
and Surgeons o f Canada, Quebec, Que.,
Sept. 21, 1991
Accepted for publication Mar. 6, 1992
Reprint requests to: Dr. Gordon M. Lees.
Ste. 602, 8215 - 112th St., Edmonton, AB
T6C 2C8

CHOLEDOCHAL CYSTS

presented directly to the hospitals,
and 2 were referred because of
complications after surgery. Twen
ty-five patients were 30 years of age
or younger. The mean age at the
time of presentation was 14.9 years
(range from 6 weeks to 46 years).
Sixteen patients were white. Native
Indian patients (eight) made up the
largest nonwhite ethnic group. In
addition, there were three Orientals
and one East Indian.
Abdominal pain and jaundice
were the most common presenta
tions, alone or in combination (Ta
ble I). The classic triad of pain,
jaundice and a palpable mass was
seen in only 3 of 26 cases (11.5%).
Fifteen patients had laboratory evi
dence of hepatocellular dysfunction,
and only 2 patients had hyperamylasemia. The standard imaging

methods for diagnosing biliary tract
disease were used for diagnosing
choledochal cysts (Table II). Ul
trasonography, alone or in combi
nation with other imaging methods,
was the best diagnostic method and
was used in 12 (46%) of 26 cases.
However, the diagnosis of choledo
chal cyst was not made until opera
tion in 10 cases (38%). Only one
patient had a documented abnor
mality of the pancreaticobiliary
junction.
According to the Alonso-Lej clas
sification with Todani modification2

(Fig. 1), type I cysts were present in
23 patients, type II cysts in 2
patients and type IVB cysts in 3
patients. Associated conditions at
presentation included secondary bi
liary cirrhosis (seven patients),
cholelithiasis (four patients), portal
hypertension (two patients), pan
creatitis (two patients), biliary
atresia (one patient) and malrotation
(one patient).
Of the 26 patients presenting
directly, 11 underwent primary ex
cision of the cyst and 15 had re
tained cysts (Table III).

Table 1. C lin ic a l P re se n ta tio n o f 2 6 P atie n ts
W ith C h o le d o c h a l C y s ts b u t W ith o u t
P re v io u s S urge ry

Clinical symptoms
Pain
J a u n d ic e
Pain and ja u n d ic e
P ain, ja u n d ic e and m a s s
C h o la n g itis
F a ilu re to th riv e

No. of
patients
11
2
5
3

4
1

Table II. M e th o d o f D ia g n o s is in 26
P a tie n ts W ith C h o le d o ch a l C y s ts but
W ith o u t P re vio u s S u rg e ry
Method of diagnosis
U ltra s o n o g ra p h y
U ltra s o n o g ra p h y and
e n d o s c o p ic re tro g ra d e
c h o la n g io p a n c re a to g ra p h y
U ltra s o n o g ra p h y and
h y d ro x y im in o d ia c e tic acid
s c a n n in g
U ltra s o n o g ra p h y and
in tra v e n o u s
c h o la n g io g ra p h y
E n d o s c o p ic re tro g ra d e
c h o la n g io p a n c re a to g ra p h y
E n d o s c o p ic re tro g ra d e
c h o la n g io p a n c re a to g ra p h y
and in tra v e n o u s
c h o la n g io g ra p h y
In tra v e n o u s c h o la n g io g ra p h y
A t o p e ra tio n

No. of
patients
7

2

1

2
2

1
1
10

FIG. 1. Types of choledochal cyst. Alonso-Lej classification with Todani modifica
tion.
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The two patients referred after
complications had both undergone
internal drainage procedures and
presented with recurrent cholangitis
7 and 12 years, respectively, after
the initial operation. One patient
had secondary cyst excision with
Roux-en-Y hepaticojejunostomy,
and the other patient had revision
of the original anastomosis without
excision of the cyst. In patients who
underwent primary excision, early
postoperative complications includ
ed one case each of subphrenic
abscess, biliary-cutaneous fistula
and upper gastrointestinal bleeding.
Only the subphrenic abscess re

quired operative treatment. There
were no early postoperative compli
cations in the group with retained
cysts. There were no deaths in
either group.

Results
All patients were followed up, on
average for 10.3 years (range from
1 to 20 years) after initial case
review, through personal contact
with patients, their surgeons or
family physicians and hospital re
cords. There was one death from an
unrelated cause in a patient with a

T a b le III. M an a g e m e n t o f 2 6 P a tie n ts W ith C h o le d o c h a l C ysts b u t W ith o u t P re v io u s S u rg e ry

T y p e of cyst

N o. Of
cysts

N o. of
p ro c e d u res

1

22

9

II
IVB

2
2

T y p e of procedure
E x c is io n w ith b ilia ry e n te ric a n a s to m o s is
C y s to d u o d e n o s to m y
C y s to je ju n o s to m y
E x te rn a l d rainage
C h o le c y s te c to m y
O b s e rva tio n
E xcisio n
E x te rn a l d rainage
C y s to d u o d e n o s to m y

7
2
2
1
1
2
1
1

T a b le IV . R esults o f E xcise d and R e tain e d C y s ts in 2 6 P atie n ts W ith C h o le d o ch a l C y s ts b u t
W ith o u t P re v io u s S u rg e ry

R e s u lt

No. of
cysts

A s y m p to m a tic
C h o la n g itis
A s y m p to m a tic
C h o la n g itis
A b d o m in a l pain
P o rta l h y p e rte n s io n
C h o la n g io c a rc in o m a

9
2
5
7
1
1
1

Cysts
E x c is e d , 0 = 1 1
R e ta in e d , n — 15

T a b le V. M a n a g e m e n t o f C h o la n g itis and R e su lt in 11 P a tie n ts
S u rg ic a l m a n a g e m e n t
R e v is io n o f h epaticoje ju n o s to m y (1)
D ila ta tio n o f b ile -d u ct
s tr ic tu re (1 )
E x c is io n ( 3 )*
In te rn a l d ra in a g e (3 )‘
M e d ic a l (3)

O rig in a l p ro ced u re
E x c is io n

S y m p to m a tic
E x c is io n
C y s to d u o d e n o s to m y (2)
C y s to je ju n o s to m y (1 )
C y s to d u o d e n o s to m y (1)
C y s to je ju n o s to m y (2 )
E x te rn a l d ra in a g e (1)
In te rn a l d ra in a g e (2)

'In c lu d e s re fe rre d cases
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R esult

retained cyst who suffered recurrent
abdominal pain (Table IV).
Of the 11 patients who under
went primary cyst excision, 9 were
asymptomatic and 2 had recurrent
cholangitis (Table V). Of these two,
one required revision of the biliaryenteric anastomosis but remains
symptomatic. The second patient
underwent endoscopic dilatation of
a biliary stricture and was asymp
tomatic at 15-year follow-up.
Of the 15 patients with retained
cysts, 5 were asymptomatic, 7 had
cholangitis, 1 had abdominal pain,
1 had portal hypertension and 1
had a nonresectable cholangiocarcinoma in the retained cyst 18
years after a choledochocystoduodenostomy.
Six patients required reoperation:
one had a liver transplant because
of cirrhosis with portal hyperten
sion and one had a biliary-enteric
bypass for cholangiocarcinoma. The
four remaining patients required
reoperation for recurrent cholangi
tis. Two had secondary cyst exci
sion and were asymptomatic at 2and 8-year follow-up respectively.
The other two had revision of their
previous internal drainage proce
dures. Both continued to experience
recurrent episodes of cholangitis.
Of the two referred cases, the pa
tient who had secondary cyst exci
sion was asymptomatic at 3-year
follow-up, and the other has under
gone three revisions of the initial
anastomosis. Both cyst and symp
toms remain. Overall, the long-term
morbidity for those with primary
cyst excision was 18% and for those
with retained cysts was 66.7%.
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Discussion

S y m p to m a tic (2 )

Choledochal cysts are an uncom
mon but important surgical condi
tion associated with nearly 100%
mortality if left untreated.3 Congen
ital in nature, cystic dilatation of

S y m p to m a tic (2 )

CHOLEDOCHAL CYSTS

the biliary tree is considered to be
only the most obvious manifestation
of a spectrum of pancreaticobiliary
tract anomalies. Although described
by Vater in 1723, it was not until
the first comprehensive review by
Alonso-Lej, Rever and Pessagno4 in
1959 that choledochal cysts gained
prominence. Since then, more than
3000 cases have been reported
worldwide, with more than onethird of reported cases coming from
Japan.
Choledochal cysts account for 1
in every 13 000 hospital admissions
in Western countries5 with a female-to-male ratio of 4:1. Although
generally considered a disease of
childhood and infancy, Lopez and
associates6 reported that 57% of
patients in their series were adults
at the time of diagnosis.
The origin of choledochal cysts
has been a matter of considerable
investigation and debate. Although
the exact origin is unknown, the
“common channel theory” pro
posed by Babbit7 in 1969 is the
most commonly accepted theory. It
postulates that a high insertion of
the common bile duct into the pan
creatic duct leads to reflux of pan
creatic enzymes into the biliary
tree. The pancreatic enzymes pro
gressively weaken the bile duct
walls causing inflammation and
eventual fibrosis of the distal com
mon bile duct. Distal common bile
duct obstruction leads to bile stasis,
which, in the presence of weakened
bile duct walls, causes progressive
dilatation of the biliary tree. The
occurrence of this anomalous inser
tion is seen in 36%6 to 90%8 of
cases. A high amylase content of
the cyst fluid also supports this
theory.
In the Alonso-Lej classification
with Todani modification, six types
of choledochal cysts are described
(Fig. 1). Type I cysts show a seg
mental or diffuse dilatation of the
extrahepatic biliary tree and are the

most common variant (75% of
cases). Type II cysts (2%) form a
diverticulum off the extrahepatic
bile duct and type III cysts (2%)
form a choledochocele of the distal
common bile duct. Type IV cysts
(20%) have been subclassified into
type IVA cysts (multiple intra- and
extrahepatic cysts) and type IVB
cysts (multiple cysts involving ex
trahepatic ducts only). Type V cysts
(1%), Caroli’s disease, present as
multiple cysts of the intrahepatic
biliary tree.
The clinical signs and symptoms
of a choledochal cyst are usually
intermittent and may be quite non
specific. The classic triad of pain,
jaundice and abdominal mass is
thought to be diagnostic but is
present in fewer than one-third of
cases. Intermittent jaundice is the
most common symptom in the
young infant or neonate (80%), and
abdominal pain is the commonest
symptom in older children and
adults (60%). Other symptoms oc
curring less commonly include fe
ver, vomiting, hepatomegaly and
failure to thrive. One-quarter of all
adults present with complications of
choledochal cysts that occur sec
ondary to biliary stasis,9 including
cholangitis, spontaneous or trau
matic rupture, calculus formation,
secondary biliary cirrhosis, portal
hypertension and malignant degen
eration of the biliary tract.
Malignant degeneration is the
most serious long-term complica
tion of choledochal cysts. Carcino
ma occurs most commonly in type I
and type IV cysts but has been
diagnosed in all types.10-12 The
2.5% overall incidence of choledo
chal cyst carcinoma represents a
risk 20 times that of bile duct
carcinoma in the general popula
tion.13 However, the risk is age
related, with 0.7% patients under
10 years old, 6.8% from 11 to 20
years old and 14.3% patients over
20 years old being at risk.14 The

mean age of detection is 35 years,
which is 15 years earlier than that
of carcinoma of noncystic bile
ducts.15 The most frequent site of
origin is in the cyst wall (60%).
However, in 40% of cases,16 carci
noma occurs in the intrahepatic
ducts, gallbladder, liver or pancreas.
Adenocarcinoma is the most com
mon histologic type, but squamous
cell, anaplastic and sarcomatous
types have also been reported.15
The reason for malignant degen
eration of the hepatobiliary tree is
uncertain, but it is thought to relate
to chronic inflammation due to bili
ary stasis and reflux of pancreatic
enzymes into the biliary tree via the
“common channel.” Most cases of
carcinoma have been detected an
average of 10 years after an internal
drainage procedure, suggesting that
reflux of enteric contents acceler
ates the degenerative process.15
The diagnosis of malignant dis
ease is virtually never made preoperatively, because the signs and
symptoms are usually considered to
be due to the cyst itself or to
complications of the previous inter
nal drainage procedure. Conse
quently, because of diagnostic delay
and the specific character of carci
noma arising in the cysts, the carci
noma in most patients is incurable
when diagnosed at the time of oper
ation, and patients have a mean
postoperative survival of 8.5
months.13
Before 1960 the diagnosis of
choledochal cysts was made preoperatively in only 35% of cases. Now,
with increased awareness and im
proved imaging techniques, the pre
operative diagnosis can be made in
97% of cases.17 Ultrasonography is
regarded as the best method of
making the diagnosis. Iminodiacetic
acid (IDA) scanning preoperatively
is useful to outline the anatomy of
the biliary tree and postoperatively,
is a reliable, noninvasive method of
assessing patency of the biliary tree.
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Because of technical difficulty in
young patients and its invasive na
ture, endoscopic retrograde cholan
giopancreatography (ERCP) is gen
erally reserved for cases in which
the diagnosis is uncertain. Intraop
erative cholangiography gives infor
mation regarding cyst size and type
and identifies any pancreaticobiliary
ductal anomalies that may be pres
ent.
Early surgical intervention is im
portant to prevent the complica
tions of biliary stasis previously
mentioned. The surgical procedure
performed depends upon the initial
type of the cyst. For a type I cyst,
excision in its entirety or by the
method described by Lilley,18 with
Roux-en-Y hepaticojejunostomy
and cholecystectomy is clearly the
treatment of choice. This procedure
removes tissue that may be malig
nant and decreases the incidence of
anastomotic stricture and the ac
companying complications that
occur commonly with internal
drainage operations. For type II
cysts, excision with primary duct
repair or with Roux-en-Y hepati
cojejunostomy is recommended.
The experience with type III cysts is
limited, but reports indicate that,
because of the low risk of carcino
ma, transduodenal sphincteroplasty
can safely be performed without
cyst excision.2 Type IVB cysts
require complete excision of the
extrahepatic biliary tree with Rouxen-Y hepaticojejunostomy.
The management of intrahepatic
cysts (types IVA and V) is more
difficult. If the disease is confined
to the left lobe, left hepatectomy
with hepaticoenterostomy will be
curative. However, in the case of
type IVA cysts, bilateral involve
ment requires partial cyst excision
with intrahepatic cystoenterostomy
at the porta hepatis to decompress
the biliary tree effectively.19 These
patients will then require lifelong
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surveillance to monitor the develop
ment of anastomotic stricture or
carcinoma. In Caroli’s disease, dif
fuse and bilateral disease will ulti
mately necessitate liver transplanta
tion as the only hope of cure.
Controversy remains about the
treatment of patients who have un
dergone internal drainage proce
dures previously. Because of the
retained cysts, they run a lifetime
risk of cholangiocarcinoma, which
is usually incurable when diag
nosed. If symptoms of cholangitis
develop, the patient should undergo
secondary cyst excision. However,
the situation becomes more difficult
if the patient remains completely
asymptomatic. Removal of the cyst
decreases the risk of carcinoma by
only 60%, because 40% of all cases
occur outside of the cyst. Neverthe
less, we believe that in otherwise
healthy patients the operative risk
is low enough that the benefit of
secondary cyst excision outweighs
the long-term morbidity and mortal
ity associated with the future devel
opment of cholangitis and carcino
ma. Therefore, asymptomatic pa
tients with retained cysts should, at
the very least, be allowed the option
of secondary cyst excision or care
ful lifelong surveillance using the
combination of ERCP, percutane
ous transhepatic cholangiography,
IDA scanning and liver-function
testing.
We thank all the surgeons who have
allowed their patients to be included in
this series and Colleen Gardner for help
in the preparation of the manuscript.
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Primary Cutaneous Malignant Melanoma:
Experience of the British Columbia Cancer
Agency From 1972 to 1981
Vicki E. Carmichael, BSc;* Kenneth S. Wilson, MB, ChB, FRCP(Edin), FRCPC, FACPt
A retrospective review of 891 patients with newly diagnosed primary cutaneous
malignant melanoma (CMM) registered at the British Columbia Cancer Agency from
1972 to 1981 is presented. Age-standardized incidence rates in British Columbia
have increased markedly over that time. The female-to-male ratio was 1.13:1 and the
median age overall was 47 years. A change in the size of a mole was the most
common presenting sign (in 43% of patients) and the median duration of signs was
5.9 months. Predominant tumour sites were the trunk for males and the lower limbs
for females. Dominant growth patterns were superficial spreading melanoma (65%),
nodular melanoma (25%), lentigo maligna melanoma (5%) and acral lentiginous
melanoma (2%). On staging of the primary tumour, 90% of patients had local
disease, 9% of patients had regional disease and 1% of patients had distant disease at
presentation. Median depths of tumours were 1.45 mm for males and 1.10 mm for
females; no T1 tumours (tumours 0.75 mm or less in depth [TNM classification])
were staged beyond the local area. Disease recurred in 44% of males and 32% of
females. The 15-year survival rate was 55.5% for males and 70.3% for females.
These findings are compared with those of recent international series. It is apparent
that earlier diagnosis improves survival and that more education is needed in view of
the increasing incidence and death from CMM.

On presente une etude retrospective de 891 patients souffrant d’un melanome
cutane malin (MCM) primaire nouvellement diagnostique, enregistres a l'Agence
pour le Cancer de Colombie Britannique entre 1972 et 1981. Dans cette province,
l’incidence corrigee pour Page a augmente sensiblement au cours de cette periode.
Le rapport femmes / hommes a ete de 1,13 pour 1 et Page median de 47 annees. La
signe le plus frequemment observe etait une augmentation de la taille de la mole
(chez 43 % des patients) et la duree mediane des signes a ete de 5,9 mois. Les foyers
d’apparition des tumeurs primitives etaient le tronc pour les hommes et les membres
inferieurs pour les femmes. Les caracteristiques tumorales dominantes ont ete les
melanomes malins a extension superficielle (65 %), les melanomes nodulaires
d’emblee (25 %), les melanomes sur melanose de Dubreuilh (5 %) et les melanomes
lentigineux des extremites (2 %). Lors du diagnostic, le stade evolutif des tumeurs
primitives etait le suivant: 90 % de tumeurs localisees, 9 % d’atteintes regionales et
1 % d’envahissements a distance. La profondeur mediane des tumeurs etait de 1,45
mm pour les hommes et de 1,10 mm pour les femmes; aucune tumeur de stade T1
(d’une profondeur inferieure a 0,75 mm [classification TNM]) n’a ete retrouvee au
dela de la surface locale. La maladie est reapparue chez 44 % des hommes et chez
32 % des femmes. La survie a 15 ans a ete de 55,5 % pour les hommes et de 70,3 %
pour les femmes. Ces resultats sont compares a ceux d’etudes internationales
recentes. II est evident qu’un diagnostic precoce ameliore la survie et que, devant
Paugmentation de la frequence des MCM et de la mortalite qui lui est attribuable,
une meilleure education du public s’impose.

melanoma represent
M alignant
ed 1.41% of all cancers in
British Columbia in 1974, but by
1987 the incidence had increased to
3.11% for men and 3.7% for wom
en.1 Similar increases in melanoma
incidence have been reported in the
United States, Scandinavia and Aus
tralia.2-4 This alarming increase has
prompted many studies of risk and
prognostic factors. These studies
have suggested that the increase in
incidence is real and not due to
inadequate data,5 artefacts of diag
nosis or notification, or changes in
“cosmetic factors.”6-8 Established
risk factors include the presence of
freckles9 and benign nevi,10 a his-
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tory of severe sunburn resulting
in peeling,11 exposure to ultraviolet
light,1213 occupation and socio
economic status.14' 16
Many biologic factors influence
the natural history of malignant
melanoma,17 including stage, histogenic or growth pattern, anatomic
site of the tumour, age and sex.
This report is a retrospective de
scriptive review of these factors in
patients with primary cutaneous
malignant melanoma (CMM) regis
tered with the British Columbia
Cancer Agency (BCCA) from 1972
to 1981.

study period was generated manual
ly in 1983, and the 891 patients
thereon formed the basis of this
report. In 1990, an additional 198
patients were identified as having
been registered in the study period,
but these were not included.
A total of 27 patients had malig
nant melanoma in multiple sites at
diagnosis. Primary malignant mela
noma occurred on two separate oc
casions in 25 patients. These were
counted only once in the incidence
analysis.

category of the TNM classification
system:21 T1 (less than 0.75 mm),
T2 (0.76 to 1.50 mm), T3 (1.51 to
3.0 mm) and T4 (greater than 3.0
mm). The International Classifica
tion o f Diseases, 8th revision, was
used to categorize primary sites.22
Four principal categories were used:
head and neck (H & N), trunk (T),
lower limb (LL) and upper limb
(UL). According to a modification of
the M.D. Anderson Hospital sys
tem,23 stage was categorized as
local (stages I and II), regional
(stage III) and distant (stage IV).

Data Collection
Statistical Methods

Patients and Methods
Patients
From 1971 to 1981 in British
Columbia the proportion of persons
of British origin decreased from
58% to 51%.’ Those of European
ancestry increased from 18% to
27%, and the proportion of Asians
increased from 2.6% to 4.5%. The
higher proportion of inhabitants of
British origin is significant in that
persons of Celtic origin seem to
have a higher incidence of malig
nant melanoma.4
Registration of malignant disease
with the provincial cancer registry
is mandatory for pathologists, but
clinical referral to the BCCA is
voluntary. The present study in
cluded all new cases of primary
CMM diagnosed between June 1,
1972, and May 31, 1981, and regis
tered with the BCCA. Follow-up
extended to Apr. 30, 1990. In the
defined period of this study there
were 1944 persons in British Co
lumbia registered with melanoma in
the British Columbia Cancer Regis
try. Of these, 1245 (64%) patients
were also registered with the
BCCA. A list of cutaneous melano
ma patients registered during the
590

Data on 147 demographic, his
topathologic, treatment and out
come variables were extracted from
the medical records of the study
population. Data were transcribed
on to an abstract form and later
computerized into a database
(dBase IV) to facilitate follow-up
and statistical analysis.
Histopathologic studies were per
formed at hospital laboratories
throughout the province. The ma
jority of the biopsies were reviewed
by two BCCA pathologists in Van
couver. Growth patterns of the mel
anoma were described pathological
ly by the classification system used
by Clark and associates.18 The five
main subdivisions of malignant mel
anoma used in this study were
lentigo maligna melanoma (LMM),
superficial spreading melanoma
(SSM), nodular melanoma (NM),
acral lentiginous melanoma (ALM)
and not otherwise specified (NOS).
Tumour depth was assessed by
Clark’s histopathologic method19
and Breslow’s micrometer measure
ment.20 The study included cases
antedating the universal usage of
these methods. Depth measure
ments were not available for 223
(25%) patients and diameter mea
surements were unavailable for 102
(11%) patients. Depth categoriza
tion was determined from the “T”
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Data were analysed by the Statis
tical Package for Social Sciences
(SPSS-X release 3.1 ).24 All percent
ages refer to total cases in the study
population unless otherwise stated.
Trends in incidence were analysed
by simple linear regression analysis.
The “utility test” model was used
to test statistical significance of
incidences between males and fe
males. Means and standard devia
tions are all reported as mean ±
SD. Survival as a time interval was
calculated from date of diagnosis to
date of death, last written or physi
cian contact. Statistical significance
of differences between the sexes
was tested by the Mann-Whitney
U-test.
Age-standardized rates based on
the number of tumours were adapt
ed to those of the British Columbi
an population at the 1971 census
by the direct method of standardiza
tion.25 Mortality data were provided
by the Division of Vital Statistics of
the provincial Ministry of Health.1
All population data were obtained
from Census Canada publications.26
Survival curves were generated
with the Kaplan-Meier product
limit method27 with the biomedical
computer program BMDP.28 The
Tarone-Ware x2 test29 was used to
test the significance of gender on

CUTANEOUS MALIGNANT MELANOMA

survival. Cases with missing data
were excluded from the relevant
analysis procedures. Overall mean
survival times were calculated using
only survival times of cases with a
response (death from melanoma).28

Results
Incidence and Mortality
Age-standardized incidences of
malignant melanoma in British Co
lumbia have increased significantly
(p < 0.0001) for both females and
males (Fig. 1). In 1983, the age
standardized death rate per
100 000 in Canada and British Co
lumbia was I.8.1 The death rates
associated with malignant melano
ma in British Columbia did not
change substantially for either men
or women during the period 1974
to 1985 (Fig. 1).
Clinical History
A change in the size of a mole
was the commonest (43%) present

ing sign. Other signs and symptoms
were the development of a new
mole (13%), a change in colour
(9%), bleeding or ulceration (8%)
and pain, tenderness or itching (8%)
in a mole.
Bleeding or ulceration was a pre
senting sign in 4% of UL lesions,
8% of T lesions and 9% of H & N
and LL lesions.
Development of a new mole was a
presenting sign in 8% of T lesions,
14% of UL lesions, 16% of LL
lesions and 20% of H & N lesions.
Melanoma was recognized by a phy
sician in 7% of patients who did not
bring it to the physician’s attention.
Age and Sex Distribution
There were 472 females and 419
males, an overall female-to-male
ratio of 1.13:1, but this was not
constant over the study period.
From 1972 to 1975 the ratio aver
aged 0.84:1 and from 1976 to
1981, 1.25:1. Patients’ ages ranged
from 9 to 99 years for males and
from 3 to 93 years for females.
Overall, the median age was 47

FIG. 1. Melanoma incidence by sex (+ = male, H = female) and mortality by sex (X
= male, ▲ = female) in British Columbia 1971 to 1988.

years and the mean age 48.2 ±
16.9 years; for males, the mean age
was 49.7 ± 17.4 years, and for
females the mean age was 46.9 ±
16.3 years. The difference between
the means was not significant.
Times From First Sign or Symptom
to Death
Median times from first sign or
symptom to diagnosis were 5.6 and
6.2 months in males and females
respectively. Females had longer
median time from diagnosis to first
recurrence (24.2 v. 19.7 months).
Median times from recurrence to
death were similar for females and
male (10.9 and 11.6 months).
Distribution by Age, Site, Growth
Pattern and Stage
Table I illustrates the distribution
of age, Clark’s level, growth pattern
and stage according to site and sex.
Predominant sites were the trunk
for males (46% [193 of 419] of the
total male population) and lower
limb for females (44% [206 of 472]
of the total female population). T
lesions occurred predominantly in
patients under 60 years of age (81%
[156 of 193] of all male and 86%
[96 of 112] of all female T lesions).
In contrast 48% (46 of 96) of all
male and 44% (26 of 59) of all
female H & N lesions occurred in
patients over 60 years of age. The
distribution of LL lesions was simi
lar to that of T lesions: 74% (46 of
62) of LL lesions in males and 80%
(164 of 206) of LL lesions in fe
males occurred in patients under 60
years of age.
Overall there was little difference
in the ages of patients for lesions at
the major body sites except for the
H & N where median ages were
higher (Table II). Females had lower
median ages for T and UL lesions.
The recorded distribution of spec
ified growth patterns was SSM
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(65%), NM (25%), LMM (5%), and
ALM (2%). Fig. 2 illustrates growth
patterns by age. LMM proportions
increased with age and occurred
mainly on the H & N (80%). Only
13% of all LMMs occurred in pa
tients under age 50 years of age.
SSM proportions declined over age
60 years.
Staging information was com
plete in 870 cases: 90% had local
disease, 9% had regional disease
and 1% had distant disease. Region
al lymph node dissection was per
formed in 282 patients and in 84
(29.8%) patients the nodes were
found to contain malignant cells on
histologic examination. The inci
dence of regional or distant disease
according to the site of the primary
lesion in the total staged population
was 6.2% for UL lesions, 9% for T
lesions, 11.8% for H & N lesions
and 12.6% for LL lesions and ac
T a b le 1.

mours was 31% for T1 tumours,
29% for T2 tumours, 25% for T3
tumours and 14% for T4 tumours.
Females made up 62% of patients
with T1 lesions, 55% of those with
T2 lesions, 52% of those with T3
lesions and 43% of those with T4
lesions. Males made up 69% of
patients with T3 and T4 H & N
lesions and 70% of patients with T3
and T4 T lesions. T1 and T2 tu
mours constituted 55% (59 of 107)
of all H & N lesions, 57% (119 of
209) of all LL lesions, 61% (147
of 241) of all T lesions and 69% (77
of 111) of all UL lesions. Clark’s

cording to the site in males and
females respectively was 14.7% and
7% for H & N lesions, 8.8% and
7.1% for T lesions, 5.2% and 7% for
UL lesions, and 24.6% and 9.1% for
LL lesions.
Distribution by Depth

Table III shows depth of invasion
by sex according to age, site,
growth pattern and stage. Overall
the median depth was 1.20 mm
(females 1.10 mm and males 1.45
mm).
The depth distribution of tu
T a b le II.

Mean (and Median) Ages (Years) at Time of Diagnosis of New Patients With Primary
Cutaneous Malignant Melanoma According to Sex and Tumour Site
Site

S ex

H e a d and neck

Trunk

U p p er lim b

L o w er lim b

58 (57.4)
56 (54.5)

46 (46.4)
39.5 (42.5)

48 (49.8)
43 (47.1)

48 (48.1)
47 (46.7)

Male
Female

New Cases of Primary Cutaneous Malignant Melanoma According to Age, Clark’s Level, Growth Pattern, Stage, Site and Sex
S ite
H e a d and
neck

U pper
lim b

T ru n k

Low er
lim b

G ro u p in g s

M

F

M

F

M

F

M

F

T o ta l*

Age, yr
0 -3 9
4 0 -5 9
6 0 -9 9
Total
Clark’s level

22
28
46
96

15
18
26
59

67
89
37
193

56
40
16
112

18
20
19
57

34
32
21
87

20
26
16
62

75
89
42
206

307
342
223
872

5
13
16
37
10
81

0
15
8
19
10
52

4
33
58
74
6
175

3
22
39
35
2
101

2
9
16
23
2
52

0
18
31
26
4
79

0
4
16
27
9
56

7
46
45
84
9
191

21
160
229
325
52
787

17
25
30
1
21
1
95

12
27
7
0
11
2
59

0
111
40
0
35
6
192

0
74
20
0
18
0
112

1
31
7
4
13
1
57

2
47
17
4
14
3
87

1
26
19
5
10
1
62

3
119
37
2
35
8
204

36
460
177
16
157
22
868

81
12
2
95

53
4
0
57

176
15
2
193

104
7
1
112

55
2
1
58

80
5
1
86

46
15
0
61

189
19
0
208

784
79
7
870

1
II

III
IV
V
Total
Growth pattern
LMM
SSM
NM
ALM
NOS
Other
Total
Stage
Local
Regional
Distant
Total

'M issing data account for differences between total study population (891) and totals in different categories above.
LMM = lentigo maligna melanoma, SSM = superficial spreading melanoma, l\IM = nodular melanoma, ALM = acral lentiginous melanoma, NOS = not
otherwise specified
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No T1 lesions had spread beyond
the local area at the time of diagno
sis. Regional metastases were pres

levels were assessed in 88% of
cases, and their distribution in rela
tion to depth is shown in Fig. 3.

ent in 2.5% of all T2, 11.3% of all
T3 and 17.2% of all T4 lesions at
the time of presentation.
Growth patterns indicate th at
both SSM and LMM tend to be thin
lesions: 42% of SSMs and 62% of
LMMs were T1 tum ours. NMs were
thicker lesions: 46% were T3 and
37% were T4. ALM was an infre
quent growth pattern: 66% of ALMs
were T3 and T4.
Recurrence
Disease recurred in 38% of the
total study population (32% of all
females and 44% of all males). Five
patients had recurrence 10 or more
years after the initial diagnosis.
Recurrences were predominantly
(54% of all first recurrences) in the
regional lymph nodes. The frequen
cies of primary sites responsible
for all first recurrences were as
follows: T, 38%; LL, 25%; H & N,
22%; and UL, 13%. Of patients
experiencing a first recurrence, 27%
had recurrence in two sites, 16% in

FIG. 2. Growth patterns of primary tumour by age (years). LMM = lentigo maligna
melanoma, SSM = superficial spreading melanoma, NM = nodular melanoma, ALM
= acral lentiginous melanoma.

Table III. Age, Site, Growth Pattern and Stage of New Cases of Primary Cutaneous Malignant Melanoma According to Depth of Invasion and Sex
Depth of invasion*
T1
Groupings
Age, yr
0 -3 9
4 0 -5 9
6 0 -9 9
Total,
No.
%
Site
Head and neck
Trunk
Upper limb
Lower limb
Growth pattern
LMM
SSM
NM
ALM
NOS/other
Stage
Local
Regional
Distant

T2

T3

T4

Totalt

M

F

M

F

M

F

M

F

No.

%

31
31
18

54
55
19

19
45
23

47
37
23

33
29
19

40
36
12

12
20
23

11
15
16

247
268
153

37
40
23

80
12

128
19

87
13

107
16

81
12

88
13

55
8

42
6

668

100
100

17
45
14
4

17
32
28
51

15
46
13
13

10
24
22
51

14
47
8
12

9
14
16
49

19
19
5
12

6
14
5
17

107
241
111
209

16
36
17
31

8
65
0
1
6

8
110
1
0
9

2
63
12
1
9

2
75
12
2
16

1
30
33
3
14

1
45
32
1
9

3
12
30
2
8

1
11
22
2
6

26
411
142
12
77

4
62
21
2
12

80
0
0

128
0
0

84
3
0

105
2
0

72
9
0

78
10
0

44
11
0

36
6
0

627
41
0

94
6
0

* TNM classification
t Total study population
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three sites and 10.5% in four or
more sites.
Survival
Five-, 10- and 15-year survival
rates were 68.9%, 58.2% and 55.5%
for males and 82.9%, 74% and
70.3% for females (p < 0.0001).
Overall mean survival of those who
died from CMM was 11.3 years for
males and 13.7 years for females.
Malignant melanoma was the
cause of death for 31% of the study
population and accounted for 82%
of all deaths. Of all patients who
had a recurrence, 16% were disease
free at last follow-up.
Other Cancers
Thirty (3%) of the 891 patients
had a previous basal cell cancer and
16 (2%) a squamous cell cancer.
Other malignant tumours occurred
in 48 patients (5%) before and 115
(13%) after the diagnosis of CMM.

Subsequent malignant tumours
were mainly nonmelanoma skin
cancers (66% of total subsequent
malignant tumours).

Discussion
CMM has been studied extensive
ly over the last 20 years, seeking a
better understanding of demograph
ic, environmental, clinical and
pathological factors. The increase
in age-standardized incidence in
Western developed countries has
been well documented,3031 and a
similar pattern was seen in this
study. Melanoma incidence in sever
al countries increased by 5% per
annum in the 1960s and 1970s.32
These increasing rates suggest that
the trends observed are the results
of true changes in risk. Data from
the Surveillance Epidemiology and
End Results Program33 showed that
the incidence in males exceeds that
in females and is increasing at a

Depth of invasion
FIG. 3. Depth of invasion by Clark’s level.
594

JCC, VOL 35, N ° 6, DECEMBRE 1992

faster rate (4.8% per year compared
with 3.6%); the death rates for
males and females are increasing at
2% and 1.3% per year respectively.
In our study the death rate for
males exceeded that for females in
8 of the 9 years from 1977 to 1985,
and overall survival for males was
shorter for new patients registered
from 1972 to 1981.
Data on sex, age, site and growth
patterns have been compared with
the findings of major series from
the United States,34-38 Canada,39
New Zealand,40 Scotland,4142 Den
mark,43 Australia44 and Ireland.45
This study’s sex ratio was similar to
those in all series except the one in
Ireland and the two in Scotland,
where the female-to-male ratios
were 2.8:1, 1.9:1 and 2.17:1 respec
tively. All series except two in the
United States35-36 showed a female
preponderance. The median age (47
years) of all patients in our study
was virtually the same as those
reported from Sydney and Alabama
(48 and 44 years respectively).38
The commonest primary site in
females in all studies has been the
LL, accounting for 33% to 67% of
all cutaneous melanomas. For
males, the T was the commonest
primary site (33% to 47%) in all
studies except those in Ireland,
Scotland and Rochester where the
H & N was the commonest site.
The findings in this study that 46%
of all male melanomas were located
on the T and 44% of all female
melanomas were on the LL are
consistent with the findings in most
other series. A trend of increasing
frequency of T melanomas and de
creasing frequency of H & N mela
nomas in males has been reported
from Sydney and Alabama38 for the
period 1958 to 1985.
In our study, the observed
growth-pattern distribution was
consistent with that of most previ
ous reports. The most frequent
(65%) growth pattern was SSM,

CUTANEOUS MALIGNANT MELANOMA

with NM and LMM accounting for
25% and 5% respectively. SSM is
usually the most common growth
pattern (51% to 73%), followed by
NM (14% to 35%) with LMM be
tween 4% and 9%. In Ireland, NM
was the most common type, and
LMM caused 18% of all melanomas
in that series.45
Depth measurement by microme
ter is now accepted as the most
important indicator of prognosis.46
The observations that 61% of the
total population had primary tu
mours less than 1.5 mm in depth
and that no T1 primary lesions were
spread beyond the local area at
diagnosis provide both encourage
ment and incentive to increase edu
cational efforts toward earlier rec
ognition and diagnosis of melano
ma. Depth comparisons with other
series are hindered by lack of stan
dard reporting practices. In the se
ries from Scotland for the period
1971 to 1976,41 only 30% of pa
tients had T1 and T2 tumours. In a
worldwide comparative study,47 12%
of patients had primary tumours
more than 4 mm thick, and in our
series 15% were more than 3 mm
thick. In the combined experience
of the Sydney melanoma group and
the University of Alabama, median
tumour thickness for males and
females has decreased since the
1950s38 to 1.4 and 1.2 mm, respec
tively, during the period 1976 to
1980. These median depths are
close to those depths observed from
1972 to 1981 in our series (1.45
mm for males and 1.10 mm for
females). Poorer prognoses in
NMs46 are related to their depth.
For example, 83% of NMs but only
24% of SSMs were T3 or T4 in our
series. ALM is also usually a deep
lesion, 66% being T3 or T4 in our
series.
The poorer prognosis of malig
nant melanoma in males is well
documented46 and has been con
firmed here. The sex difference in

survival in the present study could
be due to several factors: the gener
ally thicker and larger volume tu
mours in males, the predilection to
T and H & N lesions, the majority
of thick lesions at those sites, the
majority of regional or metastatic
disease in all sites except UL at
presentation and a tendency to
shorter disease-free intervals from
diagnosis to recurrence. The role of
hormonal factors in the etiology
and natural history of melanoma
has been recognized and investigat
ed for over 40 years,48 but this
association has yet to be successful
ly exploited therapeutically.
Most series report that the major
ity of patients have stage I disease
at presentation, consistent with the
findings in our series. Correlation of
primary sites with potential meta
static disease at diagnosis according
to sex showed that males had about
twice the likelihood of regional or
metastatic disease with H & N
primary lesions than females, and
almost three times the likelihood
with LL primary tumours. An analy
sis of the elective and therapeutic
lymph node dissections that were
performed in this series appears
elsewhere in this issue (pages 600
to 604).
The pattern of recurrent disease
in melanoma is now well known.
The disease-free interval is directly
related to the depth of the primary
lesion.49 Regional lymph nodes are
the commonest site of first metastases. In this series, 54% of first
recurrences were in regional nodes.
Elective lymph node dissection is
known to be associated with a dif
ferent pattern of metastatic disease,
that is, fewer regional metastases
(down from about 60% to 5%) and a
proportional increase in other
sites.50 The prognostic importance
of the development of recurrent
disease is very clear from this se
ries. Only 16% of patients experi
encing recurrence were free of dis

ease at last follow-up. New treat
ments are urgently required for this
group of patients.
Several factors must be taken
into account when comparing sur
vival of patients between series.47
Referral-centre results differ from
population-based studies. Results
from the last decade may be superi
or due to earlier diagnosis. The
distribution of tumour thickness
must be considered. Patterns of
surgical practice, especially the rate
of elective lymph node dissection
will have a significant effect on
staging and possibly on ultimate
survival. Relapse is less likely in
patients with pathological than with
clinical stage I disease. In our se
ries, 5-year survival rates of 68.9%
and 82.9% for males and females
(10% of whom had regional or
distant metastases at diagnosis)
compare favourably with those from
other centres in which 5-year sur
vival rates for stage I melanoma
ranged from 62% to 81% and 70%
to 100% in males and females re
spectively.
Early diagnosis is the best avail
able method of improving survival
in CMM. Since CMM can be found
readily by self-inspection, the medi
an time to diagnosis can be short
ened with patient education. A pub
lic-health education program in
Queensland has resulted in an in
crease in the number of thin tu
mours registered.51 Awareness of
warning signs in a mole — asymme
try, border irregularity, colour var
iegation and diameter (over 6 mm)
or the ABCD of melanoma52 —
must be emphasized along with
assessment and surveillance of indi
viduals with dysplastic nevus syn
drome or family members with mel
anoma, or both.53-54 Public cam
paigns and further research aimed
at early detection and treatment
should reduce melanoma mortality,
especially in areas of higher inci
dence such as British Columbia.
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SESAP VII Question / Question
SESAP VII
Item 3
A surgical condition characterized by a necrotic center with overhang
ing skin edges and irregular purple zone surrounded by an outer rim of
erythema is most likely

(A) necrotizing fasciitis

...Proctosedyl
can change
their tune.

(B) clostridial gangrene
(C) the result of progressive venous thrombosis
(D) progressive synergistic bacterial gangrene
(E) actinomycosis

For the incomplete statement above select the one completion that is
best of the five given.

proctosedyl V //^
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With an anesthetic for a
comforting note of relief.
Available in 30 g tubes of o in tm e n t and 24
suppositories for a full course o f tre atm e nt.
Prescribing inform ation available on request.

For the critique of Item 3 see page 623.
(Reproduced by permission from SESAP ’9 2 - ’93 Syllabus; Surgical
Education and Self-Assessment Program No. 7. For enrolment in the
Surgical Education and Self-Assessment No. 7, please apply to the
American College of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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BABY MICHAEL, 11 MONTHS OLD,
BROUGHT TO FAMILY DOCTOR WITH
FEVER, CONGESTION AND IRRITABILITY.
DIAGNOSED HAVING INFECTION OF THE
UPPER RESPIRATORY TRACT PRESCRIBED
AN ORAL ANTIBIOTIC AND SENT HOME.
4 DAYS LATER, TAKEN TO EMERGENCY
WITH CONTINUING FEVER, HEADACHE,
NECK STIFFNESS, RASH AND VOMITING.
PRESUMED MENINGITIS.
Suspected

pathogens

Haemophilus influenzae
Neisseria meningitidis
Streptococcus pneumoniae

cephin

T R I A X 0 N E

PAAB
CCPP

CANADA’S ONLY ONCE-A-DAY ™ v ANTIBIOTIC

For prescribing information see page 642
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Elective and Therapeutic Regional Lymph
Node Dissection for Cutaneous Malignant
Melanoma: Experience of the British
Columbia Cancer Agency, 1972 to 1981
Vicki E. Carmichael, BSc;* R. Edward Robins, MD, FRCSC;t
Kenneth S. Wilson, MB, ChB, FRCP (Edin), FRCPC, FACP$
The authors present a 10-year review of patients registered at the British Columbia
Cancer Agency (BCCA) who underwent lymph node dissection for malignant
melanoma. Pathological findings in the regional lymph nodes were correlated with
primary site, growth pattern, depth of invasion and Clark’s level. Elective lymph
node dissection (ELND) was performed in 223 patients, and the overall positivity
rate (pathologically involved nodes) was 16%. Survival rates for patients who had
ELND were compared with those for BCCA patients not having had ELND and
patients from the University of Sydney, Sydney, Australia. Although patients who
underwent ELND had thicker and more frequently ulcerated primary tumours than
patients with stage I disease who did not undergo ELND, survival was better in the
group who had ELND. However, when all potential prognostic factors were analysed
by multivariate analysis, ELND was not a significant factor in prognosis.
Therapeutic lymph node dissection (TLND) was performed in 50 patients at the time
the primary tumour was diagnosed, and involvement of the lymph nodes was found
in 36. Of 525 patients with clinical stage I disease who did not have ELND, disease
recurred in the regional lymph nodes in 119; 86 of them had TLND for recurrence
(RTLND). Median survival rates from the time of diagnosis of the primary lesion for
ELND-positive, TLND-positive and RTLND patients were 4.2, 2.7 and 4.4 years
respectively; the differences were not significant. New treatments are required for
patients with involved regional lymph nodes.
Les auteurs decrivent les resultats d’une etude d’une duree de 10 ans portant sur les
patients de l’Agence pour le Cancer de Colombie Britannique (ACCB) qui subirent
une dissection ganglionnaire pour un melanome malin. Les constatations des
examens pathologiques ont ete reliees au foyer primaire, aux caracteristiques de
croissance, a la profondeur et au niveau selon la classification de Clark. Une
dissection ganglionnaire non urgente (DGNU) fut pratiquee chez 223 patients et le
taux d’examens positifs fut de 16 %. Le taux de survie des patients qui subirent une
DGNU a ete compare a celui des patient de l’ACCB qui ne subirent pas de DGNU et
a celui des patients de l’Universite de Sydney, Sydney, Australie. Meme si les
patients qui subirent une DGNU avaient des tumeurs plus profondes et plus
frequemment ulcerees que les patients de stade I qui n’eurent pas de DGNU, la
survie fut meilleure dans le groupe DGNU. Neanmoins, l’analyse multifactorielle de
tous les facteurs pronostiques possibles n’a pas fait ressortir la DGNU commme
facteur pronostique determinant. Une dissection ganglionnaire therapeutique (DGT)
fut effectuee chez 50 patients au moment du diagnostic primaire et une atteinte
ganglionnaire fut constatee chez 36 d’entre-eux. Des 525 patients au stade clinique I
qui n’eurent pas de DGNU, une recidive ganglionnaire regionale survint chez 119;
de ce groupe, 86 subirent une DGT pour recidive (DGTR). Les survies medianes a
partir du diagnostic de la lesion primaire pour les patients DGNU-positifs,
DGT-positifs et DGTR furent de 4,2, 2,7 et 4,4 annees, respectivement; la difference
n’est pas statistiquement significative. II existe un besoin de therapies nouvelles
pour les patients souffrant d’atteintes ganglionnaires regionales.
600
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he role of surgery in removing
clinically malignant or equiv
ocal regional lymph nodes (thera
peutic lymph node dissection
[TLND]) either when the diagnosis
of primary malignant melanoma is
made or subsequently for recur
rence (recurrent therapeutic lymph
node dissection [RTLND]) is firmly
established.1 However, the survival
benefit of removing clinically nor
mal regional lymph nodes as soon
as the primary lesion is diagnosed
(elective or prophylactic lymph node
dissection [ELND]) is controversial.1
Since 1976, the Melanoma Tu
mour Group of the British Colum
bia Cancer Agency (BCCA) has rec
ommended ELND for patients with
“high-risk” clinical stage I malig
nant melanoma, defined as those
with primary tumour of Clark’s
level III and depth of dermal inva-
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sion greater than 0.76 mm, those
with Clark’s level 4 or 5, and those
in whom one anatomic lymph node
drainage site could be identified.
This recommendation was modified
in 1983 to stage I patients with
tumours more than 1.5 mm deep.
In this study we report the BCCA
experience with ELND, TLND and
RTLND for malignant melanoma.
Factors influencing the ELND posi
tivity rate are presented. Survival in
patients who had ELND is com
pared with that of a concurrent
control group of clinical stage I
patients who, in the same decade,
were treated without ELND (desig
nated BCCA control patients), and
with that of other series. Reasons
for omitting ELND included patient
and referring surgeon’s decisions in
the light of possible expected bene
fits. The effect of ELND on survival
of all patients with clinical stage 1
malignant melanoma who were reg
istered at the BCCA during the
study period and were treated by
wide primary excision has been
analysed by multifactorial analysis
according to whether or not they
underwent ELND.
Patients and Methods
In 1983 we began a retrospective
review of all patients who had regis
tered at the BCCA with malignant
melanoma between June 1, 1972,
and May 31, 1981.2 The records of
891 patients were reviewed, and all
of those who underwent ELND,
TLND and RTLND and BCCA con
trol patients (vide supra) form the
basis of this report. Lymph node
dissection for cure was performed
by referring surgeons throughout
the province.
The data were analysed with the
Statistical Package for Social Sci
ences (SPSS-X, release 3.1 ).3 Sur
vival was analysed by the product
limit method. Multifactorial analysis
was undertaken with the Cox pro

portional hazards model. Differ
ences between survival curves were
calculated with the log rank test.
Results
ELND
ELND was performed in 223 pa
tients, 104 male and 119 female. In
patients with specified negative clin
ical evaluation of regional nodes,
ELND was pathologically positive in
19 (18%) males and 16 (13%) fe
males for a combined positivity rate
of 16%. ELND positive and negative
frequencies and overall percent pos
itivity according to site and growth
pattern of the primary tumour,
depth of invasion and Clark’s level
are summarized in Table I.
Depth measurements were avail
able in 202 patients who underwent
ELND. Median depths of primary
tumours in ELND-positive and
ELND-negative patients were 3.0

mm and 1.6 mm respectively. Med
ian depth of primary tumours was
greater in all patients who had
ELND (1.64 mm) than in 530
BCCA control patients (1.00 mm) (p
< 0.0001). Site distribution of the
primary tumour in patients who had
ELND and in BCCA control pa
tients was 20% and 17% (upper
limb), 41% and 25% (lower limb),
26% and 41% (trunk), and 13% and
18% (head and neck). Primary ul
ceration was present in 53% of
patients who had ELND and in 20%
of BCCA control patients. In pa
tients with positive ELND, 18 had
one positive node, 7 had two posi
tive nodes and 7 had three or more
positive nodes; 3 patients had an
unspecified number of positive
nodes. The number of positive
nodes made no significant differ
ence to the patient’s survival. Dis
ease recurred in 27% (50 of 188) of
the ELND-negative patients. There
were 23 (66%) recurrences in the 35

Table I. Characteristics of Patients With Pathologically Positive and Negative Nodes on Elective
Lymph-Node Dissection (ELND)
Characteristics
Sex
Male
Female
Site of primary
Upper limb
Lower limb
Head and neck
Trunk
Growth pattern
SSM
NM
LMM
ALM
NOS
Depth of invasion of primary tumour*
T1
T2
T3
T4
Unspecified
Clark’s level
II
III
IV
V

ELND
positive

ELND
negative

19
16

85
103

3
16
4
12

41
77
24
46

16
14
0
0
5

102
57
1
4
24

0
5
12
13
5

15
67
67
24
15

0
3
24
6

4
65
108
7

SSM = superficial spreading melanoma, NM = nodular melanoma, ALM = acral lentiginous
melanoma, LMM = lentigo maligna melanoma, NOS = not otherwise specified
*TNM classification
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ELND-positive patients. In these pa
tients the median survival was 4.2
years, and 37% of them survived 10
years. Median survival of ELNDnegative patients has not been
reached (Fig. 1).
Ten-year disease-specific survival
rates according to depth and level
of invasion of the primary tumour
in BCCA control patients and those
who had ELND are shown in Figs.
2 and 3. Survival differences were
significant in favour of patients who
had ELND when grouped according
to either level or depth of invasion
(p < 0.0001). In patients with a T2
primary tumour, the group with the
largest difference in survival (23%),
only five (7%) had pathologically
positive lymph nodes out of a total
of 72 dissections.
Univariate and multivariate analy
sis of survival was undertaken in
720 clinical stage I patients. Of
these patients, 192 had local exci
sion (LE), 3 had LE and ELND, 327
had wide excision (WE) (more than
5 cm total width) and 198 had WE
and ELND. Ten-year disease-specif
ic survival rates for patients who

underwent the various types of sur
gical excision were 38% for those
with LE. 50% for those with LE and
ELND, 67% for those with WE and
67% for those with WE and ELND.

1
•4 •■'i

A

A

FIG. 2. Ten-year disease-specific survival rates in patients with malignant
melanoma registered with British Columbia Cancer Agency (BCCA) according to
depth of primary tumour. Solid bars = no ELND, dotted bars = ELND.

FIG. 1. Ten-year disease-specific sur
vival rates in patients with nega
tive elective lymph node dissection
(ELND) (solid line), positive ELND
(short dashed line), positive therapeu
tic lymph node dissection (TLND) (dot
ted line) and therapeutic lymph node
dissection for recurrence (RTLND)
(long dashed line).
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Multivariate analysis did not show
ELND to be a significant factor
determining prognosis. Univariate
analysis showed that patients hav
ing only LE had significantly poorer
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FIG. 3. Ten-year disease-specific survival rates according to level of invasion of
primary tumour. Solid bars = no ELND, dotted bars = ELND.
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survival, and multivariate analysis
showed this to be significant as well
(p = 0.0015).
Three subgroups of patients were
identified in the present series to
allow comparison of outcome in
patients who appeared to benefit
most from ELND in the University
of Sydney series, that is, males with
T3 trunk primaries and males and
females with T3 extremity prima
ries.4 Ten-year survival rates for
four groups of patients are shown
in Fig. 4. The groups were Univer
sity of Sydney patients and BCCA
patients who had ELND and Univer
sity of Sydney patients and BCCA
patients who did not have ELND.
Patient numbers for each of these
groups were 81, 19, 104 and 26
(T3, male, trunk); 55, 11, 61 and 4
(T3, male, extremity); 71, 41, 135
and 18 (T3, female, extremity). Sur
vival differences between the two
cohorts of BCCA patients — those
who had ELND and control — for

these specific sex and primary-site
groups were not significant (p —
0.1175). The numbers of patients in
the BCCA ELND groups were
small, especially male patients with
T3 extremity primary tumours. Sur
vival rates for all BCCA patients in
these categories were intermediate
between the University of Sydney
patients who did not have ELND
and those who did.
TLND
TLND was performed in 50 pa
tients at the time the primary tu
mour was diagnosed, and 36 (24
males and 12 females) had patho
logically positive nodes. Of these 36
patients, 12 had one positive node,
3 had two positive nodes, 12 had
three or more positive nodes and 9
had an unspecified number of posi
tive nodes. The median depth of the
primary tumour was 2.0 mm. Dis
ease recurred in 24 (67%) patients

90

with positive nodes, and median
survival was 2.7 years. The 10-year
survival rate was 45%.
RTLND
Of 525 clinical stage I patients
who did not have ELND, 119 (70
male and 49 female) had regional
lymph node recurrence. RTLND
was performed in 86 of these pa
tients. The median depth of the
responsible primaries in these pa
tients was 2.3 mm. The site distri
bution of these primary tumours
was 47% in the trunk, 21% in the
lower limb, 18% in the head and
neck and 14% in the upper limb.
Median time to regional lymph node
recurrence from primary treatment
was 1.4 years. For all RTLND pa
tients the median survival was 1.8
years from the date of recurrence
and 4.4 years from the date of
primary-tumour diagnosis. Ten-year
survival was 26%. Survival curves
for ELND-positive, TLND and
RTLND patients (Fig. 1) were not
significantly different (p = 0.82).

Discussion

—

—

M TRUNK

---------------“ “

—

—

M UL.LL

-----------------—

F UL.LL

T3 Subgroup
FIG. 4. Ten-year disease-specific survival rates in patients with T3 primary
malignant melanoma registered with BCCA and from University of Sydney, Sydney,
Australia, according to sex, site of primary tumour and whether or not ELND was
performed. Black bars = Sydney series, no ELND; dotted bars = BCCA series, no
ELND; cross-hatched bars = Sydney series, ELND; chequered bars = BCCA series,
ELND. M = male, F = female. UL = upper limb, LL = lower limb.

The role of ELND in the surgical
management of cutaneous malig
nant melanoma has been extensive
ly studied in both nonrandomized
and randomized clinical trials.1 Re
sults of two randomized trials did
not confirm the apparent benefits
seen in nonrandomized studies, but
reanalysis of the World Health Or
ganization (WHO) Trial suggested
that a subgroup of patients at inter
mediate risk of recurrence had a
superior survival with ELND.
The rationale for ELND is based
on the hypothesis that microscopic
metastases may disseminate sequen
tially from primary to regional
lymph nodes to distant sites and
that removal of nodal micrometastases will prevent the development
of incurable distant metastases.5
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The present study confirms the
high subsequent death rate in pa
tients with lymph node positive mel
anoma. We were unable to show,
however, that patients who had
pathologically positive nodes on
ELND had a better survival than
patients who underwent either
TLND or RTLND. We confirm the
finding of a previous report that the
number of positive nodes in patients
who had ELND is not significant
for survival.6 However, if the num
ber of positive nodes is expressed as
a percentage, some patients with
ELND (those in whom the depth of
invasion of the primary tumour was
less than 3.5 mm and less than 20%
of the nodes were positive) have a
good prognosis (i.e., 66% 7-year
survival).7
The yield (percent probability of
detecting lymph node metastases)
of ELND in this study (16%) is
within the range (4% to 25%) of
previous reports.48 Yields according
to depth of the primary tumour are
also consistent with those of previ
ous reports: 5% to 10% for T2, 17%
to 20% for T3 and 39% for T4
tumours.9 Interestingly, the series
with the lowest reported overall
yield (4%) showed the largest appar
ent treatment effect of ELND. Some
patients in the group with patho
logically negative nodes on ELND
may in fact be those who are likely
to benefit most from the procedure.
In the present series, the yield in
patients with the largest survival
difference (T2 primary tumours)
was only 7%. Most studies, includ
ing ours, have reported higher
lymph node relapse rates in patients
who did not have ELND than the
yield at ELND, suggesting that
some patients have lymph node me
tastases that are not identified at
ELND.8
Survival of BCCA patients who
had ELND has been compared with
BCCA control patients and patients
from the University of Sydney with
604
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melanoma of the trunk and extremi
ties. Although depth of invasion
among BCCA patients who had
ELND was significantly greater and
primary ulceration was more fre
quent than in concurrent BCCA
control patients, 10-year survival
rates were significantly better, espe
cially for T2 and Clark’s level IV
primary tumours. However, Clark’s
level IV primary tumours accounted
for 43% of T2 primaries, and, con
versely, T2 primaries accounted for
only 29% of Clark’s level IV prima
ry lesions.2 These figures suggest
that factors other than ELND con
tribute to the survival differences.
BCCA patients who had ELND had
more favourable primary sites, more
lower limb primaries and fewer
trunk and head-and-neck primaries.
In addition, ELND was performed
only when a single lymphatic drain
age area was present, not in pa
tients with midline or watershed
primary tumours.
The results of multifactorial anal
ysis in patients with clinical stage I
melanoma in our series showed that
ELND was not an independently
significant factor for survival. Nor
was there any significant benefit for
patients in the three groups of T3
primary melanomas who appeared
to benefit in the report from the
University of Sydney.4 The analysis
of survival after ELND according to
tumour depth showed the largest
difference in patients with T2 pri
mary tumours, a group for whom
we currently do not recommend
ELND.
The role of ELND in any sub
group of clinical stage I melanoma
remains uncertain. Ultimately, fur
ther prospective randomized trials
are required to define the therapeu
tic role of ELND, There are two
current prospective randomized tri
als addressing the role of ELND. An
American intergroup study has in
cluded patients with intermediate
thickness (1 to 4 mm) melanoma of

6, D EC E M B R E 1992

the trunk and extremities. The
WHO Melanoma Group is studying
trunk primary melanomas greater
than 2 mm thick.
Median survival rates for patients
with positive nodes on ELND and
TLND and patients who had
RTLND in the present series com
pare favourably with those of previ
ous reports.61011 However, all the
results confirm the need for new
treatments in patients with lymph
node positive melanoma.
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Clinical Performance of the Duromedics
Bileaflet Pyrolite Mechanical Prosthesis
W.R. Eric Jamieson, MD, FACC, FACS, FRCSC;* L. Conrad Pelletier, MD, FACS, FRCSC;t
Jose L. Pomar, MD$
The Duromedics (Baxter Healthcare Corp., Edwards CVS Div., Irvine, Calif.)
mechanical cardiac valvular prosthesis was implanted in 480 patients between 1984
and 1987 at the Montreal Heart Institute, the Hospital Clinic of Barcelona and the
teaching hospitals of the University of British Columbia. The mean age of the
patients was 52 years. The early mortality was 7.9% and the late mortality was 4.1%
per patient-year. The overall survival at 4 years for aortic valve replacement (AVR)
was 87.0% ± 3.7% and for mitral valve replacement (MVR) was 81.9% ± 2.9%. There
were 16 valve-related reoperations in 14 patients — for prosthetic valve endocarditis
in 9 patients, for thromboembolism in 1 patient and for nonstructural dysfunction in
4 patients. The freedom from thromboembolism at 3 and 4 years was 94.3% ± 3.1%
for AVR and 95.1% ± 1.8% for MVR. The freedom from prosthetic valve endocarditis
at 3 and 4 years was 95.3% ± 2.2% for AVR and 96.2% ± 1.6% for MVR. The
freedom from structural valve deterioration for all positions was 100%. The freedom
from reoperation at 4 years was 95.3% ± 2.1% for AVR and 92.3% ± 4.3% for MVR
and from valve-related death was 98.7% ± 1.3% for AVR and 96.2% ± 1.6% for MVR.
The freedom from all valve-related complications at 4 years was 87.7% ± 3.8% for
AVR and 85.7% ± 2.9% for MVR. Long-term evaluation of the Duromedics
prosthesis is required to determine the influence of documented structural valve
deterioration.

De 1984 a 1987, 480 patients ont re?u une prothese valvulaire cardiaque cardiaque
mecanique Duromedics (Baxter Healthcare Corp., Edwards CVS Div., Irvine, Calif.) a
l’lnstitut de cardiologie de Montreal, a THopital clinique de Barcelone ou aux
hopitaux d’enseignement de TUniversite de Colombie-Britannique. L’age moyen des
patients etait de 52 ans. La mortalite precoce fut de 7,9 % et la mortalite tardive de
4,1 % par annee-patient. La survie globale a 4 ans a ete de 87,0 % ± 3,7 % pour les
valvuloplasties aortiques (VA) et de 81,9 % ± 2,9 % pour les valvuloplasties mitrales
(VM). II y a eu 16 reinterventions valvulaires chez 14 patients — pour endocardite
prosthetique valvulaire chez 9 patients, pour thromboembolie chez 1 patient et pour
dysfonctionnement non structurel chez 4 patients. L’absence de thromboembolie
apres 3 et 4 ans a ete de 94,3 % ± 3,1 % pour les VA et de 95,1 % ± 1,8 % pour les
VM. L’absence d’endocardite prosthetique valvulaire apres 3 et 4 ans a ete de 95,3 %
± 2,2 % pour les VA et 96,2 % ± 1,6 % pour les VM. L’absence de deterioration
structurelle valvulaire a ete dans tous les cas de 100 %. L’absence de reoperation a
4 ans a ete de 95,3 % ± 2,1 % pour les VA et de 92,3 % ± 4,3 % pour les VM et,
l’absence de mortalite reliee aux valvules, de 98,7 % ± 1,3 % pour les VA et de
96,2 % ± 1,6 % pour les VM. L’absence de toutes complications valvulaires a 4 ans a
ete de 87,7 % ± 3,8 % pour les VA et de 85,7 % ± 2,9 % pour les VM. L’evaluation a
long terme des protheses Duromedics demeure necessaire afin de constater
Tinfluence de la deterioration structurelle valvulaire.

he valve-related complications
of mechanical valvular prostheses have been structural failure,
thromboembolism and thrombosis
and hemorrhage related to anti
coagulation management. Newer
mechanical valve designs have been
developed to reduce or eliminate
thromboembolism and thrombosis.
These valve designs have led to
isolated cases of structural failure
as has occurred with the B jorkShiley Convexo-Concave (Shiley
Inc., Irvine, Calif.) and Duromedics
(Baxter Healthcare Corp., Edwards
CVS Div., Irvine, Calif.) prostheses.1-8 The experiences with the
Duromedics mechanical prosthesis
at the Montreal Heart Institute, the
Hospital Clinic of Barcelona and the
teaching hospitals of the University
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of British Columbia have been com
bined to bring together an adequate
patient population to assess the
valve-related complications, espe
cially structural valve deterioration,
associated with the prosthesis.

There were 16 valve-related reop
erations in 14 patients (Table III).
These included replacement of five
aortic valve prostheses, replacement
of six mitral valve prostheses, re
placement of one tricuspid valve

embolic therapy, 15 of prosthetic
valve endocarditis, 2 of nonstructural dysfunction and no structural
valve deterioration. Nonstructural
dysfunction was due to periprosthetic leakage.

. Patient Population

T a b le 1

Patients

T y p e o f v a lv e r e p la c e m e n t, n o. o f p ts .

The Duromedics prosthesis was
implanted in 480 patients between
1984 and 1987 at three centres:
214 in Montreal, 141 in Barcelona
and 125 in Vancouver (Table I).
The mean age of the patients was
52.2 years (range from 14 to 76
years). There were 174 aortic valve
replacements (AVRs), 225 mitral
valve replacements (MVRs), 3 tri
cuspid valve replacements and 78
multiple valve replacements. The
total cumulative follow-up was 682
years, with a mean of 1.4 years
(AVR 246 years, MVR 315 years
and multiple valve replacements
116 years).

C ity

Vancouver
Montreal
Barcelona
Total

M it r a l

T r ic u s p id

M u ltip le

T o ta l

50
69
55

55
101
69

0
0
3

20
44
14

125
214
141

174

225

3

78

480

A o rtic

Results
The early mortality was 7.9% (38
patients). The mortality for AVR
was 5.2% (9 patients), for MVR was
8.0% (18 patients) and for multiple
valve replacement was 12.8% (10
patients). The late mortality was
4.1% per patient-year (28), ex
pressed as linearized occurrence
rate (AVR 2.0%, MVR 4.8% and
multiple valve replacement 6.9%).
The overall patient survival for the
three centres is illustrated in Fig. 1.
The survival rate for AVR was
87.0% ± 3.7% at 3 and 4 years and
for MVR was 81.9% ± 2.9% at 3
and 4 years.
The linearized occurrence rate
for valve-related complications was
5.8% per patient-year (47 events)
(Table II). There were 19 episodes
of thromboembolism, 11 of he
morrhage related to antithrombo606

FIG. 1. Patient survival.
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T a b le II.

V a lv e -r e la te d
c o m p lic a tio n s

Thromboembolism
Hemorrhage related
to antithromboembolic therapy
Prosthetic valve
endocarditis
Nonstructural
dysfunction
Structural valve
deterioration
Total

Valve-Related Complications

T y p e of v a lv e re p la c e m e n t,
no. o f e p is o d e s
A o rtic

M it r a l

T ric u s p id

M u ltip le

T o ta l

5

8

0

6

19

3

8

0

0

11

5

6

0

4

15

0

1

0

1

2

0

0

0

0

0

13

23

0

11

47

DIJROMEDICS CARDIAC VALVE PROSTHESIS

prosthesis and four replacements of
multiple valve prostheses. Of the 14
reoperations, 9 were for prosthetic
valve endocarditis, 1 was for throm-

boembolism and 4 were for nonstructural dysfunction. There were
no cases of structural valve deterio
ration.

Table III. Causes and Number of Valve-Related
Reoperations (VRRs)
Type of valve replacement,
no. of pts. (reoperations)
Cause of VRR

Aortic

Mitral

Thromboembolism
Hemorrhage related
to antithromboembolic therapy
Prosthetic valve
endocarditis
Nonstructural
dysfunction
Structural valve
deterioration

0

0

Tricuspid
1

Multiple
0

Total
1

0

0

0

0

0

3

3

0

3

9

1

2

0

1

4

0

0

0

0

Total

4 (5 )

5 (6 )

1 (1)

4 (4 )

14 (16)

Multiple

Total

0

Table IV. Causes and Number of Valve-Related
Deaths (VRDs)
Type of valve replacement,
no. of pts. (total deaths)
Cause of VRD

Aortic

Mitral

Thromboembolism
Hemorrhage related
to antithromboembolic therapy
Prosthetic valve
endocarditis
Nonstructural
dysfunction
Structural valve
deterioration

0

1

0

0

1

1

3

0

0

4

0

2

0

2

4

0

0

0

0

0

0

0

0

0

0

Total

1 (14)

6 (33)

0 (1 )

2 (1 8 )

9 (66)

FIG. 2. Freedom from thromboembolism.

Tricuspid

There were 66 deaths, early and
late, with only 9 being valve-related
(Table IV). One was from thrombo
embolism, four were from hemorrh
age related to antithromboembolic
therapy and four were from pros
thetic valve endocarditis.
The valve-related complications
and composites are illustrated in
Figs. 2 to 7 and summarized in
Table V for aortic, mitral and multi
ple valve replacements. Freedom
from thromboembolism ranged
from 95.1% ± 1.8% for MVR at
both 3 and 4 years to 88.5% ±
4.6% for multiple valve replacement
also at 3 and 4 years (Fig. 2).
Freedom from prosthetic valve en
docarditis ranged from 96.2% ±
1.6% for MVR at both 3 and 4 years
to 84.1% ± 10.8% for multiple
valve replacement at 4 years (Fig.
3). Freedom from reoperation
ranged from 96.3% ± 1.7% for
MVR at 3 years to 77.2% ± 13.2%
for multiple valve replacement at 4
years (Fig. 5). Freedom from valverelated death ranged from 98.7% ±
1.3% for AVR at both 3 and 4 years
to 94.4% ± 3.2% for multiple valve
replacement at 3 and 4 years (Fig.
6). Freedom from valve-related com
plications ranged from 87.7% ±
3.8% for AVR at 3 and 4 years to
79.8 ± 5.4% for multiple valve

FIG. 3. Freedom from prosthetic valve endocarditis.
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replacement at 3 and 4 years (Fig.
7).

Discussion
The major concerns with me
chanical valvular prostheses have
been durability, thrombosis, throm
boembolism and hemolysis.1-13 The
characteristics of these prostheses
are summarized in Table VI. There
has been limited documentation on
the overall experience with the Duromedics prosthesis. In 1987, Klepetko and associates14 reported sat

isfactory clinical performance in
400 patients.
Structural valve deterioration has
been a concern only with the
Bjork-Shiley Convexo-Concave me
chanical prosthesis and the Duromedics mechanical prosthesis.1-8
The clinical performance of the Duromedics mechanical prothesis, im
planted between 1984 and 1987 at
three centres, is under continuing
evaluation to determine the influ
ence of altered durability. This pros
thesis was voluntarily removed from
the market by the manufacturer in
1987 after structural failure was

identified in several patients.121415
Of the early failures three have been
documented in the surgical litera
ture.12 In 1989, Deuvaert and asso
ciates1 reported a case of leaflet
embolization causing pulmonary
edema. The patient was managed
initially with thrombolytic therapy
with a provisional diagnosis of valve
thrombosis. The patient subse
quently had reoperation for struc
tural failure but died of sepsis. In
1989, Klepetko and associates2 re
ported two cases of leaflet fracture
managed with successful reopera
tion. One valve had a housing frac-

Years

FIG. 4. Freedom from structural valve deterioration.

FIG. 5. Freedom from reoperation.

FIG. 6. Freedom from valve-related death.

FIG. 7. Overall freedom from valve-related complications.
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Australia, Canada, Europe and
South Africa. There were 52 outlet
strut fractures, a rate of 5.2% for
the 70° valve and 1.6% for the 60°
valve in the mitral position with
sizes 29 to 33 mm. The strut
fracture occurred at the smaller
outlet, at the site of the junction
weld. Casarotto and associates6 re
ported sudden fatal malfunction
with outlet fracture and disc embol
ization, and Larrieu, Puglia and
Allen8 reported patient survival
from strut fracture and emboliza
tion.
Several reports have compared
the hemodynamic and clinical per
formance of the Duromedics pros

ture with tissue ingrowth and a
recent transverse leaflet fracture,
and the other valve had a leaflet
fracture near the pivot mechanism.
No cases of structural valve failure
were identified in our series. The
manufacturer is conducting an ex
tensive evaluation into the cause of
the structural failure in an attempt
to correct it.
Strut fracture of the outlet strut
of the Bjork—Shiley 60° and 70°
Convexo-Concave prosthesis has
been extensively reported.3-9 Ostermeyer and colleagues3 reported on
the incidence of strut fractures ob
served in over 4000 prostheses im
planted between 1980 and 1983 in

thesis with that of various other
m echanical p ro th e se s.111216-18
Chandran and colleagues16 studied
the in vitro performance of the
Duromedics and St. Jude Medical
(St. Jude Medical Inc., Irvine, Calif.)
mechanical prostheses. The Du
romedics had slightly greater transvalvular pressure difference and a
smaller projected valve orifice than
the St. Jude Medical prosthesis,
whereas the percentage regurgita
tion was smaller with the Durome
dics prosthesis than with the St.
Jude Medical prosthesis. Yoganathan and colleagues17 determined
low-pressure gradients and effective
orifice areas in the Bjork-Shiley

Table V. Summary of Valve-Related (VR) Complications and Composites (% Freedom at 3 and 4 Years)
Type of valve replacement, %
Aortic

VR composite
complications

4 yr

3 yr

Thromboembolism
Prosthetic valve
endocarditis
Structural valve
dysfunction
Reoperation
VR death
VR complications

Multiple

Mitral
3 yr

4 yr

3 yr

4 yr
88.5 ± 4.6

94.3 ±3.1

94.3 ±3.1

95.1 ± 1.8

95.1 ± 1.8

88.5 ± 4.6

95.3 ± 2.2

95.3 ± 2.2

96.2 ± 1.6

96.2 ± 1.6

95.3 ± 2.7

84.1 ± 10.8

100
95.3 ±2.1
98.7 ±1.3
87.7 ± 3.8

100
95.3 ± 2.1
98.7 ± 1.3
87.7 ± 3.8

100
96.3 ± 1.7
96.2 ± 1.6
85.7 ± 2.9

100
92.3 ± 4.3
96.2 ± 1.6
85.7 ± 2.9

100
91.2 ± 3 .9
94.4 ± 3.2
79.8 ± 5.4

100
77.2 ± 13.2
94.4 ± 3.2
79.8 ± 5.4

Table VI. Characteristics of Mechanical Prostheses
Characteristic

Prothesis
Starr-Edwards

Opening
angle,0 Radiopacity

Orifice
construction

Occluder
(leaflet)

Occluder
retention

Machined
Haynes
Cobaltchromium

Siliconic
Ball
Pyrolitic
Carbon
monoleaflet
Pyrolitic
Carbon
monoleaflet
Pyrolitic
Carbon
monoleaflet
Pyrolitic
Carbon
monoleaflet
Pyrolitic
Carbon
bileaflet
Pyrolitic
Carbon
bileaflet

Metallic
cage
Integral
struts

Excursion of Backflow
cage
Rotation and Low-velocity
translation
backflow

None

Nonrotatable

—

None

Nonrotatable

60-70

Integral
struts

Rotation and Low-velocity
translation
backflow

None

Rotatable

70

Integral
struts

Rotation and Low-velocity
translation
backflow

None

Nonrotatable

80

Central guide Rotation and Low-velocity
titanium
translation
backflow

None

Rotatable

70-75

Disc

Pivot guards
(raised)

None

Nonrotatable

85

Leaflets
(3-axis
views)
Housing
and
leaflets

Bjork-Shiley
ConvexoConcave
Bjork-Shiley
Monostrut

Cobaltchromium

Omniscience

Titanium

Medtronic—Hall Titanium
St. Jude
Medical

Pyrolitic
carbon

Duromedics

Pyrolitic
carbon

Pivot hinge
housing

Occluder
(motion)

Housing
rotation
(within
sewing ring)

Rotation

Retrograde
washing

Relatively
high-velocity
backflow
Rotation and Relatively
translation
high-velocity
backflow

Orifice
reinforcement

Metallic band Mitral
prothesis
rotatable

77—Aortic
73—Mitral

Cage

Disc
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Monostrut (Shiley Inc., Irvine, Ca
lif.), Omniscience (Medical Inc.) and
Duromedics prostheses that were
comparable to the Medtronic-Hall
(Medtronic Heart Valves, Minneapo
lis) and St. Jude Medical prostheses.
They predicted that these newer
prostheses would not eliminate
thrombosis, thromboembolism and
hemolysis. Heiligor, Geks and Mittermayer18 found that the Durome
dics prosthesis had superior in vitro
performance when compared with
the Bjork-Shiley Monostrut pros
thesis.
The clinical performance docu
mentation of various mechanical
prostheses provides contradictory
and confusing information. Kuntze
and associates12 found that the inci
dence of thromboembolism was
higher with the Duromedics pros
thesis than with the Medtronic-Hall
and Bjork-Shiley prostheses. Mikaeloff and colleagues13 found more
early deaths, valve thrombosis,
valve dysfunction and sudden late
deaths with the Bjork-Shiley Mo
nostrut than with the St. Jude
Medical and the Starr-Edwards
(Baxter Healthcare Corp., Edwards
CVS Div., Irvine, Calif.) prostheses.
The Starr-Edwards prosthesis was
associated with more peripheral em
boli than the other two mechanical
prostheses. In the present study the
Duromedics prosthesis performed
with early and late death rates and
clinical performance characteristics
comparable to those of standard
prostheses. We identified no cases
of valvular thrombosis or structural
failure. Lindblom and associates19
had similar results with the BjorkShiley Monostrut prosthesis, with
no mechanical failures, no thrombo
sis and no fatal thromboembolism
when the patient was receiving an
ticoagulants.
The complication of valvular
thrombosis has been a major con
cern with some mechanical pros
theses. 20~23 There were no docu
610

mented cases of thrombosis in our
series with Duromedics prostheses.
The management of valvular throm
bosis has been varied. Ayuso and
associates22 performed thrombec
tomy on 7 of 12 thrombosed
Bjork-Shiley prostheses. In a series
of over 900 patients with BjorkShiley prostheses, Daenen and as
sociates21 reported that 12 of 13
patients survived reoperation for
thrombosis. The reoperation rate in
patients receiving anticoagulants
was 0.63% per patient-year. Massad
and colleagues20 reported an inci
dence of 3.9% thrombosed valves in
a series of patients who had re
ceived a mechanical valve and found
that inadequate anticoagulation was
the causative factor. In that series
three mechanical valves thrombosed
during pregnancy and required me
chanical declotting. That procedure
resulted in two abortions and one
cesarean section. Ryder and col
leagues23 had 19 cases of throm
bosed obstructed Bjork-Shiley
prostheses in over 800 patients for
an overall incidence of 0.46% per
patient-year (0.79 for mitral pros
theses, 0.18 for aortic prostheses
and 0.63 for tricuspid prostheses).
Graver, Gelber and Tyras24 reported
on thrombolytic therapy for throm
bosed St. Jude Medical prostheses
in 58 patients treated on 62 occa
sions. The thrombosis had caused
critical hemodynamic compromise.
There have been a few other
complications reported with me
chanical prostheses. Montero and
colleagues25 and Williams, Pluth
and Orszulak26 reported on disc
suture interference and chordae
disc interference resulting in stick
ing of the disc occluder in the
closed position. This complication
must be prevented or recognized
and treated to avoid unnecessary
death from insertion of mechanical
prostheses.
Our experience with the Durome
dics mechanical valve has been sat

JCC, VOL 35, NO 6, DECEMBRE 1992

isfactory, but continued evaluation
is necessary to determine the influ
ence of potential structural valve
deterioration.
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Acute Mesenteric Ischemia:
an Aggressive Diagnostic and Therapeutic
Approach. 1991 Roussel Lecture
Ronald N. Kaleya, MD;* Scott J. Boley, MDf
The incidence of acute mesenteric ischemia (AMI) has increased substantially over
the last few decades. Death rates of 70% to 90% have been reported for traditional
methods of diagnosis and therapy. Use of an aggressive radiologic, pharmacologic
and surgical approach has decreased the mortality and morbidity associated with
AMI. The cornerstones of management are prompt diagnosis by the earlier and more
liberal use of angiography and the incorporation of intra-arterial papaverine in the
treatment of both occlusive and nonocclusive AMI. Widespread adoption of this
protocol in patients at risk might improve the overall results of treatment of AMI.
L’incidence de l’ischemie mesenterique aigue (IMA) a augmente sensiblement au
cours des dernieres decennies. Une mortalite de 70 %a 90 %a ete signalee en
rapport avec les methodes classiques de diagnostic et de traitement. L’utilisation
d’une approche chirurgicale, pharmacologique et radiologique agressive a permis de
reduire la mortalite et la morbidity reliees a 1’IMA. La pierre angulaire de ce
traitement repose sur un diagnostic rapide grace a l’utilisation precoce et plus
liberate de l’angiographie, et a l’addition de la papaverine intra-arterielle au
traitement des IMA occlusives aussi bien que non occlusives. L’emploi elargi de ce
protocole chez les patients a risque pourrait ameliorer les resultats therapeutiques
dans LIMA.

interruption or diminu
A brupt
tion of blood flow to the small

intestine or the right colon may
lead to acute mesenteric ischemia
(AMI). The term AMI is used to
cover a wide spectrum of bowel

injury ranging from reversible alter
ations in bowel function to trans
mural necrosis of the bowel wall.
The clinical presentation varies, de
pending on the degree and duration
of the ischemia and the length of
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bowel involved. Clinical and animal
research has provided a better un
derstanding of the clinical syn
dromes and pathophysiological
basis of AMI and has led to the
development of an effective multi
disciplinary approach to the patient
with suspected AMI.
Mesenteric ischemia can be
broadly classified into acute and
chronic forms and into conditions
of venous or arterial origin (Fig. 1).
In the chronic forms, bowel viability
is not compromised, but blood flow
is inadequate to support the func
tional demands of the intestine; in
the acute forms, bowel viability is
threatened. Atherosclerotic narrow
ing or occlusion of the mesenteric
arteries, producing intestinal angina
and gradually evolving mesenteric
venous thrombosis are the common
forms of chronic ischemia. AMI is
much more common than the
chronic form, and ischemia of ar
terial origin is much more frequent
than venous disease. The arterial
forms of AMI include superior mes
enteric artery embolism, nonocclu
sive mesenteric ischemia (NOMI),
superior mesenteric artery (SMA)
thrombosis and cases of focal seg
mental ischemia resulting from
local atherosclerotic emboli or vasculitides. Acute mesenteric venous
thrombosis and focal segmental
ischemia caused by strangulationobstruction of the small intestine or
by localized venous thrombosis
comprise the venous forms of AMI.
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Patient Population
AMI has been diagnosed increas
ingly frequently in the past 25
years. The exact incidence of AMI is
difficult to determine, but in our
large metropolitan medical centre
AMI is responsible for approximate
ly 0.1% of all admissions. The in
creasing incidence has been attri
buted to the aging of the popula
tion, because AMI occurs predomi
nantly, but not exclusively, in geri
atric patients, especially those with
cardiovascular and systemic disor
ders. Similarly, the widespread use
of coronary and surgical intensive
care units and other extraordinary
means of cardiopulmonary support
has salvaged patients who previous
ly died rapidly of cardiovascular
conditions, only to have AMI devel
op as a later consequence of their
primary disease.
SMA embolism and nonocclusive
mesenteric ischemia together are
responsible for 70% to 80% of cases
of AMI as reported in most recent
series.1 A decline in the incidence of
nonocclusive ischemia has been
noted, possibly due to the increas
ing use of systemic vasodilators,
such as the calcium-channel block
ing agents and nitrates, in coronary
intensive care units. These agents
may protect the mesenteric vascular
bed from vasospasm and decrease
the period of profound hypotension
associated with acute myocardial
events. Further, the more common

use of left ventricular assist devices
in the treatment of cardiogenic
shock has decreased the period of
profound hypotension associated
with left ventricular failure and,
presumably, has attenuated its ef
fect on the mesenteric circulation.

Causes of AMI (Table I)
Arterial

SMA embolism is responsible for
40% to 50% of episodes of AMI.
The emboli usually originate from a
left atrial or ventricular mural
thrombus. The thrombus embolizes
after being dislodged or fragmented
during a period of arrhythmia.
Many patients with SMA embolism
have a history of peripheral artery
embolism, and approximately 20%
have synchronous emboli in other
arteries. Emboli to the SMA tend to
lodge at points of normal anatomi
cal narrowing, usually immediately
distal to the origin of a major
branch. In 10% to 15% of patients,
the emboli lodge peripherally in
branches of the SMA or in the SMA
itself distal to the origin of the
ileocolic artery. The embolus may
completely occlude the arterial lu
men, but often only partially oc
cludes the vessel.
Experimental studies suggest
that, initially, the collateral circula
tion can adequately maintain intesti
nal viability after most acute SMA

Mesenteric vascular diseases
Acute

Chronic

“1

i
Arterial

r

Superior
mesenteric
artery
embolism

1

i

Superior
mesenteric
artery
thrombosis

Venous

1

1
Nonocclusive
mesenteric
ischemia

i

Mesenteric
venous
thrombosis

FIG. 1. Causes of acute mesenteric ischemia (AMI).
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occlusions, but after a period of
partial occlusion and diminution of
blood flow distal to the embolus,
vasoconstriction develops in arteries
both proximal and distal to the
embolus. This vasoconstriction can
sufficiently impair the collateral
blood flow to the SMA and its
branches distal to the embolus to
cause or exacerbate an ischemic
injury.
NOMI causes 20% to 30% of
episodes of AMI and is thought
to result from splanchnic vasocon
striction initiated by a period of
decreased cardiac output associated
with hypotension caused by ar
rhythmias, cardiogenic shock, hy
povolemic shock or vasoactive med
ications. The vasoconstriction may
persist even after the precipitating
cause has been eliminated or cor
rected. Predisposing factors for
NOMI include acute myocardial inTable I. Causes of Acute Mesenteric
Ischemia (AMI)
Hemodynamic causes
Cardiogenic shock
Hemorrhagic shock
Arrhythmia
Occlusive causes
Inferior or superior mesenteric artery
emboli - minor or major
Cholesterol emboli syndrome, especially
after angiography or angioplasty
Inferior mesenteric artery thrombosis
Traumatic causes
Blunt or penetrating trauma
Ruptured ectopic pregnancy
Aneurysmectomy
Aortoiliac reconstruction
Gynecologic operations
Colonic bypass procedures
Lumbar aortography
Colectomy with high ligation of the inferior
mesenteric artery
Strangulated hernia
Drug-induced causes
Digitalis
Oral contraceptives
Cocaine
Systemic causes
Periarteritis nodosa
Systemic lupus erythematosus
Rheumatoid arthritis
Necrotizing arteritis
Thromboangiitis obliterans
Polycythemia vera
Parasitic infestation

ACUTE MESENTERIC ISCHEMIA

farction, congestive heart failure,
aortic insufficiency, hepatic diseas
es, renal diseases, especially in pa
tients requiring hemodialysis,2*3 and
major cardiac or intra-abdominal
operations. Frequently, a more im
mediate precipitating cause, such as
acute pulmonary edema, cardiac ar
rhythmia or shock is present, al
though the consequent intestinal
ischemia may not become manifest
until hours or days later.
SMA thrombosis occurs at areas
of severe atherosclerotic narrowing,
most often at the origin of the
SMA. The acute ischemic episode is
commonly superimposed on chronic
mesenteric ischemia, hence approxi
mately 20% to 50% of these pa
tients have a history of abdominal
pain with or without evidence of
malabsorption and weight loss dur
ing the weeks to months preceding
the acute episode. Additionally,
most patients with SMA thrombosis
have severe and diffuse atheroscle
rosis with a history of coronary,
cerebrovascular or peripheral arteri
al insufficiency.
Venous

Approximately 2 patients per
100 000 admitted to our institution
have had operative or pathological
confirmation of mesenteric venous
thrombosis. This represents less
than 5% of all cases of AMI. Al
though a review of the literature
suggested a male predominance of
up to 1.5:1,45 a review of our
experience showed no such prefer
ence. In the literature, the mean
age was 48 years, whereas at our
institution it was 60 years. We
attributed these differences to the
higher proportion of geriatric pa
tients seen at our medical centre
compared with most other institu
tions.
Many conditions have been asso
ciated with mesenteric venous
thrombosis. Although all of the

causes listed in Table I have been
implicated in patients with mesen
teric venous thrombosis, in 20% to
35% of patients no contributing or
associated factors has been identi
fied. Many of the cases cited in
retrospective reviews, however,
were reported before hematologic
diseases such as antithrombin III,
protein C and protein S deficiencies
were described. It is expected that
the number of cases of mesenteric
venous thrombosis in which no
cause can be found will decrease as
other causes are uncovered and
tests for those that have already
been identified are introduced.
Oral contraceptive-related mesen
teric venous thrombosis accounted
for about 9% of females in our
series and approximately 4% of our
total study population. This finding
was corroborated by Abdu, Zakhour
and Dalis,5 who reported a 5% inci
dence in their study. There was,
however, an 18% incidence in the
female population they reviewed.
The differences in these two series
possibly reflect the older population
seen at our institution. In addition,
there has been a spate of isolated
case reports relating oral contracep
tives to mesenteric venous thrombo
sis, and these may skew the compo
sition of cases reported in literature
reviews.

Collateral Circulation and
Mesenteric Vasoconstriction
The intestines are protected from
ischemia by their abundant collater
al circulation. Communications be
tween the celiac, superior mesenter
ic and inferior mesenteric vascular
beds are numerous, and it has be
come axiomatic that at least two of
these vessels must become compro
mised to produce symptomatic
chronic intestinal ischemia.
Collateral flow around occlusions
of smaller arterial branches in the

mesentery of the small intestine and
right colon is made possible by the
branching primary, secondary and
tertiary arcades. Within the bowel
wall is a network of communicating
submucosal vessels that can main
tain the viability of short segments
of intestine where the extramural
arterial supply has been compro
mised.
Collateral pathways open immedi
ately upon occlusion of a major
vessel in response to arterial hypo
tension distal to the obstruction.
Increased blood flow through the
collateral pathways continues as
long as the pressure in the vascular
bed distal to the obstruction re
mains below the systemic pressure.
If, however, vasoconstriction devel
ops in the distal arterial bed, the
arterial pressure rises due to in
creased resistance, which ultimately
impairs collateral flow to the depen
dent segment.
Despite adequate collateral vas
culature in most cases, acute inter
ruption or dimunition of blood flow
in the mesenteric circulation caused
by emboli or hypotension results in
intestinal ischemia secondary to
persistent vasospasm. A decrease in
SMA flow initially produces local
mesenteric vascular responses that
tend to maintain intestinal blood
flow, but if the diminished flow is
prolonged, active vasoconstriction
develops and may persist even after
the primary cause of decreased flow
is corrected. Boley and associates6
have shown that after a 50% reduc
tion in SMA blood flow in anesthe
tized dogs, the mesenteric arterial
pressure in the peripheral mesenter
ic arteries fell to 49% of mean
control values. When the SMA flow
was maintained at 50% of normal,
the mesenteric arterial pressure re
turned to control values within 1 to
6 hours, and the celiac flow, which
had initially increased, fell to con
trol levels. The increased vascular
resistance caused by vasoconstric-
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tion ultimately resulted in decreased
collateral perfusion from the celiac
and inferior mesenteric systems. If
the flow restrictor was removed
from the SMA as soon as the
mesenteric arterial pressure rose to
control values, the flow through the
SMA also returned to normal. How
ever, if the SMA occlusion was
maintained for 30 to 240 minutes
after the mesenteric arterial pres
sure had returned to control levels,
the flow in the SMA never returned
to normal. It remained at 30% to
50% of control levels because of
persistent arterial vasoconstriction
despite the removal of the SMA
flow restrictor. This decreased flow
continued for up to 5 hours of
observation but could be corrected
by direct infusion of papaverine into
the SMA. In this manner, mesenter
ic vasoconstriction plays a signifi
cant role in the development of
ischemia, both in the acute occlu
sive and nonocclusive arterial
forms.
When papaverine was infused
during the 50% flow restriction, the
mesenteric arterial pressure re
mained low throughout 4 hours of
observation and the SMA flow re
turned to normal upon release of
the obstruction. On the basis of
these observations, the use of intra
arterial papaverine infusions is rec
ommended in the management of
both the occlusive and nonocclusive
forms of AMI. Papaverine given
intra-arterially is also recommended
for some patients with the venous
forms of mesenteric vascular diseas
es because venous thrombosis has
been shown, experimentally, to
cause arterial spasm.7
In NOMI it was presumed that
the bowel injury occurred during
the period of diminished cardiac
output or hypotension and that
with correction of the cardiovascu
lar problems the mesenteric blood
flow would return to normal. This
simplistic concept has been contra
616

dicted by operative findings of per
sistent bowel ischemia when no
arterial or venous obstruction is
found and cardiac function has been
optimized. It is known that in pa
tients with NOMI, the onset of
abdominal signs and symptoms
caused by intestinal ischemia may
actually begin after the correction
of the primary systemic problem.
This paradox can be explained by
the experimental observations that
an episode of low mesenteric flow,
as short as 2 hours in duration, can
produce mesenteric ischemia as a
result of vasoconstriction and that
the vasoconstriction and ischemia
may continue after correction of the
initiating problem.
The end result of an ischemic
episode depends on many factors.
Thus, the extent of intestinal injury
is a function of the following: (a)
the state of the systemic circula
tion; (b) the degree of functional or
anatomic compromise; (c) the num
ber and calibre of vessels affected;
(d) the response of the vascular bed
to diminished perfusion; (e) the na
ture and capacity of the collateral
circulation to supply the needs of
the dependent segment of bowel; (f)
the duration of the insult; and (g)
the metabolic needs of the depen
dent segment as dictated by its
function and bacterial population.
Because vasospasm may persist
even after the initial cause of the
ischemia is corrected, bowel injury
continues unless the vasospasm is
relieved. An aggressive radiologic
and surgical approach to these dis
eases targets both the cause and
the persistent vasospasm.
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Diagnosis and Management
Signs and Symptoms

Early identification of AMI re
quires acute awareness by the clini
cian in patients having significant

risk factors for this disease. AMI
occurs most frequently in patients
over 50 years of age who have
chronic heart disease and long
standing congestive heart failure,
especially those poorly controlled
with diuretics or digitalis. Cardiac
arrhythmias, commonly atrial fibril
lation, recent myocardial infarction
or hypotension due to burns, pan
creatitis or hemorrhage all predis
pose the patient to AMI. Previous
or synchronous arterial embolism
increases the likelihood of acute
SMA embolism. The development of
sudden abdominal pain in a patient
with any or all of these risk factors
should suggest the diagnosis of
AMI.
Acute abdominal pain varying in
severity, nature and location occurs
in 75% to 98% of patients with
intestinal ischemia. A history of
postprandial abdominal pain in the
weeks to months preceding the
acute onset of severe abdominal
pain occurs in only the small frac
tion of patients with AMI caused by
acute thrombosis superimposed on
chronic mesenteric ischemia, as in
the case of SMA thrombosis. In
early AMI, the pain experienced by
the patient is markedly out of pro
portion to the physical findings.
Therefore, sudden severe abdominal
pain accompanied by rapid and
often forceful bowel evacuation, es
pecially with minimal or no abdomi
nal signs, strongly suggests an
acute arterial occlusion in the mes
enteric circulation.
Unexplained abdominal disten
sion or gastrointestinal bleeding
may be the only indications of acute
intestinal ischemia, especially in no
nocclusive disease, because pain is
absent in up to 25% of these pa
tients. Patients surviving cardiopul
monary resuscitation in whom cul
ture-proven bacteremia and diarrhea
without abdominal pain develop
should be suspected of having
NOMI.8 Distension, although absent
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early in the course of mesenteric
ischemia, is often the first sign of
impending intestinal infarction. The
stool contains occult blood in 75%
of patients, and this bleeding may
precede any other symptom of isch
emia. Right-sided abdominal pain
associated with the passage of ma
roon or bright red blood in the
stool, though characteristic of co
lonic ischemia, also suggests the
diagnosis of AMI.
Although there are no abdominal
findings early in the course of intes
tinal ischemia, as infarction devel
ops, increasing tenderness, rebound
tenderness and muscle guarding re
flect the progressive loss of intesti
nal viability and the presence of
transmural gangrene. Significant
abdominal findings strongly indi
cate the presence of infarcted bow
el. Nausea, vomiting, hematochezia,
hematemesis, massive abdominal
distension, back pain and shock are
other late signs that often indicate
compromise of bowel viability.
Laboratory Signs

Leukocytosis exceeding 15.0 X
109/ L occurs in approximately 75%
of patients with AMI, whereas
about 50% present with a metabolic
acidemia. Elevated levels of serum
amylase, phosphatase and other
specific enzymes as well as perito
neal fluid intestinal alkaline phos
phatase and inorganic phosphate
have been described, but the sensi
tivity and specificity of these mark
ers of intestinal ischemia have not
been established. Leukocytosis out
of proportion to the clinical find
ings, elevated hemoglobin and he
matocrit levels, indicating hemoconcentration as a result of fluid loss
into the bowel and peritoneal cavity,
and blood-tinged peritoneal fluid,
often with an elevated amylase con
tent, are not specific for AMI but
suggest advanced intestinal necrosis
and sepsis.

Radiologic Signs

Plain abdominal radiographs are
usually normal in early mesenteric
ischemia, before infarction occurs.
Late in the course of the disease,
formless loops of small intestine or
small intestinal “thumbprinting”
can suggest the diagnosis of AML
Less commonly, isolated “thumb
printing” of the right colon may be
the only indication of AML The
finding of colonic ischemia confined
to the right colon may be the result
of disease in the main SMA rather
than simply interference of colonic
blood flow.
Other Diagnostic Modalities

Laparoscopy9 may be useful in
patients whose clinical status pre
cludes angiography. However, lapa
roscopic examination of the bowel
is limited to the serosal surface,
making the procedure unreliable for
diagnosing early mucosal necrosis
at a time when the serosa still
appears relatively normal.
Duplex scanning has been of
some value in identifying portal and
superior mesenteric venous throm
bosis and, in a few patients, SMA
occlusion. Computed tomography
has also been used to identify arteri
al and venous thromboses as well as
ischemic bowel but only in the late
stages of the disease.
Angiography

Historically, angiography was
limited to identifying arterial occlu
sions by embolism or thrombosis.
Currently, selective angiography is
the mainstay of diagnosis and initial
treatment of both occlusive and
nonocclusive forms of AMI.10 Four
reliable angiographic criteria for the
diagnosis of mesenteric vasocon
striction,11 the cause of NOMI, have
been identified: (a) narrowing of the
origins of multiple branches of the

SMA; (b) alternate dilatation and
narrowing of the intestinal branches
(string of sausage sign); (c) spasm
of the mesenteric arcades; and (d)
impaired filling of intramural ves
sels.
While mesenteric vasoconstric
tion occurs in hypotensive patients
and in those with pancreatitis, its
presence in patients with suspected
intestinal ischemia who are not in
shock do not have pancreatitis and
are not receiving vasopressors is
diagnostic of NOMI. Therefore, if
angiography is performed suffi
ciently early in the disease, patients
with occlusive and nonocclusive
AMI can be identified before bowel
infarction develops, and before clini
cal and radiologic signs of infarc
tion make the diagnosis of intesti
nal ischemia evident.
An Aggressive Diagnostic and
Therapeutic Approach to Suspected
AM I

Patients over 50 years of age
with any of the previously enume
rated risk factors for AMI, who
experience sudden onset of abdomi
nal pain that is severe enough to
call it to the attention of a physician
and that lasts for more than 2
hours should be suspected of hav
ing AML These patients should be
managed according to an aggres
sive radiologic and surgical algo
rithm (Figs. 2 and 3). Less absolute
indications for inclusion into this
protocol include unexplained ab
dominal distension, colonoscopic
evidence of isolated right-sided co
lonic ischemia or acidosis without
an identifiable cause. Because the
presence of diagnostic clinical or
nonangiographic radiologic signs
usually indicates irreversible intesti
nal injury, broad selection criteria
are essential if early diagnosis and
successful treatment are to be
achieved. Some negative studies
must be accepted so as to identify
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and salvage patients who do have
AMI.
General Principles o f Management
Initial treatment is directed to
correcting the predisposing or pre
cipitating causes of the ischemia.
Relief of acute congestive heart
failure and correction of hypoten
sion, hypovolemia and cardiac ar
rhythmias must precede any diag
nostic evaluation. Efforts to im
prove mesenteric blood flow will be
futile if low cardiac output, hypovo
lemia or hypotension persist. Fre
quently, patients with AMI are sep
tic, having a very low systemic
vascular resistance and sequestra
tion of fluid into the “third space.”
Optimal cardiac performance can
best be achieved under these cir
cumstances with the aid of a SwanGanz catheter, using serial cardiac
profiles to ensure maximal systemic
perfusion. After resuscitation is ac
complished, plain films of the abdo
men are obtained to exclude other
identifiable causes of abdominal
pain, such as a perforated viscus
with free intraperitoneal air. A nor
mal plain film does not exclude
AMI; indeed, ideally patients will be
studied before radiologic signs are
present because such findings indi
cate the presence of infarcted bow
el. If no alternative diagnosis is
made on the basis of the plain
abdominal films, selective SMA an
giography is performed immediate
ly. From the angiographic findings
and the presence or absence of
peritoneal signs, the patient is treat
ed according to the algorithms in
Figs. 2 and 3.
Even when the decision to oper
ate has been made on clinical
grounds, a preoperative angiogram
must be obtained to manage the
patient properly at celiotomy. More
over, relief of mesenteric vasocon
striction is essential to treat the
emboli and thromboses as well as
618

the nonocclusive “low flow” states.
Intra-arterial infusion of papaverine
though an angiography catheter
placed percutaneously in the origin
of the SMA is the best method for
relief of mesenteric vasoconstriction
pre- and postoperatively. Papaverine
is infused at a constant rate of 30
to 60 mg/h with an infusion pump.

Although almost all of the papaver
ine infused into the mesenteric cir
culation is cleared during its pas
sage through the liver, under some
circumstances this rate of delivery
may cause systemic effects. There
fore, the systemic arterial pressure
and cardiac rate and rhythm must
be monitored constantly during the
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papaverine infusion. The clinical
and angiographic responses of the
patient to the vasodilator therapy
determine the duration of the pa
paverine infusion.
Operative Management

Laparotomy is indicated in AMI
to restore intestinal arterial flow
after embolism or thrombosis or to
resect irreparably damaged bowel.
Revascularization should precede
any evaluation of intestinal viability,
because bowel that initially appears
infarcted may show surprising re
covery after adequate blood flow is
restored.
Intestinal viability can be as
sessed by several methods. Tradi
tionally, the bowel is placed in
warm, saline-soaked laparotomy
pads and observed over a period of
10 to 20 minutes for return of
normal colour, peristalsis and the
presence or absence of pulsations in
the intestinal arteries. This clinical
assessment is of limited accuracy;
more sensitive and specific evalua
tion depends on technologic aids.
Techniques that have been pro
posed include surface fluores
cence,12 perfusion fluorometry,13
Doppler measurements of arterial
flow,14 electromyography,15 mea
surements of surface temperature,
serosal pH, surface oxygen con
sumption and radioisotope uptake.
Only Doppler pulse determinations,
fluorescence with an ultraviolet
light after intravenous injection of
fluorescein and perfusion fluorome
try have gained wide clinical accep
tance. Surface fluorescence in
creases the accuracy of differentiat
ing viable from nonviable bowel, the
equipment is inexpensive and the
dye is safe, but the technique re
mains subjective. Perfusion fluo
rometry is more objective, allows
repeated determinations and is more
accurate, in general, than surface
fluorescence. The equipment is,

however, expensive, and only small
areas of the bowel can be evaluated
at one time. Although Doppler
probes are available in most operat
ing rooms, this modality is, again,
limited to examining small areas of
the intestine. A practical solution is
the initial use of surface fluores
cence, with either perfusion fluo
rometry or Doppler examination re
served for evaluation of the equivo
cal areas.
Short segments of bowel that are
nonviable or questionably viable
after revascularization are resected.
If extensive portions of the bowel
are involved, only the clearly ne
crotic bowel is resected, and a
planned re-exploration is performed
within 24 hours. A decision to
perform a “second-look” operation
is made during the initial celiotomy
if major portions or multiple seg
ments of intestine are of equivocal
viability. The purpose of the se
cond-look celiotomy, as proposed
by Shaw16 is “not just to allow a
clear definition between dead and
live bowel to take place, but also to
allow time for the institution of
supportive measures which may
render more of the bowel viable.”
Such measures may include, among
others, optimizing cardiac output,
SMA infusion of papaverine, antibi
otic therapy and anticoagulant ther
apy. The decision to perform a
second-look operation is inviolate
and it must be done irrespective of
the patient’s clinical course. If a
second-look procedure is planned,
no anastomoses need be made until
the time of the re-exploration.
Sachs, Morton and Schwartz17
found that 18% of “second look”
procedures contributed to patient
survival.
If, at the initial laparotomy, there
is obvious infarction of all or most
of the small bowel with or without a
portion of the right colon, then the
surgeon is faced with a philosoph
ical decision whether to do any

thing at all. Resection of all of the
involved bowel will inevitably result
in short-bowel syndrome with its
attendant problems and almost cer
tainly in these older patients, a
commitment to lifelong parenteral
nutrition. A discussion preoperatively with the patient and family
about this problem is warranted so
that an acceptable decision can be
reached if this situation is encoun
tered at surgery.
Postoperative Care

The use of anticoagulants in the
management of AMI remains con
troversial. Heparin anticoagulation
may cause intestinal, submucosal or
intraperitoneal hemorrhage, and,
except in the case of mesenteric
venous thrombosis, we have not
used it in the immediate postopera
tive period. Late thrombosis after
embolectomy or arterial reconstruc
tion, however, occurs frequently
enough that anticoagulation 48
hours postoperatively seems advis
able.
Both systemic and locally admin
istered antibiotics have been shown
to improve the survival of ischemic
bowel.18 For this reason, because of
the high incidence of positive blood
cultures in patients with AMI and
because of the clinical and experi
mental evidence that ischemic
bowel permits translocation of in
traluminal bacteria,19 broad-spec
trum antibiotics are begun, systemically, as soon as the diagnosis is
entertained and are continued
throughout the postoperative peri
od as dictated by the findings at
celiotomy.

Management of Specific Types
of AMI
SMA Embolism

On identification of an SMA em-
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bolus at angiography, papaverine
infusion is begun through the cath
eter placed selectively in the origin
of the SMA, proximal to the occlu
sion. The patient is then managed
according to the algorithm in Fig.
3, based on the site of the embolus,
the presence or absence of peritone
al signs, the extent of the collateral
blood flow and the degree of vaso
spasm in the vascular beds both
proximal and distal to the embolus.
The degree of vasospasm is deter
mined by angiography repeated
after a selective intra-arterial bolus
injection of 25 mg of tolazoline.
Minor emboli are those limited to
the branches of the SMA or to the
SMA distal to the origin of the
ileocolic artery. Patients with minor
emboli whose pain is relieved by
vasodilator therapy can be managed
expectantly. However, patients with
major emboli selected for nonopera
tive therapy must have significant
contraindications to surgery, no
peritoneal signs and adequate perfu
sion of the vascular beds distal to
the embolus after initiation of vaso
dilator therapy. Direct infusion of
thrombolytic agents through selec
tively placed catheters has been
employed successfully in few pa
tients. Thrombolytic agents may re
quire up to 36 hours to dissolve the
embolus,20 during which time there
may be continued ischemia and ulti
mate necrosis of the bowel. This
approach remains experimental.
Embolectomy is always per
formed before assessing intestinal
viability. The embolus is ap
proached directly or, less optimally,
through a proximal arteriotomy.
The proximal SMA is exposed by
drawing the transverse colon cephalad and anteriorly, as the small
intestine is retracted interiorly. The
inferior leaf of the transverse meso
colon is incised, and the proximal
SMA is dissected free between the
pancreas and the fourth portion of
the duodenum. The SMA is exposed
620

for 2 to 3 cm proximal and distal to
the origin of the middle colic artery.
The SMA is palpated gently to
determine the most distal extent of
arterial pulsation or the artery may
be examined directly with a Doppler
probe to identify the site of the
embolus. Once the embolus is
found, the SMA and its branches
are controlled proximally and distally with vessel loops or gentle vascu
lar clamps. We use a longitudinal
arteriotomy over the embolus or
just proximal to it. The embolus is
removed, and residual clots are
flushed out of the artery by briefly
releasing the vessel loops. A Fogar
ty balloon catheter is then passed
proximally and distally to remove
all remaining clots. The arteriotomy
is closed with or without a vein
patch.
After embolectomy, bowel viabili
ty is determined. If no second-look
operation is planned, the papaverine
infusion is continued for an addi
tional 12 to 24 hours. An arterio
gram is then obtained to exclude
persistent vasospasm before remov
ing the arterial catheter. If a se
cond-look is to be performed, the
infusion is continued through the
second procedure and until no vaso
constriction is present on follow-up
angiography.
NOMI

NOMI is diagnosed when the an
giographic signs of mesenteric va
soconstriction are seen in a patient
who has the clinical picture of mes
enteric ischemia and is neither in
shock nor receiving vasopressors.
The angiographic findings may vary
from the previously described local
signs to a pruned appearance of the
entire mesenteric vasculature (Fig.
4a). A selective SMA infusion of
papaverine is begun in all patients
with NOMI as soon as the diagnosis
is made. In those with persistent
peritoneal signs, the infusion is con
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tinued during and after exploration.
At operation, manipulation of the
SMA is minimized. Overtly necrotic
bowel is resected, and a primary
anastomosis is performed only if no
second-look procedure is planned.
We believe it is better to leave
bowel of questionable viability than
to perform a massive enterectomy,
because frequently the bowel will
improve with supportive measures
or demarcate more clearly by the
time of the second-look operation.
When a papaverine infusion is
used as the primary treatment for
NOMI, it is continued for approxi
mately 24 hours, after which the
infusion is changed to normal saline
for 30 minutes before repeat angi
ography. On the basis of the clinical
course of the patient and the pres
ence or absence of vasoconstriction
on the repeat angiogram, the infu
sion is either discontinued or main
tained for an additional 24 hours.
Angiography is repeated daily until
there is no radiologic evidence of
vasoconstriction (Fig. 4b) and the
patient’s clinical symptoms and
signs are gone. Infusions usually
have been discontinued after 24
hours but have been maintained for
as long as 5 days.
When papaverine is used in con
junction with surgery for nonocclu
sive disease, a second-look opera
tion is frequently necessary. In such
cases, the infusion is continued as
previously described for secondlook operations following embolec
tomy. The arterial catheter is re
moved when no angiographic signs
of vasoconstriction are seen 30 min
utes after cessation of vasodilator
therapy.
Acute SMA Thrombosis

SMA thrombosis is most often
identified on a flush aortogram
showing complete occlusion of the
SMA within 1 to 2 cm of its origin.
Some filling of the SMA distal to
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the obstruction via collateral path
ways is almost always present.
Branches both proximal and distal
to the obstruction may show local
spasm or diffuse vasoconstriction.
Differentiation between thrombosis
and embolism can be difficult, and
in such cases the patients are treat
ed initially for SMA embolism. A
more difficult problem arises in pa
tients with abdominal pain without
abdominal signs and complete oc
clusion of the SMA on the aortogram. In these cases, it is important
to differentiate between an acute
and a long-standing occlusion, as
the latter may be coincidental to an
unrelated presenting illness. Promi
nent collateral vessels between the

superior mesenteric and the celiac
or inferior mesenteric circulation, or
both, are characteristic of chronic
SMA occlusion. If large collaterals
are present and there is good filling
of the SMA on late films during
angiography, the occlusion can be
considered chronic, and the abdomi
nal pain is probably unrelated to
mesenteric vascular disease. In the
absence of peritoneal signs, such
patients are treated expectantly.
The absence of collateral vessels or
the presence of collaterals with in
adequate filling of the SMA indi
cates an acute occlusion. In the
latter instance the middle colic ar
tery has probably occluded, inter
rupting the collateral circulation to

an already marginal system. Prompt
intervention is indicated irrespective
of the abdominal findings in these
cases.
If possible, an angiographic cath
eter is placed in the proximal SMA,
and a papaverine infusion is begun.
If the origin of the SMA cannot be
identified or cannulated at angiog
raphy, a small Silastic catheter
should be advanced proximally into
the SMA through a jejunal artery at
the time of revascularization to
treat the associated vasospasm.
This catheter is brought out
through a separate incision in the
abdominal wall and is used for
postoperative papaverine infusion.
Revascularization procedures for

FIG. 4. Patient with nonocclusive AMI managed with papaverine infusion for 3 days, (a) Initial angiogram showing spasm of
main superior mesenteric artery, origins of branches and intestinal arcades, (b) Repeat angiogram after 36 hours of papaverine
infusion. Study was obtained 30 minutes after papaverine infusion was replaced with saline. At this time patient’s abdominal
symptoms and sign were gone. (Reproduced by permission from Ravitch MM (ed): Current Problems in Surgery, Yr Bk Med
Pubs, New York, 1978.)
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SMA thrombosis are similar to
those used for chronic mesenteric
ischemia, in which reimplantation,
thrombectomy and endarterectomy
or some form of bypass grafting to
the SMA distal to the obstruction is
employed. Although a short graft
from the aorta to the SMA is the
simplest procedure, the optimal site
o f origin of the graft has been
disputed. Because o f the mobility of
the SMA, grafts originating from
the infrarenal aorta may be occlud
ed with the movement o f the mes
entery o f the small intestine. In
addition, late failure due to progres
sive atherosclerotic disease o f the
infrarenal aorta has led some sur
geons to use the supraceliac aorta
as the inflow for the graft. Most
infrequently, the common, external
or internal iliac arteries are the only
noncalcified vessels, and we have
successfully used these as the
source o f inflow. Although autolo
gous reversed saphenous vein is the
preferred conduit, polytetrafluoroethylene has been used successfully,
even in the presence o f peritoneal
contamination.
Percutaneous balloon and laser
angioplasty of the SMA also have
been reported.21 Because there is
presently no good method to moni
tor end-organ injury and because of
the danger of repeat thrombosis
with irreparable bowel loss, as was
the case with one o f our patients,
we do not recommend these tech
niques for acute SMA occlusion.

Results of Therapy for AMI
Although death rates o f 70% to
90% have been reported through
1980 with traditional methods of
diagnosis and therapy, the aggres
sive approach described here can re
duce these catastrophic rates.1022"24
Of our first 50 patients managed
by this aggressive approach, 35
(70%) proved to have AMI. Of
622

these, 33 had angiographic signs of
ischemia. The remaining two pa
tients had normal angiograms. Of
65 patients from two institutions
that used this protocol, 36 (55%)
survived, including 14 of 26 with
NOMI, 14 o f 23 with SMA embo
lism, 4 of 6 with SMA thrombosis
and 4 of 6 with superior mesenteric
venous thrombosis. Most o f the
survivors lost no bowel or less than
1 m of small intestine.
In a separate review of 47 pa
tients with intestinal ischemia re
sulting from SMA emboli, a survival
rate o f 55% was achieved in patients
managed according to our aggres
sive protocol, whereas only 20% of
patients treated by traditional meth
ods survived. Intra-arterial papaver
ine as the primary treatment was
successful in four patients; two of
these were not operated upon and
the other two had normal intestine
at the time o f delayed laparotomy.
Of special interest in this study was
the observation that o f those pa
tients with SMA emboli who were
placed in the protocol within 12
hours of reporting their pain to
their physician and who were ma
naged strictly according to this pro
tocol, two-thirds survived.
With the aggressive approach
outlined, the catastrophic death
rate has been substantially reduced.
Overall, 50% or more o f the pa
tients presenting with AMI and
treated according to the present
algorithm survived, and 70% to
90% lost less than 1 m o f intestine.
Ninety percent of patients with AMI
who had angiography but no signs
o f peritonitis have survived, demon
strating the potential value o f early
diagnosis. Ideally, all patients with
AMI should be studied at a time
when the plain films o f the abdo
men are normal and before the
development o f an acute surgical
abdomen.
Our approach to the diagnosis
and management o f AMI is based
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upon several observations: (a) if the
diagnosis is not made before intesti
nal infarction occurs the death rate
is 70% to 90%; (b) the diagnosis of
both the occlusive and nonocclusive
forms of AMI can be made in most
patients by angiography; (c) vaso
constriction, which persists even
after the cause of the ischemia is
corrected, is the cause o f NOMI and
a contributing factor in the other
forms of AMI; and (d) the vasocon
striction can be relieved by vasodila
tors infused into the SMA. The
cornerstones o f our approach,
therefore, are prompt diagnosis by
the earlier and more liberal use of
angiography and the incorporation
of intra-arterial papaverine in the
treatment of both occlusive and
nonocclusive mesenteric ischemia.
The widespread adoption of this
protocol for the treatment of pa
tients at risk could potentially im
prove the overall results o f treat
ment of AMI.
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SESAP VII Critique / Critique SE SA P VII
Item 3
The surgeon may often have to discriminate between limb-threatening and life-threatening infections based on
clinical criteria. Necrotizing fasciitis, clostridial gangrene, and progresssive synergistic bacterial gangrene fall
into this category. Clostridial infections are characterized by crepitant cellulitis that spreads rapidly along fascial
planes. Necrosis and sloughing o f areolar tissue, fascia, and skin may eventually occur. Necrotizing fasciitis may
be difficult to discriminate from clostridial gangrene, but again it is associated with significant edema,
crepitance, and eventual lack of vascularity within the central portion o f the wound.
In contrast, synergistic bacterial gangrene is described in this case presentation. Its clinical course is less rapid
than with either necrotizing fasciitis or clostridial gangrene, and yet it can be limb threatening. Progressive
venous thrombosis can be limb threatening, particularly if it takes the form o f phlegmasia cerrulia dolens.
Actinomycosis is a more indolent infection, and is clearly not as serious as the other four. It does not produce
the wound appearance described.
___
D
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There is no evidence in animal o r human studies that ketorolac trom etham ine induces or inhibits the hepatic enzymes
capable o f metabolizing itself o r other drugs. Hence, it w o uld n o t be e xpected to alter the pharmacokinetics o f other
drugs d ue to enzyme induction o r inhibition mechanisms.
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effects include: Gastrointestinal: dyspepsia (2%), g astrointestina l pain (2%), nausea (2%). Central nervous system:
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ACTION
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of action is to inhib it the cyclo -oxygenase enzym e syste m , th ereby inhibiting the synthesis of prostaglandins, and is c on 
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nia. Hemic and lymphatic: purpura. M usculoskeletal: myalgia.
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days.
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More tha n 99% o f th e ketorolac in pla sm a is p rotein bound o v e r a w ide c oncentratio n range.

INDICATIONS
O rally adm inistered Toradol (ketorola c trom etham ine) is indicated for the short-term management o f m ild to m oder
ately severe pain, including post-surgical pain (such a s general, orthopedic and dental surgery), acute musculoskeletal
traum a pain and post-portum u terin e c ram pin g pain

OVERDOSAGE
The absence o f experience with acute overdosage precludes characterization o f sequelae and assessm ent o f a nti
dotal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
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Intram uscula r inje ctio n of Toradol is in dicated fo r th e short-term management o f m oderate to severe pain, including
p ain follow in g m a jo r abdominal, orthopedic and g ynecolo gical operative procedures.

DOSAGE AND ADMINISTRATION

CONTRAINDICATIONS

Adults: Dosage should be adjusted according to the severity o f th e pain and the response o f the patient.

Toradol (ketorola c tromethamine) should n ot be used where there is a known or suspected h ypersensitivity to the drug.
Because o f the possib ility of cross-sensitivity, ketorola c trom etham in e should not be used in patients in w hom acetylsalicylic a cid (ASA) o r other non-steroid al anti-in fla m m atory agents induce acute a sthm atic a ttacks, urticaria, rh initis
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Toradol (ketorola c trom etham ine) a lso should n ot b e used in patie nts with p eptic u lc e r or active infla m m atory disease
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ity (see W arnings & Precautions). If supplemental analgesia is required, a concomitant low dose of opiate can be used.
The adm inistration o f continuous m ultiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for m ore than 5 days since the vast m ajority o f p atients have transferred to
ora l medication o r no longer required analgesic therapy a fter th is time.

symptoms. Elderly and debilitated individuals are most susceptible to these complications, the incidence o f which increases
w ith d ose a nd d uratio n o f treatm ent. C lo se m ed ic al supervision is recomm ended in patie nts prone to g astrointestinal
tra c t irritatio n, p artic ula rly those w ith a history o f p eptic ulcer, diverticulosis o r o th e r inflammatory d isease of the g a s
trointestinal tract. In these cases th e physic ia n m ust w eig h the benefits o f treatm ent a ga in st the possib le hazards.
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G UARD, apply q uick, firm pressure to the plunger to b reak the inner seal (you w ill feel it let go). Pull back on the plunger
slightly to relieve pressure. Remove the needle guard by tw isting a s you pull. Use the unit as you would a norm al syringe.
Dispose o f properly. Single use only. Discard unused portions.

Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to contact
a p hysic ia n im m edia tely if they e xp erie nce sym p tom s or sig ns suggestive of peptic ulceration or gastrointestinal b leed 
ing. These re actio ns can occur at a n y tim e d urin g th e treatm ent. If p eptic ulceratio n is suspected o r confirm ed, o r if
gastrointestinal ble edin g occurs, ketorola c trom etham ine should be discontinued a nd appropriate treatm ent instituted
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CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets may be used either as m onotherapy or as follow -on therapy to parenteral ketorolac. In the latter case,
the total combined daily dose o f ketorolac should not exceed 120 m g on the day the c hange of form ulation is m ade,
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Ketorolac trom etham in e is not re com m ended for routin e use with other non-steroidal anti-inflammatory d rugs because
o f the p otential fo r additiv e side effects.

Toradol (ketorolac tromethamine) is a Schedule F drug.

Use in pregnancy, lactation and labour: The adm inistratio n of ketorolac trom ethamine is not recommended during preg

Toradol Tablets: Each Toradol tablet contains ketorolac tro m etha m ine, the active ingredient, with m icrocrystalline cel

nancy o r lactation.
Ketorolac trom etham in e is not recom m ended fo r use a s an obstetric al preoperative medication or for obstetrical a nal
gesia b ecause o f the known effects o f non-steroidal anti-inflam matory drugs on uterine contraction and fetal circulation.

Use in children: Safety a nd efficacy in c hildren have n ot been established. Therefore, Toradol is not recom m ended for
use in c hild ren under a ge 16.

Use in the elderly: Because ketorolac is c le ared som ew hat m ore slowly by the e ld erly (See PHARMACO KIN ETICS) w ho
a re also m ore sensitive to the renal effe c ts o f non-steroid al anti-inflam matory drugs, extra caution and the low est effec
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PRECAUTIONS
Renal effects: As w ith othe r drugs th a t in hib it prostagla ndin biosynthesis, e levations of blood urea nitrogen (BUN) a nd
creatinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and its metabo
lites are excreted prim arily by the kid ney, p atients with sig nific ant im pairm ent o f renal function (serum creatinine
va lu es g reater tha n 5 m g /d l) should n o t receive ketorolac trom etham ine unless the e xpected benefits outw eigh the
risks. In p atients with moderately im p aire d renal functio n serum creatinin e valu es ranging from 1.9 to 5,0 mg/dL, the
rate of ketorolac cle arance was reduced to approxim ately half of normal. The total daily dose of ketorolac tromethamine
should b e reduced by h a lf in such patie nts. The d isposition o f ketorola c in d ialysis p atients has not been studied.
Pa tie nts w h o a re vo lu m e depleted b e ca u se of b lood lo ss or seve re d e hyd ra tio n m a y be d epend ent on renal
prostaglandin p rod uctio n to maintain renal perfusion a nd therefore glom erula r filtration rate. In such situations the use
of drugs whic h in hibit prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised
if ketorolac tro m e tha m in e is used in such c ircum stances. C lose m onitoring o f urine output, serum urea a nd serum cre
a tin ine is recom m ended until the p atie nt is norm ovole m ic .

Hepatic effects: Meaningful elevations (greater than 3 tim es norm al) of serum transam in ases (glutamate p yruvate (SGPT
o r A LD and g lutam ic oxalacetic (SG O T o r AST)) occurred in controlled clinical trials in le ss than 1% o f p atients. If clini
cal signs and sym p tom s consistent w ith liver d isease develo p, o r if systemic m anifestatio ns occur (e.g., eosinophilia,
rash, etc.), ketorola c tromethamine sh ou ld b e d iscontinued. Patients w ith impaired hepatic function from cirrhosis do
not have a ny clinic ally important c hanges in ketorola c trom etham ine clearance. Studie s in patients with a ctive hepati
tis o r c h olesta sis have not been p erform ed.

Fluid and electrolyte balance: Fluid re tentio n and edem a have been observed in patients treated w ith Toradol
Therefore, a s w ith m any other non-steroid al anti-infla m m atory drugs, the possib ility o f precipitating c ong estive heart
failu re in eld erly p atie nts o r those with c om p rom ised cardia c function should be borne in mind. Toradol should b e used
with c autio n in p atie nts w ith cardiac d ecom p ensa tio n, hypertensio n o r other conditions predisposing to flu id retention,
Hematologic effects: Ketorolac trom etham in e in hib its p latele t function and may prolong bleeding tim e. It d oes not
a ffect p la tele t count, prothrombin tim e (PT) o r partia l th rom bopla stin time (PTT). Pa tie nts w ho have coagulation dis
ord ers o r are receivin g d rug therapy th a t interferes with hem ostasis should be c are fully observed when ketorolac
trom etham ine is adm inistered. Unlike th e prolonged effects from aspirin, the inhibitio n o f platelet function by ketoro
lac trom etha m in e is norm alized within 2 4 to 4 8 h ours a fte r the d rug is d iscontinued.
Blood dyscrasias a ssocia ted with the u se o f non-steroid al anti-in flam m atory d rugs a re rare, but could oc c ur with severe
consequences.

Infection: In com m on with other anti-infla m matory drugs, ketorolac trom etham ine may m ask the usual sig ns o f infection.
Drug Interactions: Toradol (ketorolac trom etham in e) is highly bound to human plasma protein (mean 99.2%) and binding
is independent of concentration.
Prothrombin tim e should b e carefully m onitored in all p atients receiving oral anticoagulant therapy concom itantly with
ketorolac trom etham in e.

COMPOSITION
lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyl-methytcellulose, titanium dioxide
and polyethylene glycol.

Toradol IM: Toradol IM is available fo r intram uscular a dm inistration as: 15 m g in 1 m L (1.5%), or 30 mg in 1 m L (3%) of
ketorolac tromethamine in sterile solution. The 15 m g/mL solution c onta ins 10% (w/v) alcohol, USP, and 6.68 mg sodium
chloride in sterile water. The 30 m g/mL solution contains 10% (w/v) a lcohol, USP and 4.35 mg sodium chloride in sterile
water. The pH is adjusted w ith sodium hydroxide o r hydrochloric acid. The sterile solutions a re c lear and slig htly yellow
in c olour.

STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store a t room tem perature, The blister package tablets should b e p rotected from light.
Toradol IM: Store a t room tem perature with protection from light.
AVAILABILITY OF DOSAGE FORMS
Toradol (ketorolac tromethamine) is available as 10 mg w hite round film coated tablets with one side printed in red
with TO RADOL inside a bold T and the other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are avaiF
a ble in bottles of 100 and 500 tablets.
Toradol IM is available in 1 m L syringes containing 15 o r 30 m g/m L o f ketorolac tromethamine.
Product M onograph available o n request.
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Routine Omission of Nasogastric
Intubation After Gastrointestinal Surgery
Helen M. MacRae, MD; James D. Fischer, MD, FRCSC; Walter W. Yakimets, MD, FRCSC
The need for routine nasogastric-tube decompression after gastrointestinal surgery
has been challenged repeatedly for several years. To determine whether nasogastric
intubation can be omitted routinely, 101 consecutive patients who underwent
gastrointestinal surgery were managed prospectively without nasogastric tubes.
Excluded were patients with complete bowel obstruction and those who required
prolonged endotracheal intubation. These patients were compared with 101
retrospective controls who had nasogastric decompression routinely. There were
four protocol violations in the prospective group (nasogastric tubes were left in
place postoperatively) and one in the retrospective group (no nasogastric tube
postoperatively), leaving 97 and 100 patients, respectively, for follow-up. The mean
duration of hospitalization in comparable patients was 10.6 days in patients without
decompression and 11.9 days in those with routine decompression. Subsequent
nasogastric-tube insertion was required in nine patients who did not undergo
routine decompression, compared with two patients who had routine decompression.
There were no statistically significant differences in the rates of anastomotic leaks,
wound disruptions and pulmonary or other complications between the two groups.
The authors conclude that nasogastric decompression can be safely omitted as a
routine part of postoperative care after gastrointestinal surgery.

Le besoin, apres une chirurgie gastro-intestinale, de produire systematiquement une
decompression a l’aide d’une sonde nasogastrique est regulierement mis en doute
depuis plusieurs annees. Afin d'etablir si l’intubation nasogastrique peut etre omise,
101 patients consecutifs qui ont subi une operation gastro-intestinale furent traites
de fa?on prospective sans sonde nasogastrique. Furent exclus, les patients qui
presentaient une obstruction intestinale complete et ceux qui necessitaient une
intubation endotracheale prolongee. Ces patients furent compares a un groupe
temoin retrospectif compose de 101 patients qui avaient eu une decompression
nasogastrique de routine. II y a eu quatre violations de protocole dans le groupe
propectif (les sondes ayant ete laissees en place apres l’operation) et une dans le
groupe retrospectif (aucune sonde en postoperatoire), ce qui laissa, respectivement,
97 et 100 patients pour la surveillance des suites therapeutiques. La duree moyenne
de l’hospitalisation pour des patients comparables fut de 10,6 jours pour les patients
sans decompression et de 11,9 jours pour ceux qui avaient eu une decompression de
routine. L’insertion subsequente d’une sonde nasogastrique fut necessaire chez neuf
patients du groupe prospectif, comparativement a deux patients du groupe
retrospectif. Entre les deux groupes, il n’y eut aucune difference statistiquement
significative en ce qui a trait au taux de fuite d’anastomose, aux disunions des
sutures de plaies, et aux complications pulmonaires ou autres. Les auteurs
concluent done que la decompression nasogastrique systematique peut etre omise
des soins postoperatoires apres chirurgie gastro-intestinale.

he belief that nasogastric de
compression is required as a
routine part of postoperative care
after abdominal procedures has per
vaded surgical thinking for most of
this century. Theoretically, naso
gastric decompression decreases the
distension caused by the accumula
tion of gas and secretions within
the intestines, potentially leading to
a lower incidence of anastomotic
leaks and wound disruption. To our
knowledge, no study in the litera
ture has supported this contention.
Nasogastric decompression is un
comfortable for the patient and car
ries its own risks. Nasogastric tubes
have been implicated in the patho
physiology of atelectasis, gastroeso
phageal reflux, aspiration, pneumo
nia, gastric and esophageal erosions
and perforation.1”4 Hypersalivation,
a decreased cough reflex and vari
ous pharyngeal and laryngeal ab
normalities have also been shown to
occur with nasogastric intubation.
During the past decade, several
studies have challenged the practice
of routine decompression in colo
rectal surgery and have shown it to
be of no significant benefit.5-7 Few
studies have addressed this issue in
all types of gastrointestinal sur
gery.8-10 In view of the risk of
nasogastric decompression and the
lack of data supporting its use, the
goal of this study was to determine
if nasogastric decompression can
routinely be omitted after gastroin
testinal surgery.

T
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underwent elective or emergency
laparotomy, performed by the two
senior authors, were treated pro
spectively without nasogastric de
compression (group 1). Before Jan
uary 1988 these surgeons routinely
used nasogastric decompression in
all laparotomies. We reviewed 101
consecutive laparotomies done in
1987, and these form a retrospec
tive control group (group 2). There
was no difference in perioperative
routine between the two groups
except for the use of nasogastric
intubation. Diet was advanced ac
cording to the same criteria in both
groups. Patients excluded from
both arms of the study were those
requiring prolonged endotracheal
intubation (more than 24 hours)
immediately postoperatively, pa
tients whose laparotomy was for
trauma and those with a complete
bowel obstruction. Patients who
had laparotomy for cholecystecto
my, splenectomy and appendecto
my, who would not routinely under
go decompression at our institu
tion, were also excluded from the
study. All other patients who under
went elective or emergency laparot
omy were included.
In group 1, the stomach was
decompressed by a nasogastric tube
intraoperatively if it was distended,
and the tube was removed at the
end of the procedure. In group 2, a
nasogastric tube was inserted in
traoperatively and left in place at
the end o f ' the procedure. Clear
fluids were started once flatus was
passed and diet advanced according
ly. The following information was
recorded: diagnosis; type of opera
tion; intraoperative complications;
occurrence of postoperative nausea
and vomiting; postoperative day
when clear fluids were started; ad
vancement of diet; and postopera
tive day of discharge. Pulmonary
complications, anastomotic leaks,
wound disruptions or infections and
other complications were recorded.
626

Differences between the two
groups were analysed by the Stu
dent’s f-test.

Results
There were four protocol viola
tions in group 1: three patients had
a subtotal gastrectomy for carcino
ma of the stomach, and one patient,
who had a duodenal resection, was
decompressed postoperatively.
There was one protocol violation in
group 2: a patient who underwent
creation of an end colostomy for
perforated diverticulitis was not de
compressed. Data were recorded on
the remaining 100 patients.
The operative procedures per
formed in each group are listed in
Table I. The 11 miscellaneous pro
cedures in group 1 included enteroenterostomy (3), enterotomy (2),
lysis of adhesions (2), total eso
phagectomy (1), a duodenal patch
(1), closure of fistula (1) and inter
nal drainage of a pancreatic pseudo
cyst (1). The 10 miscellaneous pro
cedures in group 2 were vagotomy
and antrectomy (6), duodenal repair
(1), duodenal patch (1), oversewing
of a jejunal perforation (1) and
distal pancreatectomy (1).
In group 2, the nasogastric tube
was removed after an average of 4.5
days (± 1.3 days). Two patients
required reinsertion of a nasogastric
tube, one for a small-bowel obstruc
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tion following an anterior resection
and the second for persistent nau
sea and vomiting after a right hemi
colectomy.
Nine nasogastric tubes had to be
placed in group 1 patients: four
after a right hemicolectomy, two
after an abdominoperineal resection
and one each after an enteroenterostomy, a revision colostomy and
a choledochojejunostomy with gas
troenterostomy. Nasogastric tubes
had to be inserted between postop
erative days 1 and 7 (mean, day 4).
Persistent nausea and vomiting was
the reason for nasogastric intuba
tion in all but one case. Septic
shock developed in one patient 12
hours after a revision colostomy.
She had a nasogastric tube placed
as part of the intensive-care-unit
routine. None of these complica
tions could be attributed to failure
to decompress.
The mean postoperative day on
which clear fluids were started, diet
was advanced and patients were
discharged is detailed in Table II.
The differences between the two
groups were significant (p < 0.01),
although the use of a retrospective
control group made it difficult to
attribute the cause of the earlier
discharge.
The rate of complications was
similar in the two groups (Table
III). There was no statistically sig
nificant difference in the rate of

Table 1. Type o f Procedure
Procedure

Group 1

Group 2

R ig h t hem ico lecto m y
L e ft hem ico lecto m y
A n te rio r resection
A bd o m inoperineal resection
T o ta l abdom inal c o le cto m y /p ro cto co le cto m y
C o lo s to m y /ile o s to m y ± resection
C losure o f co lo sto m y o r ile o sto m y
S m a ll-b o w e l resection
C h o le d o ch o e nte ro stom y
E ndorectal pull th ro u g h
F undoplication
S ub to ta l ga stre cto m y
M iscellaneous

11
8
13
4
6
14
11
9
5
2
2
1
11

12
8
10
7
5
12
12
12
0
8
2
2
10

Total

97

100

NASOGASTRIC INTUBATION AND GASTROINTESTINAL SURGERY

anastomotic leak or of wound dis
ruption. There was also no differ
ence in the rate of pulmonary com
plications. In group 1 (not routinely
decompressed) other complications
included cardiac complications
(two), urinary-tract infections
(three), septic shock (one) and ne
crosis of an ostomy (one). In group
2 (routine decompression) other
complications included urinary-tract
infections (four), otitis media (in
children) (two), bleeding from a
gastric erosion (one), deep vein
thrombosis (one) and small-bowel
obstruction (one).

Discussion
The belief that nasogastric de
compression is required after ab
dominal surgery can be traced to
the introduction of the nasogastric
tube by Levin in 1921.11 Its use was
advocated by Mclver, Benedict and
Cline12 in 1926, who hypothesized
that abdominal distension caused by
swallowed air might be prevented
by the use of a nasogastric tube.
Wangensteen and Paine13 further
popularized the use of the naso
gastric tube during the 1930s, es
pecially in the treatment of smallbowel obstruction. Since then, na
sogastric decompression has been a
routine part of postoperative care.
Gerber14 challenged this routine
in 1963 when he stated that naso
gastric decompression was often
unnecessary and led to complica
tions. Several recent reports have
also challenged the routine use of
nasogastric decompression, primari

ly in colorectal surgery. No signifi
cant differences in morbidity or
mortality were found when naso
gastric decompression was omitted.
In all of these studies, approximate
ly 10% of patients not routinely
decompressed required insertion of
a nasogastric tube postoperatively.
Thus, 90% of patients would have
been needlessly decompressed if
routine decompression had been
used.5-715 Studies of the use of
nasogastric decompression after
truncal vagotomy with a drainage
procedure have also shown no bene
fit accruing to routine decompres
sion.1617 Few studies have ad
dressed the issue of nasogastric
intubation in all types of abdominal
surgery. Reasbeck, Rice and Herbison,9 in a randomized prospective
study of 97 patients who underwent
gastrointestinal surgery, found no
significant difference between those
with decompression and those with
out decompression with respect to
anastomotic leaks, wound dehis
cence or other complications. Bauer
and associates,10 in a study of 200
patients, including patients who un
derwent cholecystectomy, splenec
tomy, exploratory laparotomies and
drainage of appendiceal abscesses,
also found no significant differences
in the incidence of complications
between patients decompressed and
those not routinely decompressed.
In their study, 6% of patients not
routinely decompressed required in
sertion of a nasogastric tube post
operatively.
In the present study, inclusion
criteria differed from those of earli
er reports. All patients who under

Table II. Postoperative Course

Postoperative course

Group 1

Group 2

Clear fluids
Full fluids
Full diet
Discharge

3.8 ± 2.3
4.8 ± 2.3
6.1 ± 2.6

5.4 =t 2.3
6.4 ± 2.4
7.4 ± 2.5

Numbers are means ± standard deviation.

±

6.0

Table III. Complications
Complication

Day ol occurrence

10.6

went a laparotomy, whether emer
gency or elective, were included.
We did not include cases in which
most surgeons in our institution
would not use routine nasogastric
intubation, such as cholecystectomy
or appendectomy. Unlike previous
studies,810 we included patients
with peritonitis. The rate of compli
cations between the two groups was
not significantly different. Specifi
cally, there was no increased inci
dence of wound disruption or anas
tomotic leaks in patients not rou
tinely decompressed. There was
also no significant difference in the
rate of pulmonary complications be
tween the two groups. This may be
because nasogastric tubes were re
moved relatively early in the postop
erative course of patients in group
2. The 9% insertion rate of naso
gastric tubes in group 1 was similar
to that found in other studies.
A significant difference in the
length of hospital stay between the
two groups was found. Although
this could result from comparison
with a retrospective control group,
the same criteria were used in both
groups to start clear fluids and to
advance the diet. The data show
that there are significant differences
in the timing of all phases of diet
advancement. The differences in
diet advancement may account for
the earlier day of discharge from
hospital. No other differences in the
perioperative course were found to
account for this difference, al
though the use of a retrospective
control rendered it difficult to as
sess other variables that may have

12.0 ± 6.2

Anastomotic leak
Wound dehiscence
Wound infection
Pulmonary
Other
Tube inserted
or reinserted

Group 1

Group 2

3
2
4
4
7

4
3
8
5
9

9

2

Differences were not significant.
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contributed to the longer hospital
stay of the decompressed group.
In conclusion, the routine omis
sion of nasogastric intubation was
not associated with an increased
risk of anastomotic leaks, wound
disruption or other postoperative
complications and spared 91% of
patients the discomfort and risks of
nasogastric decompression. We
conclude that nasogastric intuba
tion can safely be omitted as a
routine part of postoperative care.
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A Prospective Randomized Trial
of Routine Postoperative Nasogastric
Decompression in Patients With Bowel
Anastomosis
Johann Cunningham, MD, CM; Walley J. Temple, MD, FRCSC, FACS;
James M. Langevin, MD, FRCSC; John Kortbeek, MD, FRCSC
Until relatively recently, the nasogastric (NG) tube has been used routinely for
decompression in the patient with small- or large-bowel anastomosis. To determine
if routine postoperative NG decompression benefited such patients, 102 patients
were randomized prospectively to either NG decompression or no-NG tube.
Excluded were patients with chronic bowel obstruction, peritonitis, gross fecal
contamination or spillage, and previous abdominal or pelvic irradiation. There were
52 patients in the no-NG group and 50 in the NG group. Patients in the no-NG
group had earlier bowel sounds, return of flatus, oral intake and first bowel
movement. Four patients (8%) in the no-NG group, compared with one patient (2%)
in the NG group, required subsequent decompression. Length of hospital stay was
significantly (p < 0.001) shorter in the no-NG group. There were no significant
differences in the presence of atelectasis, postoperative fever, wound infections and
anastomotic leaks between the two groups.
The authors conclude that routine nasogastric decompression is not warranted
after elective surgery involving small- or large-bowel anastomosis.

II n'y a pas si longtemps, les sondes nasogastriques (NG) etaient utilisees
regulierement pour fins de decompression chez les patients qui avaient subi une
anastomose du grele ou du gros intestin. Afin de mesurer si une decompression NG
systematique beneficiait a tous les patients, 102 malades on ete randomises de fa?on
prospective pour former deux groupes : avec ou sans decompression NG. Furent
exclus, les patients souffrant d’obstruction intestinale chronique, de peritonite, de
contamination evidente par les feces, et ceux qui avaient refu une irradiation
abdominale ou pelvienne prealable. Cinquante-deux patients n’ont pas eu de
decompression NG (sans NG) et 50 en ont eu une (NG). Les patients du groupe sans
NG eurent un retour des bruits intestinaux et du passage des flatuosites plus
precoce, ils recommencerent a s’alimenter plus rapidement et eurent plus tot leur
premiere selle. Quatre patients du groupe sans NG (8 %) necessiterent une
decompression NG subsequente, comparativement a 1 patient du groupe NG (2 %).
La duree d’hospitalisation fut significativement plus courte pour le groupe sans NG
(p < 0,001). On n’a constate aucune difference entre les deux groupes en ce qui a
trait a 1’atelectasie, a l’hyperpyrexie postoperatoire, aux infections de plaie ou aux
fuites anastomotiques
Les auteurs concluent que la decompression nasogatrique de routine n’est pas
indiquee apres une chirurgie non urgente pour anastomose du grele ou du gros
intestin.

From the Division o f General Surgery, Department o f Surgery, University o f Calgary, Calgary,
Alta.
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asogastric intubation for intes
tinal decompression is a com
mon practice after abdominal sur
gery. Its use was introduced by
Wangensteen and Paine1 who de
scribed a duodenal tube for relief of
distension associated with peritoni
tis. In 1921, Levin2 introduced a
smooth, blunt-ended tube for nasal
intubation. Mclver, Benedict and
Cline3 performed a series of experi
ments, published in 1926, demon
strating that the principal source of
gas in postoperative distension was
swallowed air. These historical de
velopments led to the widespread
use of postoperative nasogastric de
compression, which is commonly
believed to diminish postoperative
nausea, vomiting and distension
and to reduce the incidence of anas
tomotic leaks after bowel surgery.
However, nasogastric (NG) tubes
are not without problems. Some4-8
have claimed that they increase the
risk of aspiration, as well as leading
to sinusitis, pharyngitis or esopha
gitis. Their main detraction, howev
er, is the increased discomfort pa
tients suffer with their use.
The use of NG tubes has been
questioned. Burg and associates,4
Ibrahim and associates,5 Meltvedt
and colleagues,6 Gerber7 and Grant,
Elliot and Frederick8 retrospectively
reviewed their results in patients
with and without NG intubation.
They suggested that NG intubation
may be unnecessary.
These suggestions led to several
prospective randomized trials evalu-
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ating the effects of NG intubation.
Colvin and associates9 prospectively
randomized 138 patients who un
derwent elective colonic resection to
placement of a Cantor tube, NG
tube or no tube. Their results dem
onstrated no significant difference
between groups with respect to
length of hospital stay, duration of
postoperative ileus or operative
complications. Cheadle and associ
ates10 prospectively randomized 200
patients scheduled to undergo
major abdominal procedures into
four groups: no tube and placebo:
no tube and cimetidine; tube and
placebo; and tube and cimetidine.
They concluded that the NG tube
delayed passage of flatus and bowel
movements as well as lengthening
the duration of hospital stay. Bauer
and associates11 prospectively ran
domized 200 consecutive patients
who were to undergo gastrointesti
nal surgery into NG-tube and noNG-tube groups and found no dis
cernible difference in efficacy. Final
ly, Wolff and colleagues12 random
ized 535 patients admitted for colo
rectal surgery. Their results demon
strated no significant difference in
the incidence of wound dehiscence,
anastomotic breakdown, wound in
fection or atelectasis.
These studies suggest that NG
decompression may not be neces
sary after major abdominal surgery.
The findings of a recent retrospec
tive review at Foothills Hospital in
Calgary correlated with the results
of previous authors.10' 12 The main
advantages of omitting NG intuba
tion appeared to be a lessening of
patient discomfort, a decrease in the
need for nursing care, a decrease in
costs, a decrease in electrolyte and
respiratory problems and an im
proved outcome.
It was therefore decided to look
at patients who had the most inva
sive of abdominal procedures —
bowel resection and anastomosis. A
prospective randomized study was
630

set up to determine if the NG tube
had any effect on patient outcome,
well-being and rate of complica
tions.

Patients and Methods
All patients who underwent elec
tive colorectal or small-bowel sur
gery with primary anastomosis dis
tal to the ligament of Treitz were
considered eligible for this study,
which was approved by the Univer
sity of Calgary ethics and research
and development committees.
Excluded were patients with
chronic small- or large-bowel ob
struction, a history of abdominal or
pelvic radiation, peritonitis, abscess,
gross fecal contamination, ischemic
bowel and those who, despite hav
ing a small- or large-bowel anasto
mosis, had a proximal defunctional
ostomy. All remaining patients were
randomized at the time of the oper
ation from previously prepared ran
domization tables. If the surgeon
thought a patient in the no-NG
group required intraoperative de
compression, an NG tube could be
placed as long as it was removed at
the end of the operation.
Tubes of sizes 16 and 18 French
were used throughout. Patients in
the NG group had the tube left in
place for at least 72 hours or until
bowel sounds returned, as recorded
by the patient’s nurse. If the tube
was draining copious amounts of
fluid, it was left in place until the
drainage was less than 100 mL in 8
hours. Failure was defined as the
need to insert an NG tube in a
patient in the no-NG group and to
reinsert the tube in a patient in the
NG group. Insertion was done when
clinically indicated, as in repeated
episodes of vomiting, nausea, ab
dominal distension, discomfort or
respiratory compromise from intra
abdominal distension, as determined
by the attending physician. Patients
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were followed up by a study nurse
who did the data collection. Data
recorded were the time of return of
bowel sounds, passage of flatus,
oral intake and first bowel move
ment, the presence of anastomotic
leaks, atelectasis, potential and ac
tual wound infections, NG-tube in
sertion or reinsertion and postoper
ative fever. For the purposes of this
study, postoperative fever was de
fined as a body temperature greater
than 38°C. Anastomotic leak was
defined as a leak of clinical signifi
cance, necessitating reoperation and
repair. Potential and actual wound
infections were defined according to
the criteria of Cruse13 as erythema
and induration, and purulent drain
age respectively. Atelectasis was de
fined as changes seen on the x-ray
film that were consistent with the
diagnosis.
Statistics
Before the study was initiated, it
was determined that at least 50
patients were needed per arm to
have a 90% chance of detecting a
10% difference in the continuous
variables. A much larger sample
size of 250 patients per arm would
be needed to have an 80% chance of
detecting a 10% difference in the
complication rates. Analysis was
done using Student’s f-test, the x2
test, covariant analysis and the
Mantel-Haenszel test.

Results
Three hundred patients had elec
tive small- and large-bowel surgery
between October 1989 and January
1991. Most of these patients were
excluded because they had proximal
defunctioning ostomies or other ex
clusion criteria. About 25% of the
patients refused to enter the study
and were treated according to their
surgeon’s preference. The remain-
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ing patients were missed at the time
of operation.
Preoperatively 109 patients were
enrolled in the study. Seven pa
tients ended up with proximal de
functioning ostomies intraoperatively and were not randomized. The
final sample population of 102 pa
tients was randomized: 50 to NG
decompression and 52 to no-NG
decompression. Fifty patients were
men and 52 were women. The mean
age was 51.7 years (range from 16
to 96 years); 60% were under the
age of 60 years. There were 16
potential wound infections and 5
actual wound infections. One pa
tient in the no-NG group had an
anastomotic leak and required reop
eration. An NG tube had to be
reinserted in the NG group and four
inserted in the no-NG group, 5% in
total (NS).
Mean age, sex distribution,

wound infection rate and anasto
motic leaks were representative of
surgical practice in that they were
comparable to other similar study
populations at the hospitals in
volved in the study.
NG Group Versus No-NG Group
The groups were stratified ac
cording to the following age
groups: less than 40 years, 40 to
59 years, and 60 years and older.
Return of bowel sounds and
bowel movements, passage of flatus
and start of oral intake were all
significantly (p < 0.05) delayed in
the NG group (Table I). The length
of hospital stay was increased in the
general study population in patients
over 60 years of age and in patients
under 40 years of age. The length
of hospital stay was not significant
ly different between the two groups

Table 1. Length of Time for Return of Bowel Function After Bowel Surgery (Hours)
Type of function
Bowel sounds
Flatus
First oral intake
First bowel movement

NG group
(/»= 50)

No-NG group
(» = 5 2 )

59.4
100.9
95.5
117.8

43.5
74.0
65.6
93.9

Table II. Length of Hospital Stay After Bowel Surgery With Bowel Anastomosis (Days)
Age group, yr
< 40
40 to 59
> 60
Mean

NG
(n = 50) *

No-NG
(n = 52) *

/rvalue

8.2
9.2
10.6

6.6
10.4
9.8

< 0.001
> 0 .2
< 0 .0 5 -0 .0 1

9.6

8.7

< 0.001

*NG = nasogastric tube, no-NG = no nasogastric tube

Table III. Morbidity in Patients Who Underwent Bowel Surgery With Bowel Anastomosis
Postoperative problem
Severe nausea, vomiting or
distension*
Fever
Atelectasis
Wound infection
Potential
Actual
Anastomotic leakage

NG
(n = 5 0 )

No-NG
(/» = 52)

p value

1
25
2

4
19
0

0 .2 5 -0 .1 0
0 .2 5 -0 .1 0
0 .2 5 -0 .1 0

10
2
0

'Necessitating late insertion of nasogastric tube

f l
3_J
1

>0 .2 5
>0 .2 5

in the 40- to 59-year age category
(Table II). However, the analysis
suffered from a smaller sample size.
Passage of flatus and start of oral
intake were significantly delayed in
the NG group in patients under 40
years of age. The return of bowel
sounds, passage of flatus, start of
oral intake and first bowel move
ment were signifiantly delayed (p <
0.05) in the 40- to 59-year age
category in the NG group.
The comparisons of discontinu
ous variables such as wound infec
tions, atelectasis, fever, reinsertion
of an NG tube and anastomotic
leakage showed no significant dif
ference between the two groups
(Table III), as predicted by the pre
trial statistical analysis.

Discussion
All gastrointestinal surgery re
sults in some degree of ileus. Those
procedures that include primary
anastomosis of bowel cause not
only a physiological but also ana
tomic disruption of the normal pro
pulsive action of the gastrointesti
nal tract. The normal cyclic myoenteric complexes originating in the
stomach and progressing distally
through the small bowel disappear.
No longer is there any propulsive
action, clearing undigested food,
debris and gas. Secretions, gas and
debris can accumulate in the bowel
lumen, distending the bowel. Pas
sage of flatus and stool cease. Anas
tomoses are at risk of disruption,
infection and leakage.
The NG tube, introduced by Lev
in,2 was believed to improve postop
erative patient care significantly.
Mclver and colleagues3 theorized
that abdominal distension was due
to swallowed air. Until the early
1960s, placement of the NG tube
was the only acceptable method of
abdominal decompression after in
tra-abdominal surgery.
CJS, VOL. 35. NO. 6. DECEMBER 1992
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Ibrahim and associates5 found no
difference in morbidity and mortali
ty in a prospective randomized trial
for intra-abdominal surgery. Since
then, several large randomized
trials9-11 found no benefit from rou
tine decompression, and Wolff and
colleagues12 showed that nasogastr
ic decompression made no differ
ence.
A question brought up but never
addressed was whether the NG tube
actually delayed the patient’s prog
ress. In this study we found that in
a patient with a bowel anastomosis,
contrary to popular belief and tradi
tional teaching, the NG tube actual
ly delays return of bowel sounds,
passage of flatus, return of bowel
movements and, most important,
start of oral intake. The patient
with a nasogastric tube is being
starved longer, delaying a return to
normal gut function and general
recovery. In fact, in patients over
60 years of age, there is no benefit
in placing an NG tube for routine
postoperative management unless
the patient suffers from excessive
nausea, vomiting or abdominal dis
tension.
Finally, by not placing NG tubes
routinely, our hospital realizes a
saving of $164.42 per patient from
actual cost of the NG tube and
concomitant care, and another
$300 per patient for shortened hos
pital stay. This means a total sav
ings of $45 000 annually if the
standard practice of placing an NG
tube postoperatively were stopped
in this group of patients.
For these reasons we conclude
that routine nasogastric decompres
sion should not be used for surgery
in this patient population with
small- and large-bowel anastomo
ses.
We acknowlege the support given to
the trial by Drs. W.J. Buie, D.A. Jenkin,
R. Khoo, R. Lafreniere and R.M. Preshaw.
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Introducing a new solution for antibacterial therapy...

THE FIRST AND ONLY I.V. FLUOROQUINOLONE
f Broad spectrum coverage*1

’ Indicated for a wide range

▼ Additional benefits for use

for the treatment of

of difficult infections1

nosocomial infections

• Respiratory tract

• Excellent safety profile

• Skin or skin structure

• Antimicrobial streamlining

• Excellent gram
negative coverage
• Provides gram
positive activity
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in combination regimens1

• Septicemia
• Urinary tract
• Bone

In vitro activity does not necessarily imply a correlation with in vivo results.

Cipro I.V. to Cipro oral
• Cost effective2
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ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is achieved through inhibition of DNA
gyrase, an essential component of the bacterial DNA replication system. Inhibition of the alpha subunit of the DNA gyrase blocks
the resealing of the nicks on the DNA strands induced by this alpha.subunit, leading to the degradation of the DNA by
exonucleases. This bactericidal activity persists not only during the multiplication phase, but also during the resting phase of the
bacterium.
Ciprofloxacin retained some of its bactericidal activity after inhibition of RNA and protein synthesis by rifampin and
chloramphenicol, respectively. These observations suggest ciprofloxacin may possess two bactericidal mechanisms, one
mechanism resulting from the inhibition of DNA gyrase and a second mechanism which may be independent of RNA and protein
synthesis.
INDICATIONS AND CLINICAL USES
A) Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets] may be indicated for the treatment of patients with the following infections caused
by susceptible strains of the indicated microorganisms:
Respiratory Tract Infections: Acute bronchitis and acute pneumonia caused by: £ cloacae, E. coli, H. influenzae, K. pneumoniae,
P. mirabilis, P. aeruginosa, S. aureus, S. pneumoniae
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
should be performed periodically during therapy to detect the emergence of bacterial resistance.
Urinary Tract Infections: Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis, pyelonephritis,
and pyelitis, caused by: C. diversus, C. freundii, E cloacae, E coli, K. pneumoniae, K. oxytoca, M. morgana, P. mirabilis,
P. aeruginosa, S. marcescens, S. aureus, S. epidermidis, S. faecalis
Skin and Soft Tissue Infections: caused by: £ cloacae, E coli, K. pneumoniae, P. vulgaris, P. mirabilis, S. pyogenes, P. aeruginosa,
S. aureus, S. epidermidis
Bone and Joint Infections: caused by: S. marcescens, P. aeruginosa, S. aureus, £ cloacae
Infectious Diarrhea: (When antibacterial therapy is indicated) caused by: £ coli [enterotoxigenic strains], C. /ejuni, S. flexnen,
S. sonnei
B) Intravenous Administration
CIPRO® I.V. (Ciprofloxacin injection) may be indicated for the treatment of patients with the following infections caused by
susceptible strains of the indicated microorganisms:
Respiratory Tract Infections: acute pneumonia caused by: £ coli, K. pneumoniae, E. cloacae, P. mirabilis, P. aeruginosa,
H. influenzae, H. parainfluenzas, S. pneumoniae
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing
should be performed periodically during therapy to detect the emergence of bacterial resistance.
Urinary Tract Infections: Upper and lower complicated urinary tract infections including pyelonephritis caused by: C. diversus,
£ coli, K. pneumoniae, P. mirabilis, P. aeruginosa
Skin or Skin Structure Infections: caused by: £ cloacae, £ coli, K. pneumoniae, M. morgana, P. vulgaris, P. mirabilis,
P. aeruginosa. S. aureus, S. pyogenes
Septicemia: caused by: £ coli, S. typhi
Bone: caused by: £ cloacae, P. aeruginosa
Appropriate culture and susceptibility tests should be performed prior to initiating treatment in order to isolate and identify
organisms causing the infection and to determine their susceptibilities to ciprofloxacin. Therapy with CIPRO® and CIPRO® I.V.
may be initiated before results of these tests are known. However, modification of this treatment may be required once results
become available or if there is no clinical improvement. Culture and susceptibility testing performed periodically during therapy
will provide information on the possible emergence of bacterial resistance. If anerobic organisms are suspected to be contibuting
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hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded.
Pseudomembranous colitis has been reported with virtually all antibacterial agents, including ciprofloxacin, and may range in
severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients with diarrhoea subsequent
to the administration of antibacterial agents.
Subsequent to diagnosis of pseudomembranous colitis, therapeutic measures should be initiated. Mild cases will usually respond
to discontinuation of drug alone. In moderate to severe cases, consideration should be given to the management with fluids,
electrolytes, protein supplementation and treatment with an antibacterial drug effective against C. difficile.
Prolonged use of CIPRO® and CIPRO® I.V. may result in the overgrowth of nonsusceptible organisms. Careful observation of the
patient is therefore essential, and if superinfection should occur during therapy, appropriate measures should be taken.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in pregnancy has not yet been established. CIPRO® and CIPRO® I.V. should not
be used in pregnant women unless the likely benefits outweigh the possible risk to the fetus. CIPRO® and CIPRO® I.V. has been
shown to be non-embryotoxic and non-teratogenic in animal studies.
Nursing Mothers Ciprofloxacin is excreted in human milk. A decision should be made to discontinue nursing or to discontinue the
administration of CIPRO® and CIPRO® I.V., taking into account the importance of the drug to the mother and the possible risk to
the infant.
Drug Interactions Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma concentration and
prolongation of elimination half-life of theophylline. This may result in increased risk of theophylline-related adverse reactions. If
concomitant use cannot be avoided, plasma concentrations of theophylline should be monitored and dosage adjustments made as
appropriate.
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of caffeine. Excessive caffeine intake should
be avoided.
Some quinolones, including ciprofloxacin, have been associated with transient increases in serum creatinine levels in patients who
are concomitantly receiving cyclosporine.
Quinolones have been reported to increase the effects of the oral anticoagulant warfarin and its derivatives. During concomitant
administration of these drugs, the prothrombin time or other appropriate coagulation tests should be closely monitored.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an increase in the level of ciprofloxacin
in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug (fenbufen) with a quinolone (enoxacin) has been reported to
increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the absorption of ciprofloxacin. Concurrent
administration with these agents should be avoided.
Administration of sucralfate prior to CIPRO® resulted in a 30% reduction in absorption of ciprofloxacin. Concurrent
administration with ciprofloxacin should be avoided.
Oral ferrous sulfate at therapeutic doses decreases the bioavailability of oral ciprofloxacin, therefore concomitant therapy is not
advised.
The use of calcium supplement reduces the absorption of ciprofloxacin. Concurrent administration should be avoided
Renal Impairment Since ciprofloxacin is eliminated primarily by the kidney, CIPRO® and CIPRO® I.V. should be used with caution
and at a reduced dosage in patients with impaired renal function. (See DOSAGE AND ADMINISTRATION).
Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin
pharmacokinetics were observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been
fully elucidated. An increased incidence of nausea, vomiting, headache and diarrhea were observed in this patient population.
ADVERSE REACTIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are generally well tolerated. During
worldwide clinical investigation, 16,580 courses of ciprofloxacin treatment were evaluated for drug safety.
Adverse events, possibly, probably or highly probably related to ciprofloxacin occurred in 1395 (8,8%) of patients. The adverse
reactions according to treatment (oral, iv, and sequential therapy) show that the incidence of adverse reactions was 8.0% for the
group treated orally, 17% for the group treated with CIPRO® I.V. and 15.3% for the group treated sequentially. The difference
between the oral and iv group relates to adverse vascular reactions which are known to be associated with iv administration.
In orally treated patients enroled in clinical trials, the most frequently reported events, possibly,probably drug-related were:

to the infection, appropriate therapy should be administered.

nausea (1.3%) and diarrhea (1.0%).

CONTRAINDICATIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents,

In patients treated with CIPRO® I.V., the most frequently reported events, possibly, probably drug-related were: rash (1.8%),
diarrhea (1.0%), and injection site pain (1.0%).

WARNINGS
Children The safety of CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection) in children has not
yet been established. Damage to juvenile weight-bearing joints and lameness were observed both in rat and dog studies but not
in weaned piglets (see TOXICOLOGY in Product Monograph). Histopathological examination of the weight-bearing joints in
immature dogs revealed permanent lesions of the cartilage. Consequently, CIPRO® and CIPRO® I.V. should not be used in
prepubertal patients. Experience in pubertal patients below 18 years of age is limited.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in the treatment of infections in pregnant women has not yet been established
(see PRECAUTIONS).
PRECAUTIONS
General Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients receiving therapy with CIPRO®
and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). These reactions may occur within the first 30
minutes following the first dose and may require epinephrine and other emergency measures.
CIPRO® and CIPRO® I.V. may cause central nervous system (CNS) stimulation which may lead to tremor, restlessness, light
headedness, confusion, and very rarely to hallucinations or convulsive seizures. Therefore, CIPRO® and CIPRO® I.V. should be
used with caution in patients with CNS disorders, such as severe cerebral arteriosclerosis or epilepsy. Patients with known
convulsive seizure disorders should only be treated with CIPRO® and CIPRO® I.V. if anticonvulsant therapy has been initiated.
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT ADMINISTRATION OF
CIPRO® I.V. AND THEOPHYLLINE. These reactions include cardiac arrest, seizure, status epilepticus and respiratory failure.
Similar serious adverse events have been noted with administration of theophylline alone, however, the possibility that
ciprofloxacin may potentiate these reactions cannot be eliminated. If concomitant use cannot be avoided, the plasma levels of
theophylline should be monitored and appropriate dosage adjustments should be made.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia. jaundice, and hepatic necrosis with fatal outcome
have also been reported to occur very rarely in patients receiving ciprofloxacin in combination with other drugs. The possibility
that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be withdrawn at the first appearance
of a skin rash or other signs of hypersensitivity.
Crystalluna related to ciprofloxacin has been reported only rarely in man because human urine is usually acidic. Crystals have
been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well

Events possibly, probably drug-related occurring at a frequency of less than 1% with ciprofloxacin oral and i.v. treatment during
clinical trials and subsequent post-marketing surveillance are as follows:
Gastro-Intestinal: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis,
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration,
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis. The following have been reported very rarely: hypertension, hot flashes,
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris,
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion,
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine, increase of intracranial
pressure. In some instances these reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has
to be discontinued and the doctor should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis,
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, comeal
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis: very rarely,
major liver disorders including hepatic necrosis, |oint pain, Lyell Syndrome.

Sequential IV/PO Therapy

Blood and Blood constituents: eosinophilia, leukocytopenia. leukocytosis, anaemia. Very rarely: haemolytic anaemia,
thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase,
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubinemia, hyperuricemia, increased
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis,
crystalluria and haematuria.
Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in severity.There have been 54 reports of
arthropathies with CIPRO®. Ten of these reports involved children. Arthralgia was usually the first symptom which led to rapid
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.

In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated at the discretion of
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed.

Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to compensate for the
reduced renal excretion of patients with renal impairment. Nonetheless, some modification of dosage is recommended,
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However,
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin
(<10%) is removed from the body after haemodialysis or peritoneal dialysis.____________________________________________

DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the
susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function.

Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before o r after meals. Absorption is faster on an empty stomach.
Patients should be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.
A M The recommended dosages of oral CIPRO® are:______________

Location of Infection

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Mild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Lower Respiratory Tract
Bone & Joint
Skin & Soft Tissue

Mild/Moderate
Severe/Complicated5

500 mg
750 mg

q 12h
q 12h

1000 mg
1500 mg

Infectious Diarrhea

Mild/Moderate/Severe 500 mg

q 12h

1000 mg

Dose

Creatinine Clearance
ml/s CmL/min)

SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection).
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be
carefully observed and given supportive treatment.

> 0 .5 (30)

No Dose adjustment

< 0 .5 (30)
and patients on haemodialysis or
peritoneal dialysis

Use recommended dose once daily or
half usual dose twice daily

When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient)
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal
function:

In traditional units mL/min
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R enal Perfusion With the Biomedicus
Pump During Resection of an Abdominal
Aortic Aneurysm
Ved Tandan, MD; Anthony L. Panos, MD, MSc, FRCSC;* James P. Houck, MD;
Tomas A. Salerno, MD, MSc, FACS, FRCSC
Renal artery perfusion is usually unnecessary during resection of an abdominal
aortic aneurysm, because most of these aneurysms are situated below the renal
arteries. The authors report the interesting case of a patient with a solitary
functioning kidney, who had undergone previous bypass grafting from the right
iliac artery to the right renal artery and in whom the kidney was perfused with the
Biomedicus pump during the repair of an abdominal aortic aneurysm. This
technique may be useful in special situations in which any period of renal ischemia
might be hazardous to renal function.

Durant la resection d’un anevrisme de l’aorte abdominale, la perfusion des arteres
renales n’est habituellement pas necessaire puisque la plupart de ces anevrismes se
situent sous le niveau des arteres renales. Les auteurs decrivent un cas interessant,
celui d’un patient porteur d’un seul rein fonctionnel, qui avait deja subi une
derivation de l’artere iliaque droite a l’artere renale droite et chez qui le rein fut
perfuse a l’aide de la pompe Biomedicus pendant la reparation d’un anevrisme de
l’aorte abdominale. Cette technique peut servir dans des situations speciales oil
toute periode d’ischemie renale pourrait menacer la fonction renale.

aortic aneu
M ostrysmsabdominal
are located in the infrarenal position. During repair, the
aorta is usually clamped below the
renal arteries without subjecting
the kidneys to ischemia. We report
on a patient who had had a total
colectomy with ileostomy. Progres
sively severe hypertension required
a right renal artery bypass for renal

artery stenosis in the solitary func
tioning kidney, and there was en
largement of a previously small,
stable, abdominal aortic aneurysm.
The aneurysm was successfully re
sected with the aid of the Bio
medicus centrifugal pump (Bio
medicus, Eden Prairie, Minn.) to
prevent renal ischemia to his soli
tary kidney during aortic clamping.

From the Division o f Cardiovascular and Thoracic Surgery, St. Michael’s Hospital and the
University o f Toronto, Toronto, Ont.
Supported by grant MA-8044 from the Medical Research Council o f Canada
*Fellow, Medical Research Council o f Canada
Accepted fo r publication May 25, 1992
Reprint requests to: Dr. Tomas A. Salerno, Rm. 305B, St. Michael's Hospital, 30 Bond St.,
Toronto, ON M 5B 1W8
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Case Report

A 68-year-old man had under
gone total colectomy and ileostomy
for inflammatory bowel disease 4
years earlier. His stoma was placed
in the right lower quadrant, midway
between the right anterior superior
iliac spine and the umbilicus. Initial
ly, he did well, but progressively
severe hypertension and an abdomi
nal aortic aneurysm developed. In
vestigation of the hypertension in
cluded angiography, which revealed
99% stenosis of the right renal
artery, a nonfunctioning left kidney
and the previously known infrarenal
abdominal aortic aneurysm, 5 cm in
size, not involving the iliac arteries.
No significant atherosclerotic dis
ease was noted in the iliofemoral
vessels. Therefore, he underwent a
right renal artery bypass to alleviate
the stenosis, by a retroperitoneal
flank approach. A side-to-side right
renal artery bypass to the right
common iliac artery was created
with an 8-mm HemaShield graft
(Meadox Medicals, Oakland NJ).
Sixteen months later he was seen
at our institution with abdominal
tenderness over the palpable aneu
rysm. The tenderness radiated into
his left groin. On ultrasonography
the abdominal aortic aneurysm was
noted to have enlarged to 6 cm in
diameter. However, computed to
mography demonstrated no evi
dence of rupture. At surgery, the

RENAL PERFUSION WITH BIOMEDICUS PUMP

aneurysm was approached through
the left flank. After proximal con
trol was gained, both iliac arteries
were encircled with umbilical tapes
and loosely snared. The patient was
heparinized after the left femoral
vein was exposed. The vein was
then cannulated with a 26-French
venous cannula (Wm. Harvey cathe
ter; Bard Canada Inc., Toronto).
The aorta was cross-clamped proximally, the iliac arteries were occlud
ed using the previously placed
snares and the aneurysm was
opened. A large amount of throm
bus was present within the aorta.
The right iliac artery was internally
cannulated through its ostium in
the aorta with a 20-French cannula,
and the cannula was snared in
place. A cannula would not pass
into the left iliac artery. Blood was
drained from the left femoral vein,
oxygenated with a Cobe Ultra mem
brane oxygenator without the reser
voir (1.25 m2 membrane, from Cobe
Laboratories Inc., Lakewood, Colo.)
and then perfused into the right
iliac artery with the Biomedicus
centrifugal pump (model 520 with
Biohead DP 80) at an initial flow
rate of 750 mL/min that was sub
sequently increased to 1.5 L/min.
The aneurysm was repaired with a
20-mm HemaShield tube graft. Dur
ing the period of renal perfusion
urinary output was more than 50
mL/min. The total aortic cross
clamp time, and hence renal perfu
sion time, was 45 minutes.
The patient was taken to the
intensive care unit postoperatively
but was found to have an ischemic
left leg (nonperfused limb). Explora
tion of the left femoral artery re
vealed no palpable pulse, and a
3-mm Fogarty catheter would not
pass more than 15 cm proximally.
Therefore femorofemoral crossover
grafting was performed with an
8-mm velour graft.
The patient made a smooth re
covery. Pulses were palpable in

both femoral arteries. The patient’s
serum urea nitrogen level was 13.4
mmol/L urea, and the serum creati
nine level was 294 /umol/L. These
levels were essentially unchanged
from the preoperative levels (serum
urea nitrogen 13.1 mmol/L urea
and serum creatinine 307 /x mol/L).

Discussion
The role of revascularization in
renovascular hypertension with
renal insufficiency is well establi
shed.1-3 Many strategies and proce
dures have been devised to accom
plish optimal revascularization of
the kidney. They include renal ar
tery angioplasty,4 aortorenal by
pass,5-7 hepatorenal or splenorenal
artery bypass,89 renal endarterecto
my,10 inferior epigastric artery re
construction11 and autotransplanta
tion.1213 In this patient with a single
functioning hypoperfused kidney
and prior major abdominal surgery,
the merits of a dissection that re
mained in the retroperitoneal space,
coupled with the excellent inflow
provided by the available iliac ar
tery, gave an excellent alternative
to each of the above options. We
were further influenced by previous
experience reported in the literature
on renal transplantation that docu
ments the excellent results obtained
using the iliac system for renal
artery inflow.14-16 The approach of
resection of the abdominal aortic
aneurysm combined with revascu
larization of the renal artery
through a left retroperitoneal inci
sion would have been technically
hazardous and difficult to justify in
an elderly patient with a relatively
small and stable aneurysm despite
previously poor control of his hy
pertension.
The subsequent presentation
with an enlarging abdominal aortic
aneurysm necessitated special con
cern for preserving the remaining

renal function. Proponents of the
“clamp-and-sew” technique rely on
the presumed collateral circulation
to the iliac vessel to provide an
adequate perfusion pressure as well
as their ability to minimize ischemic
injury by completing the procedure
with clamp times under 60 minutes.
Although there are selected reports
of successful similar procedures
without protection of the ischemic
kidney,17-20 previous reports includ
ing the use of extra-anatomic
shunts or femorofemoral perfusion
with a roller pump and bubble
oxygenator to prevent ischemia of
the transplanted kidney have dem
onstrated the utility of ensuring
minimal renal ischemia.21-24
Use of the Biomedicus pump in
this case to drain blood from the
left femoral vein and return oxygen
ated blood to the right common
iliac artery (thereby perfusing the
transplanted renal artery) allowed
the aneurysm resection to proceed
without subjecting the kidney to
ischemia. The conduct of the opera
tion was otherwise unremarkable.
Renal perfusion was assured and
was demonstrated by the excellent
urine output during the period of
aortic clamping as well as by the
baseline renal function postopera
tively.
Our technique to avoid visceral
ischemia during thoracoabdominal
aneurysm resection seeks to perfuse
the visceral and peripheral organs
to avoid severe increases in after
load to the heart and to perform an
unhurried operation.25 Although it
is unlikely that significant renal
ischemia will occur during abdomi
nal aneurysm resection, in our case
the strategy of selective renal perfu
sion was important in successfully
achieving the goals of safe aneu
rysm resection and reconstruction
without compromising this patient’s
already-limited renal function. The
presence of the ileostomy in the
abdominal wall led us to choose the
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flank approach for the aneurysm
resection.
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Reconstruction of Avulsed Scalp
After Go-Cart Injury
Michael J. Weinberg, BSc, MSc, MD; Ronald M. Zuker, MD, FRCSC, FACS;
James L. Mahoney, MD, FACS, FRCSC; Ian R. Munro, MD, MS, FRCSC; Imad Kaddoura, MD
Scalp avulsion is a rare injury that has significant physical and psychological
consequences. It may require emergency replantation or late, challenging surgical
reconstruction, or both. The authors describe two patients who had scalp avulsion.
Each patient got long hair entangled in the uncovered engine of a go-cart. One
underwent unsuccessful replantation without vascular repair; the other had a large
segment of scalp successfully replanted with microvascular repair. Both patients
required late reconstruction with tissue expansion. The final results were good.
When feasible, microvascular replantation is the treatment of choice. If replantation
is not possible, temporary cover by skin grafts followed by later reconstruction with
tissue expansion can be effective.

L’avulsion du cuir chevelu est une blessure rare qui occasionne des consequences
physiques et psychologiques importantes. Elle peut necessiter une reimplantation
urgente ou une reconstruction chirurgicale tardive difficile, ou une association des
deux. Les auteurs decrivent deux patients qui subirent une avulsion du cuir chevelu.
Les deux patients avaient vu leurs longs cheveux s’emmeler dans le moteur non
couvert de leur kart. Un subit sans succes une reimplantation sans reparation
vasculaire; l’autre eut un segment large du cuir chevelu reimplante avec reparation
microvasculaire. Les deux patients necessiterent une reconstruction tardive avec
expansion tissulaire. Le resultat final fut bon. Lorsqu’elle est possible, la
reimplantation microvasculaire represente le traitement de premier choix. Si la
reimplantation n'est pas possible, on pourra corriger par couverture temporaire a
l’aide d’une greffe cutanee, suivie, plus tard, par une reconstruction avec expansion
tissulaire.

eports of go-cart injuries are
rare. Scalp avulsions are also
rare. In adults, “ scalping” usually
occurs in industrial settings, where
as in children the mechanism o f
injury is more varied. We report on
successful reconstruction of the
scalp after avulsion resulting from
preventable go-cart injuries.

R

Case Reports
Case 1

A 10-year-old girl sustained an
isolated 20% scalp avulsion injury
in 1984 when her below-the-waist
hair became entangled in the uncov
ered engine parts o f a go-cart. The

From the Division o f Plastic Surgery, Department o f Surgery, The Hospital fo r Sick Children,
Toronto, Ont.
Accepted for publication Mar. 5, 1992
Reprint requests to: Dr. Ronald M. Zuker. C hief o f plastic surgery, The Hospital For Sick
Children, Ste. 1524, 555 University Ave., Toronto, ON M5G 1X8

scalp was replanted directly without
microvascular anastomosis.
The
majority of the replanted tissue did
not survive. These areas required
split-thickness skin grafting.
In 1986, when this girl was first
seen at our institution, the area o f
alopecia was large (Fig. 1). At sur
gery, a 300-mL tissue expander
(Cox-Uphoff International, Carpinteria, Calif.) was placed in the right
occipital region and a 680-mL ex
pander was placed in the left pari
etal region, both in a subgaleal
plane. Expander valves were placed
subcutaneously in easily accessible
locations. The expanders were in
flated once a week with normal
saline for 12 weeks to full capacity
without complication (Fig. 2).
At that time, all o f the skin-graft
ed area was excised. The right
occipital expanded scalp was used
as a large transposition flap, and
the expanded parietal scalp was
used as a smaller rotation flap (Fig.
3). Flap survival was complete.
Two years later, several small
areas of alopecia secondary to
spread scars were excised. The inci
sions were broken up with Z-plasties. The final result is seen in
Fig. 4.
Case 2

An 11-year-old girl sustained an
85% scalp avulsion injury (Fig. 5) in
a go-cart accident in 1985 (same
mechanism as in case 1). The
CJS, VOL. 35, NO. 6, D EC EM BER 1992
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avulsed scalp segments were
wrapped in moist gauze and placed
in a plastic bag. These were trans
ported in a cooler and arrived at our
hospital 8 hours after the injury
occurred. The girl and the amputat
ed scalp were taken to the operat
ing room. The largest piece ( 1 1 X8
cm), from the left frontotemporoparietal region, contained the super
ficial temporal vessels. Exploration
of these vessels under the micro
scope revealed them to be suitable
for microvascular anastomosis. The
other pieces did not contain any
important vessels. Therefore, the
largest piece was replanted, with
microsurgical repair of the superfi
cial temporal artery and one vein
(Fig. 6). An interposition vein graft
was needed for the venous anasto
mosis.
Three days postoperatively, the
posterior nonviable part of the re
planted scalp was debrided. In the
several areas of exposed skull that
lacked periosteum, small holes were
drilled in the outer table of the skull
to facilitate the formation of granu
lation tissue. The residual defects
were covered by split-thickness me
shed grafts. Survival of these grafts
was virtually complete.
Six months later a large area of
alopecia remained (Fig. 7). Tissue
expanders (Cox-Uphoff Internation-

al) were inserted as in case 1 to
make maximal use of remaining
hair-bearing scalp. A 350-mL ex
pander was placed in the occipital
region, a 700-mL expander in the
left temporal region and a 270-mL
expander in the right temporal re
gion. Inflation was begun 10 days
later on an outpatient basis, once a
week.
Two weeks after expansion be
gan, the left temporal expander
became widely exposed, necessitat
ing removal and replacement. Two
weeks after that, the new expander
became infected. The infection re
sponded to antibiotics.
A further 2 weeks later the ex
panders were removed. An advance
ment flap from the occiput allowed
excision of a 10 X 6-cm area of
skin graft. A right temporal flap
was advanced 3 cm. New expanders
were placed in the occiput (140 mL)
and the right temple (340 mL).
After uncomplicated expansion
for 7 weeks, occipital and right
temporal advancement and rotation
flaps allowed excision of 70% of the
area of alopecia. At surgery a left
temporo-occipital expander was ins
erted; however, this became ex
posed, necessitating removal.
In late 1986 the patient under
went further expansion of the oc
cipital region (500-mL expander)

and the left temporal region
(680-mL expander). After 6 weeks,
the expanders had reached full ca
pacity. A large transposition flap in
the occipital scalp and a large rota
tion flap in the temporoparietal
scalp allowed full closure of the
residual defect (Fig. 8).
In early 1988 and 1989, several
small areas of alopecia due to
spread scars were excised.
Late in 1989 the patient com
plained of two areas of alopecia in
the right scalp and of an irregular
anterior hairline. Three expanders
were placed: one (250mL) in the
sagittoparietal region and two (250
mL and 60 mL) in the right parieto
occipital region. Expansion contin-

FIG. 1. Case 1. Area of alopecia in
volved 20% of hair-bearing scalp.

FIG. 2. Case 1. Right occipital and left
parietal scalp expanders at full capa
city.

FIG. 4. Case 1. Final result showing
luxuriant hair growth and well-hidden
scars.
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FIG. 3. Case 1. Intraoperative views of
large, right occipital and left parietal
scalp flaps (posterosuperior view ).

RECONSTRUCTION OF AVULSED SCALP

ued three times a week while the
patient was in hospital. Unfortu
nately, a painful hematoma formed
almost immediately around the pos
terior expander. The hematoma was
evacuated, and inflation of that ex
pander was halted. After 4 weeks,
expansion of the sagittoparietal re
gion was complete. The anterior
hairline with its widened scar was
excised and broken up with multi
ple Z-plasties. The alopecia in the
right temporoparietal region was
completely excised and closed with
an inferiorly based advancement

flap of the expanded tissue. The
postauricular area was excised and
closed with a combination of rota
tion and advancement flaps. The
final result, despite the multiple
procedures and a number of unfor
tunate setbacks was excellent (Fig.
9).

hair that became entangled in the
uncovered engines of go-carts.
These injuries were entirely pre
ventable had helmets and engine
covers been in place. We were un
able to determine the incidence of
this injury on a provincial and na
tional level, because no statistics

Discussion
Go-carting is popular in Canada
and there are tracks in most major
cities. Both our patients had long

FIG. 5. Case 2. Initial defect involved 85% of hair-bearing scalp.

FIG. 6. Case 2. Largest avulsed piece
was replanted using microvascular
techniques. Scalp viability was excel
lent.

FIG. 7. Case 2. (Left) Right lateral view. (Right) Posterior view. Skin-grafted area
involved 40% of hair-bearing scalp.

FIG. 8. Case 2. One week after scalp
reconstruction.
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are available from government of
fices and major insurance compa
nies.
Although scalp avulsion is rare, it
results in severe disfigurement and
psychologic distress. It is reported
approximately equally in adults and
children. Although adults are usual
ly involved in industrial injuries, the
mechanisms by which children are
injured vary and include boat en
gines,1 farm tractors,2 dog bites3'4
and car accidents.56 In general, the
frequency of this injury is highest
in children with unprotected long
hair.1'7
Scalp avulsion occurs in the
loose areola layer between the galea
(aponeurosis) and the periosteum.89
An oblique shearing force is re
quired, because force perpendicular
to the scalp causes only hair
loss.1011 The exact configuration of
the avulsed scalp depends on the
specific direction and strength of
force applied and on the amount
and location of hair.8-10 This ex
plains the difference in wound sizes
seen in our two cases. The exten
sive vascularity of the scalp usually
leads to massive hemorrhage.2'79

Although vessel retraction usually
limits blood loss,9 continuing bleed
ing may be controlled by pressure
and head elevation.2
The management of avulsed scalp
is complex and has been changed
dramatically by microvascular re
plantation and tissue expansion. Be
fore microvascular replantation sur
gery was available or when this was
not possible, the exposed calvarium
was covered by a variety of tech
niques.1112
The avulsed scalp has been re
planted directly without microvas
cular anastomosis. However, with
one exception,13 such replacements
have failed.8'10-11'14
Moderate defects extending up to
one-third of the scalp may be closed
with a variety of local scalp flaps,
the most effective911 being the
three- and four-flap methods de
scribed by Orticochea.15
In most instances, large scalp
defects may be closed with split
thickness skin grafts,11 occasionally
harvested from the avulsed scalp.16
However, these are immobile, insen
sate, unsightly, thin and tend to
break down with minor trauma.1011

FIG. 9. Case 2. Final result. (Left) Right lateral view. (Right) Top view.
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Hair loss requires the use of a
permanent hair piece.
Microvascular replantation of the
scalp was first reported in 1976.14
The results since then have been
excellent, with restoration of pro
tective sensibility, superior cosmesis
and few complications.8'912 In our
second patient, replantation of ap
proximately 60% of the scalp con
tributed significantly to the overall
cosmetic result and the ease of later
reconstruction.
Although ischemic time is impor
tant, periods of up to 24 hours with
cooling do not seem to threaten
scalp viability.8917 Thus, the isch
emic time in the first case was
relatively short.
The superficial temporal artery
seems to be the most reliable artery
for anastomosis.9'18 One artery
seems to be able to sustain the
entire scalp.8-121819 Liberal use of
vein grafts, as in case 2, has con
tributed substantially to the feasibil
ity and success of scalp reconstruc
tion.6711
It is important to note that suc
cessful replantation has occurred
even after the scalp has been
crushed by rollers20 or twisted
around a revolving shaft and con
tused.21 Thus, the decision to re
plant should not be based on the
mechanism of injury.19 Careful eval
uation in the operating room is
required before a decision can be
made as to the feasibility of scalp
microsurgical replantation.
The modern era of soft tissue
expansion began with the pioneer
ing efforts of Radovan22 and Austad
and Rose.23 This exciting new re
constructive tool allows ingenious
manipulation of normal physiologic
processes. It has many advantages
that include providing sensate,
highly vascular donor tissue with
regional peculiarities and minimal
donor-site morbidity.2224 The disad
vantages include length of treat
ment and staged operations.3 6-24'25
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RECONSTRUCTION OF AVULSED SCALP

Scalp expansion has been used
successfully to eliminate alopecia
due to a variety of conditions.1225
Expanders are placed in a subgaleal
plane, deep to the major vessels of
the skin.4 Complication rates of 3%
to 43% have been reported.25 26 The
most frequent complications seem
to occur in the head and neck
region and consist mainly of ex
pander exposure and wound infec
tion.25 Exposed implants usually
have to be removed, although sec
ondary closure is sometimes possi
ble. Infected expanders are removed
if drainage and antibiotic therapy
fail.27
Excessive widening of scars, as
seen in both our cases, is a relative
ly common problem that usually
requires revision.3 It occurs despite
flaps being sutured under minimal
tension.
During scalp expansion, the
number of hair follicles remains
unchanged.25 The reduction in hair
density is not usually noticeable
until it is more than 50%.25 Thus,
despite the large area of scalp ex
panded in our second case, the
resultant decrease in hair density is
not bothersome to the patient.
These two cases illustrate well
the tragedy of preventable scalp
avulsion in childhood and the multi
plicity of techniques available for
challenging scalp reconstruction.
The avulsed scalp should always be
preserved and microvascular replan
tation attempted. Finally, we believe
that tissue expansion is the late
reconstructive treatment of choice
for traumatic alopecia.

References
1. Cuthbertson AM, S yme GA: Avulsion
injuries of the scalp. Med J Aust 1966;
2: 1151-1152

2. Caldwell EH: Complete scalp avulsion.
Arch Surg 1976; 111: 159-161
3. Manders EK, Graham WP, S chenden
MJ et al: Skin expansion to eliminate
large scalp defects. Ann Plast Surg
1984; 12: 305-312
4. N ordstrom REA, D evine JW: Scalp
stretching with a tissue expander for
closure of scalp defects. Plast Reconstr
Surg 1984; 75: 578-581
5. F ang K, S tevenson TR: Skin g raft from
a scalp flap. Plast Reconstr Surg 1985;
79: 622-624
6. L eonard AG, S mall JO: Tissue expan
sion in the treatment of alopecia. Br J
Plast Surg 1986; 39: 42-56
7. Rus J: Open treatment of avulsion of
scalp using a Crutchfield skull caliper.
Acta Chir Plast 1976; 18: 80-90
8. Gatti JE, Larossa D: Scalp avulsions
and review of successful replantation.
Ann Plast Surg 1980; 6: 127-131
9. Alpert BS, Buncke HJ, Mathes SJ:
Surgical treatment of the totally avulsed
scalp. Clin Plast Surg 1982; 9: 145-159
10. B hattacharya V, S inha JK, T ripathi
FM: Management of scalp injuries. J
Trauma 1982; 22: 698-702
11. N ahai F, H ester TR, J urkiewicz MJ:
Microsurgical replantation of the scalp.
J Trauma 1985; 25: 897-902
12. McCarthy JG (ed): Plastic Surgery,
Saunders, Philadelphia, 1990: 15201537
13. Lu ML: Successful replantation of
avulsed scalp. Plast Reconstr Surg
1969; 43: 231-234
14. Miller GDH, A nstee EJ, S nell JA:
Successful replantation of an avulsed
scalp by microvascular anastomoses.
Plast Reconstr Surg 1976; 58: 133-136
15. O rticochea M: Surgical treatment of
alopecia. In McC arthy JC, (ed): Plastic
Surgery, Saunders, Philadelphia, 1990:
1 5 2 0 -1 5 3 7
16. F armer AW: T reatm ent of avulsed skin
flaps. Ann Surg 1939; 110: 9 5 1 - 9 6 0
17. H entz VR, P alma CR, E lliott E et al:

Successful replantation of a totally
avulsed scalp following prolonged isch
emia. Ann Plast Surg 1981; 7: 145-149
18. S akai S, S oeda S, Ishii Y: Avulsion of
the scalp. Which one is the best artery
for anastomosis? Ann Plast Surg 1990;
24: 350-353
19. S tratoudakis AC, Savitsky LB: Mi
crosurgical reimplantation of avulsed
scalp. Ann Plast Surg 1981; 7: 312316
20. S tock EBW, W olfensberger GI, G otz
WD: Successful replantation of a totally
avulsed scalp. Br J Plast Surg 1979; 32:
19-21

21. N ahai F, H urteau J, V asconez LO:
Replantation of an entire scalp and ear
by microvascular anastomosis of only 1
artery and 1 vein. Br J Plast Surg 1978;
31: 339-342
22. R adovan C: Tissue expansion in soft-tis
sue reconstruction. Plast Reconstr Surg
1984; 74: 482-492
23. Austad ED, R ose RL: A self-inflating
tissue expander. Plast Reconstr Surg
1982; 70: 588-593
24. S hively RE, B ermant MA, B ijcholtz
RD: Separation of craniophagus twins
utilizing tissue expanders. Plast Re
constr Surg 1984; 76: 765-772
25. B aker SR, S wanson NA: Clinical appli
cations of tissue expansion in head and
neck surgery. Laryngoscope 1990; 100:
313-319
26. Austad ED: Complications in tissue ex
pansion. Clin Plast Surg 1987; 14:
549-550
27. H arving S, Ravnsbaek J, V endelbo LV:
Salvage of exposed implants. Scand J
Plast Reconstr Surg 1989; 23: 143-144

Correction
In the paper “Total mastectomy is
not always mandatory for the treat
ment of recurrent breast cancer after
lumpectomy alo n e” by D.R.
McCready and colleagues (pages 485
to 488) there was an error in the
number of patients who underwent
total mastectomy (TM) alone. This
number should be 28. Therefore, in
the abstract, the penultimate sen
tence in the first paragraph should
read “Those treated with TM (28
patients) or TM plus radiation (5
patients) had rates of local control of
60% and 52% respectively.” Like
wise, the resume should read “Celles
qui furent traitees par MT (28 patientes) ou par MT et radiotherapie
(5 patientes) ont eu des taux de
controle local de 60 % et 52 % respectivement.” Also, on page 486,
the last line in the third column
should read “control of the TM (28
patients).” We apologize to the au
thors and to our readers for this
error.
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PRESCRIBING INFORMATION

Rocephin®,,m
Sterile Ceftriaxone Sodium
For Injection
Therapeutic Classification
Antibiotic
INDICATIONS AND CLINICAL USES
The treatment of the following infections when caused by susceptible
strains of the designated micro-organisms: Lower respiratory tract
infections caused by E. coli, H. influenzae, K. pneumoniae and species,
Staph, aureus, Strep, pneumoniae and species (excluding enterococci).
Urinary tract infections (complicated and uncomplicated) caused by
E. coli, Klebsiella species, P. m irabilis and P. vulgaris. Bacterial
septicemia caused by E. coli, H. influenzae, K. pneumoniae, Staph, aureus
and Strep, pneumoniae (excluding enterococci). Skin and skin structure
infections caused by K. pneumoniae and species, P. mirabilis, Staph,
aureus, Staph, epidermidis and Streptococcus species (excluding
enterococci). Bone and joint infections caused by Staph, aureus, Strep,
pneumoniae and Streptococcus species (excluding enterococci). IntraAbdominal Infections caused by £ coli and K. pneumoniae. Meningitis
caused by H. influenzae, N. meningitidis, and Strep, pneumoniae.
Rocephin* should not be used for the treatment of meningitis caused by
L. monocytogenes. Uncomplicated gonorrhea (cervical/urethral and
rectal) caused by N. gonorrhoeae (penicillinase and nonpenicillinase
producing strains). Susceptibility Testing: Specimens for bacteriologic
culture should be obtained prior to therapy in order to identify the causative
organisms and to determine their susceptibilities to ceftriaxone. Therapy
may be instituted before results of susceptibility testing are known.
However, modification of the treatment may be required once these
results become available. Prophylaxis: The preoperative administration
of a single 1 g dose of Rocephin* (ceftriaxone sodium) may reduce the
incidence of postoperative infections in patients undergoing vaginal or
abdominal hysterectomy, coronary artery bypass surgery, or in patients
at risk of infection undergoing biliary tract surgery. If signs of post
surgical infection should appear, specimens for culture should be
obtained for identification of the causative organism(s) so that the
appropriate therapy may be instituted.
CONTRAINDICATIONS
Rocephin" (ceftriaxone sodium) is contraindicated in patients with
known allergy to ceftriaxone, other cephalosporins or penicillins.
WARNINGS
Before therapy w ith Rocephin* (ceftriaxone sodium) is instituted,
careful inquiry should be made concerning previous hypersensitivity
reactions to ceftriaxone, other cephalosporins, penicillins or other allergens.
Rocephin " should only be administered with caution to any patient
who has demonstrated any form of allergy particularly to drugs. Serious,
and occasionally fatal hypersensitivity (anaphylactoid) reactions have
been reported in patients receiving cephalosporins. The reactions are
more likely to occur in persons w ith a history of sensitivity to multiple
allergens. Rocephin * should be administered with caution to patients
w ith type I hypersensitivity reaction to penicillin. If an allergic reaction
occurs, the administration of Rocephin* should be discontinued and
appropriate therapy instituted. Pseudomembranous colitis has been
reported w ith the use of Rocephin®, (and with broad-spectrum and other
antibiotics). Therefore, it is important to consider its diagnosis in
patients administered Rocephin* who develop diarrhea. Treatment with
broad-spectrum antibiotics, including Rocephin®, alters the normal flora
of the colon and may permit overgrowth of Clostridia. Studies indicate
that a toxin produced by Clostridium difficile is one primary cause of
antibiotic-associated colitis. Mild cases of colitis may respond to drug
discontinuation alone. Moderate to severe cases should be managed
w ith fluid, electrolyte, and protein supplementation as indicated. When
the colitis is not relieved by discontinuation of Rocephin* administration
or when it is severe, consideration should be given to the administration
of vancomycin or other suitable therapy. Other possible causes of the
c o litis should also be considered. Rocephin® therapy should be
discontinued in patients who develop signs or symptoms suggestive of
gallbladder disease and conservative management considered. The
effect of pre-existing gallbladder disease is not known. In a few patients
administered Rocephin®, shadows sugggesting “ sludge” have been
detected by sonograms of the gallbladder in those who remained
asym ptomatic and in those who became symptomatic. This condition
appeared to be reversible on discontinuation of Rocephin* therapy.
In a few symptomatic patients receiving 4 g of Rocephin® who under
went cholecystectomy, “sludge” containing traces of ceftriaxone was
recovered from surgical specimens. Concretions consisting of the
precipitated calcium salt of ceftriaxone have been found in the gall
bladder bite of dogs and baboons treated with high doses of ceftriaxone.
PRECAUTIONS
General Hypoprothrombinemia and alterations in prothrombin time have
occurred rarely in patients treated w ith Rocephin* (ceftriaxone sodium)
(see ADVERSE REACTIONS). Patients with impaired vitamin K synthesis
or low vitam in K stores (e.g. chronic hepatic disease and malnutrition)
may require m onitoring of hematology and coagulation parameters
during R ocephin* treatment. Vitamin K administration (10 mg weekly)
may be necessary if the prothrombin time is prolonged before or during
treatment. Prolonged treatment with Rocephin * may result in overgrowth
of non-susceptible organisms and organisms initially sensitive to the
drug. Development of resistant organisms during the administration of
Rocephin® in clinical trials has been observed in 6% of the 94 patients
infected w ith P. aeruginosa, in 33% of 3 patients infected with Citrobacter
species and in 10% of the 10 patients infected with Enterobacter
species. If superinfection occurs, appropriate measures should be taken.
R ocephin* should be administered w ith caution to individuals with a
history of gastrointestinal disease, particularly colitis. Renal and Hepatic
Impairment Although transient elevations of BUN and serum creatinine
have been observed in clinical studies, there is no other evidence that
Rocephin®, when administered alone, is nephrotoxic. In severe renal
im pairment (creatinine clearance of less than 10 mL/min), periodic
monitoring of serum ceftriaxone concentrations is recommended. The
maximum daily dose should not exceed 2 g. In severe renal impairment
associated w ith c lin ic a lly significant hepatic im pairment, close
monitoring of serum ceftriaxone concentrations, at regular intervals,
is recommended. If there is evidence of accumulation, dosage should

be decreased accordingly. Interactions Interactions between Rocephin*
and other drugs have not been fully evaluated. Pregnancy The safety
of Rocephin* in the treatment of infections during pregnancy has not
been established. Rocephin* should only be used during pregnancy if
the likely benefit outweighs the potential risk to the fetus and/or the
mother. Ceftriaxone has been detected in the umbilical cord blood,
amniotic fluid and placenta. At parturition, 1 hour after a 2 g I.V. dose of
'Rocephin®', average ceftriaxone concentrations in maternal serum,
umbilical cord serum, amniotic fluid, and placenta were 106±40 fig/mL,
19.5±11.5fiQ/mL, 3 .8 *3 .2 ^g /m L and 20.9±4.4 ^g /g . Nursing
Mothers Ceftriaxone is excreted in human milk at low concentrations,
(e.g. the peak concentration of total drug in milk ranged between 0.45
to 0.65 ^g/m L, approximately 5 hours after the administration of 1 g I.V.
or I.M.). The clinical significance of this is unknown; therefore, caution
should be exercised when Rocephin® is administered to a nursing
mother. Neonates The safety of Rocephin* in neonates (birth to one
month of age) has not been established. In vitro studies have shown
that ceftriaxone can displace bilirubin from serum albumin. Caution
should be exercised when considering Rocephin* treatm ent for
hyperbilirubinemic neonates especially if premature. Elderly Patients
The elim ination of ceftriaxone may be reduced in elderly patients
possibly due to impairment of both renal and hepatic function. DrugLaboratory Test Interactions Ceftriaxone may interfere with urine
glucose determinations utilizing the copper-reduction test (CLINITEST),
but not utilizing the glucose-oxidase test (DIASTIX or TES-TAPE).
ADVERSE REACTIONS
During clinical trials with Rocephin* (ceftriaxone sodium) the following
adverse reactions have been observed: Clinical Adverse Experiences:
Dermatological: Rash (1.3%); exanthema, allergic dermatitis and pruritis
(0.1-1.0%). Hematological: Anemia (0.1-1.0%); auto-immune hemolytic
anemia and serum sickness (<0.1%). Hepatic: Jaundice, reports (in
asymptomatic and symptomatic patients) of ultrasonographic shadows
suggesting precipitations in the gallbladder and reports of gallbladder
sludge (<0.1% ). Urogenital: M oniliasis and vaginitis (0.1 -1.0%).
Gastrointestinal: Diarrhea (3.3%); nausea, vomiting, dysgeusia and
gastric pain (0.1-1.0%); abdominal pain, colitis, flatulence, dyspepsia,
pseudomembranous co litis and stom atitis (<0.1%). Neurological.
Dizziness and headache (0.1-1.0%); ataxia and paresthesia (<0.1%).
Miscellaneous: Fever, chills, diaphoresis, malaise, burning tongue,
flushing, edema and anaphylactic shock (0.1 -1.0%); bronchospasm,
palpitations and epistaxis (<0.1%) Local Reactions at Injection Site:
Pain (9.4%)a, induration and tenderness (1-2%); phlebitic reactions
(0.1-1.0%); thrombophlebitis (<0.1%). aPain on intramuscular injection
is usually mild and less frequent when the drug is administered in sterile
1% Lidocaine solution. Laboratory Abnormalities: Hematologic:
Eosinophilia (4.6% ), throm bocytosis (5.1%), leukopenia (2.0%);
neutropenia, lymphophenia, thrombocytopenia, increase or decrease
in hem atocrit, prolongation of prothrombin tim e and decrease in
hemoglobin (0.1-1.0%); leukocytosis, lymphocytosis, monocytosis,
basophilia and decrease in prothrombin time (<0.1%). Hepatic: Increase
in AST (SGOT) (4.0%)t>, ALT (SGPT) (4.8%)&, increase in alkaline
phosphatase (1.0%); increase in bilirubin (0.1-1.0%). Urinary: Increase
in BUN (1.1 %)c, increase in creatinine, erythrocyturia, proteinuria and
presence of casts in urine (0.1-1.0%); glycosuria (<0.1%). incidence
is more frequent in patients less than one year old. cincidence is more
frequent in patients less than one year old and over 50 years old.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Ultrasonographic shadows suggesting precipitations in the kidneys
accompanied by calcium ceftriaxone precipitate in the urine was observed
in one patient dosed with Rocephin® (ceftriaxone sodium) at 10 g/day
(2.5 times the maximum recommended dose). No other case of overdosage
has been reported to date with Rocephin*. No specific information on
symptoms or treatment is available. Excessive serum concentration of
ceftriaxone cannot be reduced by hemodialysis or peritoneal dialysis.
Treatment should be symptomatic.
DOSAGE AND ADMINISTRATION
Rocephin* (ceftriaxone sodium) may be administered intravenously or
intramuscularly after reconstitution. Dosage and route of administration
should be determined by the severity of infection, susceptibility of the
causative organisms, and condition of the patient. The intravenous route
is preferable for patients with septicemia or other severe or life-threatening
infections. DOSAGE Adults: Moderate and Severe Infections: Total daily
I.M. or I.V. dose 1 or 2 g daily. The daily dose may be given as 0.5 or 1 g
q12h, or 1 or 2 g q24h. There is limited experience with daily doses of
3-4 g administered as a single dose or two equally divided doses. The
total daily dose should not exceed 4 g. Uncomplicated Gonorrhea: Single
dose of 250 mg I.M. Infants and Children (one month to 12 years of age)
Serious M iscellaneous Infections Total daily I.M. or I.V. dose 50 or
75 m g/kg administered as 25 or 37.5 mg/kg q12h. The total daily dose
should not exceed 2 g. If body weight is 50 kg or more the adult dose
should be used. M eningitis: Total daily I.M. or I.V. dose-100 mg/kg
administered as 50 m g/kg* q12h. ‘ With or without a loading dose of
75 mg/kg. The total daily dose should not exceed 4 g. With the exception
of gonorrhea, which is treated with a single dose, the administration of
Rocephin* should be continued for a minimum of 48 to 72 hours after
the patient defervesces or after evidence of bacterial eradication has
been obtained, usually 4 to 14 days. In bone and joint infections the
average duration of treatment during clinical trials was 6 weeks, with a
range of 1 to 13 weeks, depending on the severity of the infection. When
treating infections caused by beta-hemolytic Streptococcus, it is
recommended that therapy be continued for at least 10 days. The average
duration of therapy for infections associated with beta-hemolytic
Streptococcus during clinical trials was 2 weeks, with a range of 1 to
5 weeks, depending on the site and severity of the infection. Prophylaxis
For preoperative use as prophylaxis before vaginal or abdominal hyster
ectomy, coronary artery bypass surgery, or biliary tract surgery in patients
at risk of infection, a single dose of 1 g administered 1/2 to 2 hours before
surgery is recommended Impairment of Renal and/or Hepatic Function
In patients with mild to moderate renal impairment, changes in the dosage
regimen are not required, provided liver function is intact. In cases of
preterminal renal failure (creatinine clearance less than 10 mL/min),
periodic monitoring of serum ceftriaxone concentrations is recommended.
The daily dosage should be limited to 2 g or less. In patients with liver
damage, there is no need for the dosage to be reduced provided renal
function is intact. In cases of coexistent renal and clinically significant
hepatic insufficiency, close monitoring of serum ceftriaxone con
centrations, at regular intervals, is recommended. If there is evidence

of accum ulation, dosage should be decreased accordingly.
ADMINISTRATION Intramuscular: The reconstituted solution of
Rocephin* should be administered by deep intragluteal injection.
It is recommended that not more than 1 g be injected at a single site.
Pain on intramuscular injection is usually mild and less frequent when
Rocephin* is administered in sterile 1% Lidocaine solution. Intravenous
(bolus) Injection: The reconstituted solution should be administered over
approximately 5 minutes. If the distal port of an intravenous administration
set is used, stop the primary flow, inject the reconstitued 'Rocephin*'
solution and then restart the primary flow. This will prevent mixing with
the primary fluid and possible incompatibilities Short Intravenous
Infusion: The further diluted intravenous solution should be given over
a period of 10 to 15 minutes in infants and children and 20 to 30 minutes
in adults. NOTE: Rocephin* solution should not be physically mixed
w ith aminoglycoside antibiotics nor administered at the same site
because of possible chemical incompatibility.
PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute Rocephin* powder with the appropriate diluent:
• Sterile Water for Injection
• Bacteriostatic Water for Injecton
• 0.9% Sodium Chloride Injection • 1% Lidocaine Solution
• 5% Dextrose Injection
Reconstitute as follows:
_______________
Reconstitution Table (IM)
Approximate
Approximate
Volume to be
Vial
available
average
added to vial
Size
volume
concentration
mL
mL
g/mL
0.25 g
0.9
1
0.25
1.0 a
3.6
4
0.25
7.2
2.0 0
8
0.25
Shake well until dissolved.
NOTE: SOLUTION PREPARED FOR INTRAMUSCULAR USE OR ANY
SOLUTION CONTAINING LIDOCAINE OR BACTERIOSTATIC WATER
FOR INJECTION SHOULD NEVER BE ADMINISTERED INTRAVENOUSLY.
For intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute as follows:
Reconstitution Table (IV)
Approximate
Approximate
available
average
volume
concentration
mL
g/mL
2.4
0.25 g
2.5
0.1
1.0 g
9.6
10.0
0.1
2.0 g
19.2
20.0
0.1
Shake well until dissolved. The prepared solution may be further diluted
to the desired volume with any of the “ Solutions for IV Infusion" listed
below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection
5% Dextrose Injection
Dextrose and Sodium Chloride Injection
0.9% Sodium Chloride Injection in ADD-VANTAGE (Abbott) flexible
diluent container, 50 mL and 100 mL
5% Dextrose Injection in ADD-VANTAGE (Abbott) flexible diluent container,
50 mL and 100 mL.
Pharmacy Bulk Vial Reconstitution for Preparation of Intravenous
Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time
after reconstitution, using a suitable sterile transfer device or dispensing
set which allows measured dispensing for the contents.
Reconstitution Table for Bulk Pharmacy Package
Approximate
Approximate
Volume to be
available
average
Vial
added to vial
volume
concentration
Size
mL
mL
g/mL
95
100.0
0.1
10 0
Shake well until dissolved. Withdraw the required amount and dilute
with one of the "Solutions for IV Infusion” . Any unused solution remaining
w ithin a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product
Monograph.
Incompatibility:
R ocephin* should not be physically mixed with other antimicrobial
agents.
Rocephin* should not be added to blood products, protein hydrolysates
or amino acids.
Rocephin* should not be added to solutions containing calcium.
DOSAGE FORM
Availability:
1. Rocephin* Vials containing sterile powder equivalent to 0.25 g, 1 g
and 2 g of ceftriaxone.
2. Rocephin® Vials containing sterile powder equivalent to 1 g and 2 g
of ceftriaxone for use only with Abbott Laboratories Limited ADDVANTAGE (Abbott) 0.9% Sodium Chloride Injection U.S.P. or 5%
Dextrose Injection U.S.P. in 50 mL and 100 mL containers.
3. Rocephin® Pharmacy Bulk Vials containing sterile powder equivalent
to 10 g ceftriaxone (not for direct administration).
The availability o f the pharmacy bulk vial is restricted to hospitals with a
recognized intravenous admixture programme.
Storage:
Rocephin* sterile powder should be stored at a controlled room
temperature (between 15° and 30°C) and protected from light.
Product Monograph available on request.
Vial
Size

Volume to to
added to vial
mL
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Injuries to the Nervous System and Spine
in Downhill Skiing
S. Terence Myles, MD, FRCSC;* Nicholas G.H. Mohtadi, MD, FRCSC;t
Joseph Schnittker, MD, FRCSC*
The authors describe injuries to the nervous system and spine from downhill skiing
accidents through a review of the charts of downhill skiers admitted over 5 years to
the three teaching hospitals of the University of Calgary. The office of the chief
medical examiner provided details about accidental deaths from downhill skiing in
which nervous system trauma occurred. During the study period, 145 downhill
skiers suffered injury to the nervous system or spine. There were five deaths from
nervous system trauma. The mean age of the injured skiers was 23.8 years, and
these injuries were three times more common in men than in women. Eighty-eight
skiers sustained a head injury, 25 had spinal fractures alone, 20 had spinal cord or
nerve root injury and 12 had peripheral nerve injury. A simple fall on the hill was
the commonest method of injury, followed in frequency by collision with a tree,
which caused the most severe injuries. Reckless skiing, design of ski runs and
man-made snow were contributing factors. The serious nature and number of these
injuries must be recognized, and further study is needed on causal factors and
preventive measures.

Suite a l’etude des dossiers medicaux des skieurs re?us pendant une periode de 5
ans dans trois hopitaux affilies a l’Universite de Calgary, les auteurs decrivent les
lesions du systeme nerveux et de la colonne qui surviennent lors des accidents de
ski. Le bureau du medecin legiste a fourni les details des accidents mortels de ski
alpin ou il y a eu atteinte du systeme nerveux. Pendant la periode etudiee, 145
skieurs alpins ont subi des lesions du systeme nerveux ou de la colonne. On a
enregistre cinq deces resultant de traumatismes du systeme nerveux. L’age moyen
des skieurs blesses etait de 23,8 ans et ces blessures ont ete trois fois plus
frequentes chez les hommes que chez les femmes. Quatre-vingt-huit skieurs ont subi
des blessures a la tete, 25 des fractures de la colonne vertebrale seulement, 20 des
atteintes de la moelle epiniere ou des racines nerveuses et 12 ont eu des lesions des
nerfs peripheriques. La plus frequente cause de blessures a ete la simple chute dans
une pente; deuxieme en frequence, la collision avec un arbre a cause les blessures
les plus graves. La temerite des skieurs, le trace des pistes et la neige artificielle ont
ete des facteurs qui ont contribue aux accidents. La severite et le nombre de ces
blessures doivent etre reconnus; d’autres etudes sont necessaires pour analyser les
causes et proposer des mesures preventives.

From the *Division o f Neurosurgery and f Division o f Orthopedics, Alberta Children’s Hospital
and Foothills Hospital and the University o f Calgary Medical School, Calgary, Alta.
Accepted fo r publication Dec. 2, 1992
Reprint requests to: Dr. S. Terence Myles, Division o f Neurosurgery, Alberta Children's
Hospital, 1820 Richmond Rd. SiV. Calgary, A B T2T 5C7

ownhill skiing is a popular,
exciting sport. Although many
papers in the medical literature
have documented ski injuries,1' 10
few have focused on injuries to the
spine or nervous system.11-14
Lindsjo and associates13 reported
the relative frequency o f head inju
ries at ski emergency rooms in
Salen, Sweden, to be 11% and stat
ed that the relative frequency o f
head injuries was fairly constant.
The majority o f injured skiers in
that study did not require hospital
admission.
Head and spinal injuries made up
approximately 4% o f all injuries
seen at a ski injury clinic situated in
the base lodge of Sugar Bush, Vt.,
between 1972 and 1981.4 In the
under-16-years age group, these in
juries accounted for 6.2% o f all
skiing injuries.
Oh11 reported that injuries to the
cervical spine from skiing accidents
are not rare, whereas the incidence
o f thoracolumbar fractures from
downhill skiing injuries has been
reported to range from 0 to 5.2% .14
Each winter, our neurosurgical
service has been involved in the
care of children and adults injured
in downhill skiing accidents. The
range and severity o f spinal and
nervous system trauma has been
broad and has not been documented
in previous reports. The three Uni
versity o f Calgary teaching hospi
tals provide the only neurosurgical

D
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service to southern Alberta and
southeastern British Columbia, an
area with 11 downhill ski facilities.
Our patient population has there
fore been highly selected to include
the more severely injured skiers
who required neurosurgical consul
tation and hospital admission.
In this article we describe the
spinal cord and nervous system in
juries sustained by 145 downhill
skiers and the circumstances sur
rounding each injury.

Patients and Methods
We reviewed the charts of down
hill skiers admitted to the three
University of Calgary teaching hos
pitals over the 5-year period No
vember 1983 to May 1988 whose
discharge diagnosis included injury
to the peripheral or central nervous
system or the spine.
The office of the chief medical
examiner provided us with details
about accidental deaths, occurring
during the same period, from down
hill skiing in which there was injury
to the nervous system.
Details regarding the mechanism
of injury were obtained from the
hospital record. This information
was available in all but four cases.

Findings
One hundred and forty-five skiers
(109 males and 36 females) sus
tained spinal or nervous system
injury, or both, as a result of skiing
accidents during the 5-year period

— a male-to-female ratio of 3:1.
The skiers ranged in age from 6 to
64 years (mean 23.8 years); 29 of
them were under 14 years of age
(mean 11.1 years, range from 6 to
14 years).
Five skiers died of nervous sys
tem injury, three at the scene of the
accident and two in hospital. All
were men and the average age was
35 years (range from 26 to 54
years).
Head injuries were sustained by
88 skiers, spinal cord or nerve root
injuries by 20 skiers, spinal frac
tures by 25 skiers and peripheral
nerve injuries by 12 skiers (Table I).
Of the 88 patients admitted with
a diagnosis of head injury, 70 had
cerebral concussion (Table II),
which in our institutions was de
fined as a transient loss of con
sciousness due to an impact. Com
puted tomography (CT) of the head
confirmed cerebral contusion in 11
skiers and extra-axial hematomas in
5. There was one case of traumatic
carotid-cavernous fistula confirmed
angiographically. Basal skull frac
ture was diagnosed clinically or
radiologically in 18 patients, and 15
patients had fractures involving the
cranial vault. Of the 33 skull frac
tures, 5 were compound and 3 were
depressed, including 1 in a child
who had been wearing a helmet.
Three skiers had complete spinal
cord injuries (Table III), Seven ski
ers had incomplete spinal cord inju
ries, with varying degrees of loss of
motor function, sensation and
sphincter function. Transient paral
ysis led to a diagnosis of spinal cord
concussion in two patients. Eight

skiers had evidence of nerve root
injury.
In the three skiers with complete
spinal cord injury that injury re
mained complete on follow-up after
1 year; one of the skiers with an
incomplete cervical cord injury dem
onstrated improvement but had
poor hand function and bilateral leg
weakness 1 year after a burst frac
ture of the C6 vertebra. Follow-up
data on the other skiers with spinal
injury was not available.
The 20 skiers who had spinal
cord or nerve root injury had a
variety of injuries to the bony spine.
All seven patients with cervical
nerve root injury had facet fractures
of the C6 or C7 vertebra with
subluxation. Cervical spinal cord
injury was seen with two burst
fractures, one of the C5 vertebra
and one of the C6 vertebra, and
with two compression, tear-drop
fractures of the C5 vertebra. The
two patients who had complete tho
racic spinal cord injuries had fracTable II. D istribution o f Head Injuries by
Type (n = 88)
Type of injury
Concussion
Contusion
Subdural hem atom a
Acute
Chronic
Epidural hem atom a
C aro tid -ca ve rn o u s fis tu la
Skull fracture
Basal
Cranial vault

Type of injury

M ale,
no. (% )

Female,
no. (% )

Total,
no. (% )

Head
S pinal c o rd /n e rv e root
S pinal fra ctu re alone
Peripheral nerve

70 (80)
1 7 (8 5 )
14 (56)
8 (6 7 )

1 8 (2 0 )
3 (1 5 )
11 (44)
4 (3 3 )

88 (61)
2 0 (1 4 )
2 5 (1 7 )
1 2 (8 )
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70 (80)
1 1 (1 2 )
2 (2 )
1(1)
2 (2 )
1 d)
1 8 (2 0 )
1 5 (1 7 )

Table III. N um ber and Type of Spinal-C ord
or N erve-R oot Injuries (n = 20)
Type of injury

Table 1. Type o f In ju ry and Sex D is trib u tio n o f 145 Patients W ho Suffered S pinal or
N e rvous-S ystem Injuries in D o w nh ill Skiing A ccidents

No. (% ) of
injuries

Com plete spinal cord
Cervical
Thoracic
Incom plete spinal cord
Cervical
Conus m edullaris
Spinal-cord concussion
Nerve root
Cervical
Sacral

No. (°/o)
1 (5)
2 (1 0 )
3 (1 5 )
4 (2 0 )
2 (1 0 )
7 (3 5 )
1 (5 )

DOWNHILL SKIING SPINAL INJURIES

ture dislocation at the T6-7 and
T7-8 levels respectively. Injuries to
the conus medullaris were associat
ed with either thoracolumbar com
pression fractures or fracture dislo
cations. In two patients with neuro
logic deficit, no fracture could be
identified on plain radiography or
CT.
Fourteen (56%) of the 25 patients
who had spinal cord injury without
neurologic deficit sustained com
pression fractures (seven lumbar,
six thoracic and one cervical). The
remaining patients in this group
had fractures of transverse process
es (six), lamina (two), facets (one),
burst fracture (one) and the odon
toid process (one).
Of the 12 patients with peripher
al nerve injuries (Table IV), 5 with
upper extremity injuries had associ
ated shoulder fracture dislocations,
one had a shoulder dislocation and
one had fractures of the clavicle and
C7-T2 transverse process. One had
no bony injury. For the three pa
tients with peroneal nerve palsies,
T a b le IV . N u m b e r and T y p e o f
P e rip h e ra l-N e rv e In ju rie s (n = 12)
T yp e of injury

No. (% )

B ra ch ia l p le x u s
T o ta l
P artial
A x illa ry ne rve
P eron e a l n e rve
In fra o rb ita l n e rve

3 (2 5 )
2 (1 7 )
3 (2 5 )
3 (2 5 )
1 (8 )

one had a compound fracture of the
tibia and fibula, one had a dislocat
ed knee and one had a posteriorly
dislocated hip. The skier who dam
aged his infraorbital nerve and had
a partial facial-nerve injury also had
a compound mandibular fracture. In
three patients who had surgical
treatment, the nerves were seen to
be intact. No skiers sustained nerve
laceration.
The type of accident and the
number and category of associated
injuries is listed in Table V. The
commonest method of injury was
an isolated fall on the hill without
collision in 48% of the skiers. Of
the 70 injured in this way 42
suffered a head injury, 23 a spinal
injury and 5 a peripheral nerve
injury.
Collisions accounted for 41% of
injuries, with trees being the com
monest object struck (23%). Two
skiers who struck trees died of head
injuries, and four others were se
verely injured, having permanent
neurologic disability. Eight skiers
(6%) were injured in collisions with
other skiers, seven (5%) collided
with fences and five (3%) with lift
equipment. Four skiers (3%) were
injured by collision with snow-mak
ing or grooming equipment, and
one of them died. Two skiers collid
ed with a ski lodge, sustaining head
and spinal injuries respectively.

T a b le V. T y p e o f A c c id e n t V e rs u s N u m b e r and T y p e o f In ju ry
T y p e of in ju ry, no. (% )

T yp e of a c c id en t

P e rip h e ra l
n erve

T o ta l

2 3 (5 1 )
1 5 (3 3 )

5 (4 2 )
7 (5 8 )

7 0 (4 8 )
5 9 (4 1 )

10 (2 2 )
2 (4 )
1 (2 )
0 (0 )
1 (2 )
1 (2 )
2 (4 )
5 (1 1 )
0 (0 )

5 (4 2 )
0 (0 )
2 (1 7 )
0 (0 )
0 (0 )
0 (0 )
0 (0 )
0 (0 )
0 (0 )

3 3 (2 3 )
8 (6 )
7 (5 )
5 (3 )
4 (3 )
2 (1 )
3 (2 )
9 (6 )
4 (3 )

4 5 (1 0 0 )

1 2 (1 0 0 )

1 4 5 (1 0 0 )

H ead

S p in a l

Fall on h ill
T o ta l c o llis io n
C o llis io n w ith :
Tree
A n o th e r s k ie r
Fence
L ift p o s t
S n o w -m a k in g m a c h in e
L o d ge
Fall fro m lift
O ther
U n kn o w n

42 (4 8 )
37 (4 2 )
1 8 (2 0 )
6 (7 )
4 (5 )
5 (6 )
3 (3 )

T o ta l, no. (% )

8 8 (1 0 0 )

1 (1 )
1 (1 )
4 (5 )
4 (5 )

Three skiers had lift-related inju
ries, all of which were severe and
resulted in permanent disability.
One skier sustained a severe head
injury with a depressed skull frac
ture and epidural hematoma, and
two others had spinal injuries with
quadriplegia and paraplegia, both
complete and permanent.
Nine skiers were injured by fall
ing from cliffs or running into
rocks. This group included two ski
ers who died of head injury after
being swept over cliffs by ava
lanches.
The type of accident was not
recorded on the hospital chart in
four cases.
Intoxication with alcohol was
documented in three skiers and may
have contributed to the injury in
another three. Drug intoxication
was not identified in any skier.
The number of injuries per sea
son varied from a low of 16 in 1983
to 1984 to a high of 43 in 1986 to
1987. We were able to obtain the
number of skier days for each of
the 11 ski areas (Table VI). The
number of injuries per million skier
days was 17.3 in 1983 to 1984,
22.4 in 1984 to 1985, 23.5 in 1985
to 1986, 29 in 1986 to 1987 and
23.2 in 1987 to 1988. The highest
number of skier days reported was
in 1986 to 1987, the year with the
highest number of injuries per mil
lion skier days.
Our patients sustained injuries in
11 different ski areas within a
250-km radius from Calgary. Pa
tients with concussions or less se
vere spinal injuries (not requiring
neurosurgical consultation) may
have been admitted to outlying
community hospitals close to the
ski areas. During the 5-year period,
6 174 785 skier days were record
ed, giving an overall frequency of
these injuries of 23 per million
skier days. The frequency varied
from a low of 4.7 in area I to a high
of 122.6, in area F (Table VI).
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In 22 patients, the accident oc
curred during heliskiing or the site
was not specified.
Comparison of the number of
injuries with the month of the year
in which they occurred showed that
most injuries occurred in March,
whereas injury frequency was al
most the same in December, Janu
ary and February (Table VII).

Discussion
The fact that skiing injuries to
the spine or nervous system may
result in death has been emphasized
in several excellent reviews,15-18 and
our experience has been similar.
Factors involved in these injuries
include the equipment used, skier
attitude and skill, and the environ
ment, including snow and weather
conditions as well as man-made and
natural hazards.
Johnson10 reported that improve
ments in ski boots and bindings
have resulted in a decrease in the
number of skier injuries. However,
the decline has been in injuries to
the lower extremity, whereas the
frequency of upper body injury has
remained unchanged. Though our
sample was highly selected — be
cause skiers with less severe head
and spinal injuries would not have
been hospitalized or would have
been admitted elsewhere — our
numbers were consistent with an
unchanged frequency of upper body
injury during the 5 years of the
study.
This study does not allow any
conclusions to be drawn about the
role of ski helmets. Our youngest
skier, a 6-year-old child, sustained a
depressed skull fracture while wear
ing a helmet. Oh11 has suggested
that a back extension of a safety
helmet would provide additional
protection against injury to the cer
vical spine. However, such an ex
tension would limit extension of the
646

neck, which is essential in the
“tuck” position, and would not
protect against flexion or axial load
ing injuries, which occurred in 12
of our 45 patients with spinal inju
ry. Problems with helmet design
were acknowledged by Lindsjo and
associates.13 There are no Canadian
standards for ski helmets at pres
ent, though future improvements in
helmet design and use might con
tribute to a reduction in compound
and depressed skull fractures and in
concussion injuries.
The mean age of our pediatric
subgroup, 11.1 years, fits with the
experience of Blitzer and associ
ates,4 who reported that the highest
incidence of head and spine injuries
was in 11- to 13-year-old children.
Shealy16 found that the fatally
injured skier is usually male and
that fatal accidents tend to be high
speed events. Our experience was
similar in that all five fatally injured
skiers were male, and three of the
five were involved in high-speed
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collisions. The average age of our
fatally injured skiers (35 years) was
considerably older than the average
age for the entire group, consistent
with other reports.1518
Skier attitude and skill were diffi
cult to evaluate in a retrospective
chart review. However, the fact that
80% of our patients with head inju
ry and 85% of our patients with
spinal cord or nerve root injury
were male was striking. It has been
stated that most injured skiers are
young and that the male-to-female
ratio is generally about the same.16
In the group of skiers who had
spinal injury and no neurologic defi
cit, the male-to-female ratio was
1.3:1. These less severe spinal inju
ries likely occurred at lower speed
than those in which neurologic in
jury occurred.
Our population of skiers with
injury to the nervous system, with
an average age of 23.8 years and a
marked preponderance of males to
females, showed striking similarity

T a b le VI. N u m b e r o f S k ie r D a ys and S pin a l o r N e rv o u s -S y s te m In ju rie s P er M illio n S k ie r D a ys fo r
S ele cte d S ki A reas

S ki a re a
A
B
C
D
E
F
G
H
1
J
K

No. of s p in a l/n e rv o u s -s y s te m
root in ju rie s p e r m illio n
s k ie r d a y s

N o. of s kier days
(1 9 8 3 - 1 9 8 8 )
477
396
329
1 701
207
163
196
452
212
1 934
98

131
700
827
806
000
000
464
980
377
000
500

21
5
5 7 .6
1 3 .5
29
1 2 2 .6
2 0 .3
1 7 .6
4 .7
1 3 .5
4 0 .6

T a b le V II. M o n th o f Y e a r in W h ic h S kiin g In ju rie s O ccu rre d
Type of injury, no. of p atients

M o n th
N ovem ber
D ecem ber
J a n u a ry
F e b ru a ry
M a rc h
A p ril
M ay

H ead

S pinal

P e rip h e ra l
n erve

T o ta l,
no. (»/o)

3
18
16
19
24
5
3

1
10
11
8
8
4
3

0
3
3
1
4
1
0

4 (3 )
3 1 (2 1 )
3 0 (2 1 )
2 8 (1 9 )
3 6 (2 5 )
1 0 (7 )
6 (4 )

DOWNHILL SKIING SPINAL INJURIES

to skiers who had fatal injury in
other reports.15"18 Since most fatally
injured skiers died of trauma to the
head or neck, this finding was not
really surprising. Our data appeared
to support Shealy’s16 comments
that males are more inclined toward
risk-taking behaviour than females.
Although skill level was not consis
tently recorded on the hospital
chart, our own observations sup
port the hypothesis that these inju
ries occurred in skiers with more
experience and skill than the gener
al skiing public.
Our study was similar to that of
Matter, Ziegler and Holzach1 in that
the commonest type of head injury
seen was a concussion.
Although most skiers were in
jured in falls, the percentage of
collision injuries was surprisingly
high (41% overall). In this report,
42% of head injuries, 33% of spinal
injuries and 58% of peripheral nerve
injuries were from collisions. Jen
kins, Johnson and Pope9 found that
only 18.5% of their patients at a ski
injury clinic were injured in colli
sions but, like us, found that colli
sions with trees produced a dispro
portionately high number of severe
injuries. Preventing falls may be
difficult, but with skier education
programs and campaigns to reduce
reckless skiing, it should be possi
ble to reduce the number of colli
sion injuries.
Alcohol was documented as being
a factor in only 4% of our injured
skiers, a rate that is consistent with
those of other studies.117
Although our data on mechanism
of injury were obtained from the
hospital record, our staff had a high
level of interest in skiing accidents,
and we felt that the information
recorded was reliable.
The variability in the injury rate
per ski area deserves comment. The
two areas with the lowest injury
rates were a considerable distance
from our hospitals, and patients

with minor head or spinal injuries
from those areas were likely treated
in local hospitals. The two areas
with the highest number of skier
days had identical injury rates, and
most skiers with head or spinal
injuries from those areas would
have been sent to our hospitals.
Area A, which had 21 injuries per
million skier days, is in the city of
Calgary, and all injured skiers
would have been referred to our
hospitals.
The areas that had the highest
injury rates had one feature in
common. They were located in the
“chinook zone,” where rapid warm
ing and freezing occur during the
winter months. Area F, which had
the highest injury frequency, had
the most advanced snow-making
equipment. The combination of arti
ficial snow and frequent tempera
ture change may have created more
icy conditions, contributing to the
high injury rate.
The ski areas with the lowest
injury rates were located outside
the “chinook zone,” used very little
or no artifical snow and had more
wide runs.
In this study 33 skiers collided
with trees, and in that group there
were two deaths and four cases of
permanent neurologic deficit. Wid
ening intersections and changing
the design of ski runs to reduce the
probability of collision with trees
should help to reduce the frequency
of these serious injuries.
The relationship between the
number of injuries and the months
of the ski season differ from that
reported by Arnold and Ackman,6
possibly due to the longer ski sea
son in our area.
The death rate of 0.81 per mil
lion skier days was much higher
than the death rate from trauma of
0.25 reported from Australia.18
Weston, Moore and Rich15 reported
a rate of 1.71 deaths per million
skier days in the United States.

Conclusions
We have reviewed the mecha
nisms and types of spinal cord and
nervous system injury in 145 down
hill skiers. The profile of these
skiers closely matched that previ
ously described in the literature for
fatally injured skiers. This sub
group of injured skiers has not
previously been well described nor
has the fact that these injuries can
lead to permanent disability. Educa
tional programs, directed especially
at young males, need to emphasize
these hazards of downhill skiing.
Also, further studies should be un
dertaken to identify more clearly
the causal factors and to establish
effective preventive measures.
We thank Diane Beauvais-Bishop for
secretarial support.
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BOOK REVIEWS
continued from page 578

possibly because o f the breadth o f the
topics. The coverage o f Crohn’s disease
and the polyposis syndromes is some
what superficial. However, there is an
excellent chapter on early detection and
follow-up o f large-bowel cancers, and
the operative sections in the chapters
on colorectal cancer and ulcerative coli
tis are detailed and complete. In the
chapter on rectal cancer, the various
treatment options, including anterior
resection, abdominoperineal resection,
coloanal anastomosis and local treat
ment are discussed. There is a full
discussion o f the various surgical op
tions for ulcerative colitis as well as a
discussion o f the more controversial
aspects o f pouch surgery. The authors
also deserve praise for a chapter on
stomas, because o f the in-depth discus
sion o f the various types o f stomas and
their complications, and for the one on
constipation. A rationale approach to
both the investigation and management
o f this difficult topic is given.
On the whole, this is an excellent
textbook, which would be a useful
addition to a hospital library or the
personal library of a general surgeon or
surgical trainee. Professor John Goligher’s textbook has been the standard in
this field, but this textbook may well
take its place.
Robin S. M cLeod, MD, FRCSC
Department o f Surgery
Mount Sinai Hospital
60 0 University Ave.
T oron to, ON
M5G 1X5
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ATLAS OF CHEST IMAGING: COR
RELATED ANATOMY WITH MRI
AND CT. Marvin Wagner and Thomas
L. Lawson. 144 pp. Illust. Raven
Press, Inc., New York. 1992. $80
(US). ISBN 0 -8 8 1 6 7 -8 8 8 -0
This is a short, well-written and wellillustrated atlas o f anatomy of the
chest, containing an eight-reference bib
liography and a two-page index. It is
divided into three “ units” o f axial (or
transverse), sagittal and parasagittal,
and coronal views.
The axial unit consists o f transverse
sections of thoracic anatomy correlated
with magnetic resonance (MR) and com
puted tomography (CT) images, extend
ing from the base o f the neck down to
the diaphragm. Different CT windows
are selected to show the chest wall and
mediastinum (after intravenous contrast
enhancement) as well as the lungs. This
section includes the shoulder girdle and
magnified figures of the great vessels
and heart chambers, which are particu
larly useful.
The second and third units o f the
book show standard anatomy sections
with MR imaging correlation. I agree
with the authors that, since MR imag
ing is available, reformatted sagittal,
parasagittal and coronal CT scans have
been abandoned for all practical pur
poses by most radiologists. Thus, they
are not illustrated in the book.
Throughout the book, the cross-sec
tional anatomy figures are well chosen
and are extensively and correctly la-
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belled. Overall, the organization of the
book is excellent. The two authors, a
surgeon and a radiologist, have vast
experience in the subject. They previ
ously published a book entitled Seg
mental Anatomy (Macmillan, New York,
1982).
Many good atlases o f segmental
cross-sectional anatomy o f the body
with ultrasound and CT correlation
have appeared in the past 15 years. The
more recent ones have MR correlation
also, with most o f them including the
whole body. The present book is more
detailed but covers only the chest.
No colour was used in the anatomy
illustrations. This is only mentioned for
the purpose o f comparison with the
multitude o f books o f cross-sectional
anatomy now on the market.
The choice is difficult, but this book
is very useful. It provides an excellent
source of information for CT and MR
technologists, medical students, interns
and residents, surgeons and chest radi
ologists who need to consult a short
atlas o f segmental anatomy o f the tho
rax.

E. Michel A zou z, MD, FRCPC
Assistant director
Medical Imaging
The Montreal Children's Hospital
Montreal, PQ
H3H 1P3

continued on page 660
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Splenic Vein Thrombosis as a Cause
of Variceal Bleeding
Joseph Thavanathan, MB, BS;* Christopher Heughan, MD, FRCSC;t
Thomas M. Cummings, MD, FRCPCJ
Splenic vein thrombosis as a cause of variceal bleeding is underdiagnosed. Newer,
noninvasive techniques of diagnosis that have been introduced recently appear to be
accurate. Isolated gastric varices in the presence of normal liver function and
especially in the presence of pancreatic disease should prompt a search for splenic
vein thrombosis. Splenectomy is the treatment of choice.

Presentement, les thromboses des veines spleniques sont sous-diagnostiquees
comme causes d’hemorragies variqueuses. De nouvelles techniques diagnostiques
atraumatiques apparues recemment semblent precises. Des varices gastriques isolees
en presence d’une fonction hepatique normale et, tout specialement, en presence de
troubles pancreatiques, doivent faire penser a rechercher une thrombose des veines
spleniques. La splenectomie s’avere le traitement de premier choix.

he majority of cases of bleed
ing from varices are due to
cirrhosis. In a small number of
patients, however, the cause is lo
calized portal hypertension from
other causes, one being splenic vein
thrombosis. In these patients, liver
function is likely to be normal. The
management of the such patients is
very different from the management
of cirrhotic patients. Hence, prompt
and accurate diagnosis of splenic
vein thrombosis as a cause of vari
ceal bleeding is important.
In this report we present three

T

patients with upper gastrointestinal
bleeding in whom we diagnosed
splenic vein thrombosis as the
cause of bleeding varices. We also
suggest an appropriate scheme for
the recognition and management of
this condition.

Case Reports
Case 1

A 38-year-old man presented with
upper gastrointestinal bleeding. He

From the Department o f Surgery, Memorial University o f Newfoundland. Health Sciences
Centre, St. John's. Ntld.
’" Chief resident in surgery. Memorial University o f Newfoundland

had no history of alcohol abuse but
had had pancreatitis 3 years previ
ously. He was first seen at a local
hospital. Endoscopy showed no var
ices, ulcers or gastritis. He contin
ued to bleed and required transfu
sion of 23 units of blood. He under
went exploratory laparotomy at the
local hospital where he was found
to have fundic varices with an en
larged spleen and normal liver.
There was a 4-cm diameter cyst in
the head of the pancreas. He was
transferred to the Health Sciences
Centre. Endoscopy revealed a very
prominent mucosal fold in the fun
dus. Celiac arteriography showed a
bulky spleen. The splenic vein was
not identified. Splenoportography
showed large dilated veins at the
splenic hilus constituting short
gastric and gastroepiploic vessels.
Again, the splenic vein was not
visualized. The portal vein was well
visualized and was of normal ca
libre. Laparotomy was performed,
and the preoperative findings were
confirmed. Splenectomy was per
formed. The lesser sac was obliter
ated by adhesions, so prior control
of the splenic artery was not ob
tained. The patient had a smooth
recovery. Liver biopsy was not
done.

tProfessor o f surgery, Memorial University o f Newfoundland
fC lin ica l assistant professor o f radiology, Memorial University o f Newfoundland

Case 2

Accepted for publication Oct. 18, 1992

A 78-year-old woman presented
with upper gastrointestinal bleed
ing. The patient had no history of
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alcohol abuse or pancreatitis. En
doscopy showed fundic varices.
Splenic arteriography showed vari
ces in the fundus, and contrast was
shown to enter the lumen of the
stomach. The splenic and portal
veins were not opacified. At laparot
omy, the spleen was found to be
enlarged. The liver and pancreas
were normal. A splenectomy was
performed and recovery was uncom
plicated. Liver biopsy was not done.

Case 3
A 46-year-old man presented to
his local hospital with upper gas
trointestinal bleeding. He had a his
tory of alcohol abuse and had suf
fered from pancreatitis 12 years
previously. Endoscopy revealed no
abnormalities.
On examination, he had no signs
of liver disease. The spleen was
enlarged. He needed transfusion of
10 units of blood. He was trans
ferred to our hospital. Repeat en
doscopy revealed isolated gastric
varices. Computed tomography
(CT) with oral and intravenous con
trast and dynamic nonincremental
scanning were done, revealing no
evidence of cirrhosis. There was
marked splenomegaly, perisplenic
and gastric varices and nodularity
of the gastric wall. The splenic vein
was thrombosed, with calcification.
There was little pancreatic paren
chyma, and there was calcification
in the head of the pancreas. Large
retroperitoneal varices were directly
posterior to a very tortuous splenic
artery. The portal vein was normal.
At operation, the preoperative find
ings were confirmed. There were no
varices in the distribution of the
superior mesenteric vein. The pan
creas was atrophic and densely ad
herent to the posterior abdominal
wall. Prior control of the splenic
artery through the lesser sac was
obtained. This resulted in a tear in
the retroperitoneal varices, necessi
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tating tranfusion of 13 units of
blood. This area was packed, and
hemostasis was achieved. A splenec
tomy was done. The patient’s recov
ery was uncomplicated.

Discussion
In most cases of variceal bleeding
with portal hypertension, alcoholic
cirrhosis is the cause. In this dis
ease, survival seems to depend on
the underlying liver damage. In a
small number of patients who have
variceal bleeding, splenic vein
thrombosis is the cause of the vari
ces. It is important not to miss this
diagnosis, because it can be cured
by splenectomy.
Isolated splenic vein thrombosis
was first described at autopsy by
Frich in 1922.1 It has been referred
to as segmental, left-sided, compartmental, sinistral, lienal or splenoportal hypertension. Splenic blood
that is unable to drain through the
splenic vein may take three differ
ent routes: (a) through short gastric
vessels into the coronary vein
through venous channels in the
stomach wall, resulting in varices in
the gastric fundus; (b) through the
left gastroepiploic vein into the
right gastroepiploic vein and then
into the superior mesenteric vein;
and (c) through retroperitoneal
veins into the inferior vena cava.
This diversion will result in dilated
short gastric veins, gastric varices,
dilated coronary veins, dilated gas
troepiploic arcade and dilated retro
peritoneal veins in the region of the
pancreas. However, there is no ob
struction to the flow of blood in the
superior mesenteric or portal veins,
and these are normal in size. There
is no underlying liver disease, and
therefore the results of liver func
tion tests are not altered. If there is
variceal bleeding, hepatic encepha
lopathy usually does not occur be
cause liver function is intact. How
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ever, rarely, if there is associated
liver disease, encephalopathy may
occur. It appears that the resistance
to flow from the short gastric veins
through varices in the gastric fun
dus to the coronary veins is less
than that of the portoazygos sys
tems. This results in isolated gastric
fundic varices without esophageal
varices. The coronary veins may
drain into the confluence of the
superior mesenteric and splenic
veins (59%), directly into portal
veins (24%) or into the splenic vein
itself (17%).2 In splenic vein throm
bosis, if the coronary vein enters
the splenic vein, drainage through
the coronary vein is impaired, and
this promotes development of eso
phageal varices and drainage of
blood into the azygos system. The
spleen becomes congested, and
there may be associated features of
secondary hypersplenism.
The real incidence of splenic vein
thrombosis is not known. Wellrecognized causes of splenic vein
thrombosis are acute pancreatitis,
chronic pancreatitis, pancreatic
pseudocysts, carcinoma of the pan
creas, cystadenoma, islet cell tu
mour of the pancreas, trauma, lym
phoma, sarcoma, retroperitoneal fi
brosis, myeloproliferative disorders,
gastrectomy, splenic artery aneu
rysm and renal cell carcinoma.34

Diagnosis
Isolated gastric varices, normal
liver function and the presence of
pancreatic disorders that can result
in splenic thrombosis is suggestive
of this condition. Upper gastrointes
tinal hemorrhage in the absence of
a definite explanation should arouse
suspicion of the possibility of
missed gastric varices. At endosco
py, the diagnosis of gastric varices
can be difficult. These varices may
appear only as nodularity of the
gastric mucosa or just prominent
mucosal folds. A barium-meal ex-

SPLENIC VEIN THROMBOSIS

FIG. 1. Upper gastrointestinal series shows air-filled fundus with multiple,
lobulated filling defects compatible with multiple gastric varices. Esophageal
portion of film shows no evidence of esophageal varices.

amination can be helpful in demon
strating fundic varices (Fig. 1).
Splenoportography and celiac ar
teriography with delayed films of
the venous phase are well-estab
lished techniques for demonstrating
splenic vein thrombosis. In these
investigations, if the splenic and
portal veins are opacified, they are
invariably patent. However, failure
to opacify does not necessarily
prove obstruction or thrombosis.
Characteristically, in splenic vein
thrombosis, the portal vein is opaci
fied in the absence of splenic vein
opacification. Also, there will be
dilated short gastric veins and left
gastroepiploic veins. These angio
graphic techniques are invasive.
Prolonged prothrombin time may
be a contraindication to splenopor
tography. Recently, CT has proved
to be quite reliable in making a
diagnosis of splenic vein thrombo
sis.56 Findings include: abnormal
vessels medial to the stomach in the
gastrohepatic ligament; abnormal
vessels lateral to the stomach; fun
dic varices; normal portal vein and
liver; thrombus or calcification in
the splenic vein; and prominent gas
troepiploic veins.
Apparently, a prominent gastro
epiploic vein is highly specific for
splenic vein thrombosis.6 CT can
also demonstrate pancreatic or
other disease responsible for splenic
vein thrombosis (Figs. 2 and 3).
Splenic vein thrombosis is not a
diagnosis made at surgery, nor can
it be established on the basis of
abnormalities of the spleen and dis
tal splenic vein.
Management

FIG. 2. Computed tomography (CT) image demonstrating multiple varices along
posterior wall of gastric fundus.

In a patient suspected of having
splenic vein thrombosis, investiga
tions should be undertaken to con
firm the diagnosis. Sclerotherapy
appears to be rather ineffective in
controlling bleeding gastric varices.
The sclerosed varices are likely to
CJS, VOL. 35. NO. 6. DECEMBER 1992
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recur with time. Splenectomy has
been the most effective procedure in
permanently controlling hemorrh
age. During splenectomy, prior con
trol of the splenic artery has been
recommended. In patients with pan
creatic disease, the lesser sac may
be obliterated, the pancreas may be
densely adherent to the posterior
abdominal wall, plastering the sple
nic artery posterior to the pancreas
and dilated tortuous collateral veins
may surround or be adjacent to the
splenic artery. In case 3, torrential
bleeding occurred precisely for
these reasons. Therefore, we ques
tion the value of prior control of the

splenic artery in the lesser sac.
Transcatheter splenic artery em
bolization had been used to obliter
ate splenic inflow. Jones and Koos7
have reported splenic abscess after
this procedure. Whether splenecto
my is justified for segmental portal
hypertension in the absence of gas
trointestinal bleeding is not clear.
Splenic vein thrombosis may not
lead to important clinical sequelae,8
and spontaneous regression of sple
nic vein obstruction along with im
provement in the primary condition
has been reported.18 At present, in
a patient with splenic vein occlusion
without bleeding varices, splenecto

my as prophylaxis against variceal
bleeding does not seem warranted.
Splenic vein thrombosis is being
detected when CT scans are done
for other reasons, and CT may
provide better insight into the natu
ral history of this disease.

f

Summary
Splenic vein thrombosis with va
riceal bleeding can be cured by
splenectomy. Acute awareness of
the condition is necessary for diag
nosis. Noninvasive methods such as
CT show promise in diagnosis and
may replace invasive angiographic
techniques.
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Major Vessel Excision in Retroperitoneal
Lymph Node Dissection
Corrie G. Krahn, MD;* Lome D. Sullivan, MD, FRCSC;* Thomas J. Kinahan, MD, FRCSC;
Henry D. Hildebrand, MD, FRCSCf
and one case of extensive inferior
vena caval excision without replace
ment.

Retroperitoneal malignant tumours, both primary and metastatic, may involve
surrounding structures such as the aorta and vena cava, making complete tumour
excision difficult. En bloc resection of major blood vessels should be considered in
such cases. The authors describe three patients who underwent excision of major
blood vessels with retroperitoneal lymph node dissection. Two patients had aortic
resection with placement of a Dacron tube graft, and one had excision of the vena
cava from above the renal vessels to the level of the common iliac veins with distal
venous ligation. The low complication rate confirms the feasibility of excising major
blood vessels to accomplish complete retroperitoneal lymphadenectomy.

Case Reports
Case 1

Les tumeurs retroperitoneales malignes, qu’elles soient primitives ou metastatiques,
peuvent toucher a des structures telles que l’aorte et la veine cave, rendant difficile
l’excision totale de la tumeur. Une resection monobloc des principaux vaisseaux
sanguins devraient etre envisagee dans de tels cas. Les auteurs decrivent trois
patients qui subirent une excision de vaisseaux sanguins importants, en meme
temps qu’une dissection ganglionnaire retroperitoneale. Deux patients subirent une
resection aortique avec pose d’un greffon de Dacron. Le dernier eut une excision de
la veine cave, au dessus des vaisseaux renaux jusqu’au niveau de la veine iliaque
commune, avec ligature veineuse distale. Le faible taux de complications confirme la
possibilite d’exciser des vaisseaux sanguins importants dans le but de realiser une
lymphadenectomie retroperitoneale complete.

he retroperitoneum is the site
of many primary and secondary
malignant tumours. Some tumours,
such as bulky metastatic testicular
carcinoma, may become intimately
adherent to surrounding structures
including the aorta and vena cava,
often in a dense desmoplastic fash
ion. In their review, Pack and Tabah1 found major-vessel involve
ment in 47 (39%) of 120 cases of
primary retroperitoneal tumours,
claiming this as the main reason for

T

inoperability. Indeed, such intimate
vascular involvement can make it
difficult to resect the tumour mass
completely and successfully. Cases
of en bloc major-vessel excision
with removal of malignant tumours
have been reported.2-8 In three re
cent cases at our institution, major
vascular resection was necessary to
accomplish complete retroperitoneal
lymphadenectomy (RPL) — two
cases of aortic resection and re
placement with Dacron tube graft

From the *Division o f Urology and f Division o f Vascular Surgery. Department o f Surgery.
University o f British Columbia, Vancouver. BC
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A 43-year-old man presented with
a right testicular embryonal carci
noma. His tumour-marker levels,
a-fetoprotein (AFP) and human
chorionic gonadotropin (HCG), were
within the normal range (less than
15 /rg/L and less than 5 U /L,
respectively) before orchiectomy.
Computed tomography (CT) of the
abdomen was suggestive of RPL,
and a chest film demonstrated a
nodule in the right upper lung field.
For these findings the patient was
treated with four courses of vinblas
tine and cis-platinum chemothera
py. Repeat metastatic work-up
showed that the pulmonary nodule
had disappeared on chest radiogra
phy and CT, but the abdominal CT
scan demonstrated a persistent re
troperitoneal mass (Fig. 1). His
serum AFP level remained less than
15 jig /L and the HCG level less
than 5 U /L. A radical retroperito
neal lymph node dissection was per
formed.
At exploration, the tumour, mea
suring 14 X 5 cm, was found to
intimately involve the infrarenal
aortic wall in the interaortocaval
region. The mass was freed with
careful dissection, but there was
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concern about the viability of the
aortic wall. A vascular surgeon was
consulted intraoperatively and,
agreeing that the segment of aorta
was nonviable, proceeded with an
infrarenal aortic resection and re
placement with a Dacron tube graft.
The patient was well when dis
charged 11 days postoperatively.
He remained well and free of tu
mour recurrence at 45 months’ fol
low-up.
Examination of the resected spec
imen revealed extensive necrosis of
the lymph node tissues, but no
viable tumour was found. The aor
tic wall showed degenerative
changes only.

(PSA), acid phosphatase (PAP) and
carcinoembryonic antigen were all
within normal limits. A chest film
and isotope bone scan likewise gave
negative results.
Because evidence to support sys
temic disease was lacking, the pa

tient underwent surgical explora
tion. Biopsies were again inconclu
sive for tumour type. The tumour
mass, indeed, was confined, but, as
suspected on the CT scan, it was
intimately adherent to the left renal
hilum and infrarenal aorta. The tu-

Case 2

An otherwise-healthy 69-year-old
man presented with an upper ab
dominal mass after 3 months of
vague epigastric discomfort and a
5-kg weight loss. CT demonstrated
a retroperitoneal tumour. At the
referring centre, the patient had
undergone three attempts at needle
biopsy under CT and ultrasono
graphic guidance. Each time, the
histologic findings on examination
of the biopsy specimen were incon
clusive.
The patient was referred to one
of us (L.D.S.) for further evaluation
and treatment. On examination, a
nontender, fist-sized, deep epigas
tric mass was palpable. There were
no other contributory findings on
physical examination. Repeat ab
dominal and pelvic CT at our centre
confirmed the presence of left in
frarenal para-aortic masses, with
the appearance of lymphadenopathy
(Fig. 2). No other areas of primary
or metastatic disease were seen. A
fine-needle biopsy under CT guid
ance was, again, nondiagnostic for
tumour type. The findings on exam
ination and ultrasonography of the
testes were normal. Levels of serum
AFP, HCG, prostate-specific antigen
654

FIG. 1. Case 1. Preoperative computed tomography (CT) scan showing persistent
mass (arrowhead) after chemotherapy.

FIG. 2. Case 2. Preoperative CT scan showing nodal mass (arrowhead) with
possible involvement of aortic wall.
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mour mass was excised with en bloc
left nephrectomy and infrarenal aor
tic resection with standard Dacrontube-graft placement.
The patient was well when dis
charged 11 days postoperatively.

The serum creatinine level was sta
ble at 156 mmol/L (normal, 60 to
110 mmol/L). Follow-up at 15
months revealed no clinical or CT
evidence of disease, and the patient
was in good health.

FIG. 3. Case 3. Preoperative (postchemotherapy) CT scan showing persistent mass
(arrowhead) possibly involving inferior vena cava (and right renal vein).

FIG. 4. Case 3. (Left) Operative photograph and (right) illustration demonstrating
retroperitoneal lymphadenectomy with en bloc caval (and right renal) excision,
anastomosis of left renal vein to caval stump and ligation of iliac veins.

Examination of the resected spec
imen revealed very poorly differenti
ated carcinoma. Staining for AFP,
HCG, PAP and PSA was negative.

Case 3
A 16-year-old boy presented with
increasing back and abdominal pain
after neglecting the presence of a
right testicular mass for several
months. Right inguinal orchiectomy
revealed a poorly differentiated em
bryonal carcinoma. Although the
chest film was negative, the abdom
inal CT scan showed bulky retro
peritoneal involvement by metastat
ic disease. His tumour markers re
mained elevated after orchidectomy
at 33 ng/L for the serum AFP
(normal, less than 15 ng/L) and
220 U /L for the serum HCG (nor
mal, less than 5 U/L). Four courses
of cis-platinum and VP-16 (Etoposide) chemotherapy were given.
After this, repeat CT demonstrated
persistent extensive paracaval in
volvement by a tumour mass (Fig.
3). Differential renal function to
gether with isotope scanning re
vealed a glomerular filtration rate of
80 mL/min on the left and 23
mL/min on the right. The serum
AFP and HCG fell to immeasurable
levels after chemotherapy.
The patient had a radical RPL
through a right thoracoabdominal
incision. Our preoperative suspicion
was confirmed: the tumour was
intimately adherent to the right
renal vein and vena cava with a
palpable thrombus within the caval
lumen. A right nephrectomy and
cavectomy from above the renal
vessels to the level of the common
iliac veins was performed (Fig. 4).
Because well-established lumbar
and periureteral collaterals were
identified, the left renal vein was
mobilized and anastomosed to the
proximal caval stump, and the com
mon iliac veins were ligated.
On the 2nd day postoperatively,
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moderate bilateral leg edema was
identified, and Doppler ultrasonog
raphy confirmed the presence of
thrombus within the common iliac
veins bilaterally. This was treated
conservatively with low-dose (500
U /h) heparin intravenously for 14
days. The patient was well when
discharged 20 days postoperatively.
The anticoagulant therapy was
withdrawn, the leg swelling had
resolved and the serum creatinine
level was 129 mmol/L. He was well
and clinically free of disease when
seen 12 months later.
Examination of the specimen
showed extensive fibrous scarring
and tumour necrosis with no viable
tumour. The vena cava was found
to have an intraluminal necrotic
tumour thrombus.

Discussion
Dubost is credited with perform
ing the first successful resection
of an abdominal aortic aneurysm
with aortic homograft replacement
in 1951.9 However, until the
mid-1950s, the involvement of
major retroperitoneal vascular
structures (specifically, the aorta or

vena cava) by malignant tumour
precluded successful surgical exci
sion.1
In 1956, Crawford and DeBakey2
reported two cases in which retro
peritoneal malignant tumours with
such vascular involvement were
successfully resected. The first case
was an embryonal carcinoma in a
48-year-old man, who required ad
junctive aortic resection and homo
graft replacement. The second case
was a 38-year-old man with leio
myosarcoma, who required both
infrarenal aortic and caval resec
tion, with replacement of each ves
sel by aortic homograft. At follow
up after 4 months, venography re
vealed complete thrombotic occlu
sion, which was asymptomatic. Be
cause the first patient was given
radiotherapy postoperatively, the
authors also pointed out that vascu
lar graft replacement in cancer sur
gery did not preclude future radio
therapy to the area.
In 1960, Sessions and Scott3 re
ported the case of a 17-year-old boy
with a paraganglioma involving the
right kidney, aorta and vena cava,
who required en bloc excision of
these structures with the tumour
for successful extirpation. This pa

tient was reported well 20 months
later. In 1987, Smith and Starnes4
described a case of renal cell carci
noma invading a left retroaortic
renal vein over a 4-cm aortic aneu
rysm. This was treated by resection
of the left kidney, renal vein and
aortic aneurysm, with a Dacron
tube graft, to re-establish aortic
flow. These cases, along with our
first two, represent the only known
reports of concomitant aortic resec
tion in retroperitoneal malignant tu
mours (Table I).
Several case reports exist, howev
er, concerning the feasibility of in
ferior vena caval resection.2-8 Mathisen and Javadpour7 described
their experience with six patients
who had germ cell tumours; of
these, only one patient had previ
ously received cytoreductive chemo
therapy. Ahlering and Skinner8 re
viewed their experience with en bloc
caval excision in metastatic testicu
lar cancer surgery. Of their 12
patients, 10 had received cisplatinum-based chemotherapy be
fore RPL. They claimed that, be
cause tedious dissection of tumour
from the caval wall was not re
quired, the procedure was much
easier. All 12 cases involved simple

T a b le 1. Concom itant Aortic Resection With Retroperitoneal Tumour Excision

A u th o rs

T u m o u r type

Crawford and
DeBakey2

P re o p e ra tiv e
tre a tm e n t

Carcinoma
(?embryonal)

Nil

Leiomyosarcoma

Nil

Sessions and
S cott3

Paraganglioma

Nil

Sm ith and
Starnes4

Renal-cell carcinoma

Nil

Current series

Embryonal germ-cell
carcinoma
Carcinoma

Right orchiectom y.
Vinblastine and
cisplatinum
Nil

NED = no evidence of disease
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S u rg ical tre a tm e n t

“ Complete” tumour excision; aortic
resection and homograft replacement;
caval wall excision
“ Complete” tumour excision; aortic and
caval resection, each replaced with
aortic homograft
“ Complete” tum our excision; right
nephrectomy; aortic and caval
resection, each replaced with aortic
homograft
Left nephrectomy and caval cuff; aortic
aneurysmectomy and Dacron-graft
replacement
Retroperitoneal lymph-node dissection;
aortic resection and Dacron-graft
replacement
Retroperitoneal lymph-node dissection;
left nephrectomy; aortic resection and
Dacron-graft replacement

O utcom e

Radiotherapy at 3 mo; tumour
recurrence at 18 mo
Angiography at 4 mo; normal arterial
system but thrombosed
caval graft
Angiography; caval occlusion at 5 yr4

Radiotherapy for metastases

Well, NED at 45 mo

Well, NED at 15 mo

VESSEL EXCISION IN RETROPERITONEAL LYMPHADENECTOMY

proximal and distal venous ligation.
Notably, 5 of the 12 patients re
quired adjunctive nephrectomy (as
did our patient). Postoperatively, 7
of their 12 patients were free of
complications, whereas 3 had com
plications that required surgical
correction. The overall survival rate
was 58% over 2 to 12 years of
follow-up. Pathologically, 8 of the
12 patients had viable disease, ei
ther carcinoma (5) or mature terato
ma (3). Both Mathisen and Javadpour7 and Ahlering and Skinner8
reported the common occurence of
limb edema after venous ligation,
but we concur that this seems a
relatively mild and self-limiting
problem, as in our third case.
The relative merits of graft re
placement versus simple stump liga
tion in excision of the inferior vena
cava continue to be a matter of
debate in the literature. Therefore,
we will not deal with this matter in
detail here except, in regard to our
third case, to propose that the
patency rate of caval grafts is gen
erally poor and that if adequate
collaterals exist, it is unlikely that
any benefit results from graft re
placement. Similarly, concern may
be raised as to the threat of cavalgraft thrombus formation with the
risk of embolism.
Our series of three cases provides
further evidence of the feasibility of
major-vessel excision in retroperito
neal cancer surgery. These patients
did well, being discharged an aver
age of 14 days postoperatively, and
remained well and free of disease
after 12 to 45 months of follow-up.
The possibility of great-vessel in
volvement by retroperitoneal malig
nant tumours should be considered
when resection is planned. Presurgical chemotherapy, as for bulky
metastatic germ cell testicular can
cer, may create further difficulties
by causing tumour necrosis and
fibrosis. To our knowledge, there
does not exist a previously docu

mented case report of adjunctive
aortic resection in postchemothera
py lymph node dissection for meta
static nonseminomatous testicular
carcinoma.
From our experience and litera
ture review, the indications for ad
junctive excision of major vessels in
retroperitoneal lymph node dissec
tion include the following: cases in
which the vessel is involved to such
a degree that fear of vascular dam
age may jeopardize complete tu
mour removal; cases in which com
plete dissection has left a potential
ly weakened vessel wall (as in our
first case); cases in which suspicion
of associated vessel-tumour throm
bus exists (as in our third case);
and, finally, cases in which there is
associated vascular anomaly or dis
ease (as in the case reported by
Smith and Starnes4).

NOTICES
AVIS
HIV Infection of the Gastro
intestinal T ract
An international congress on the impact
of HIV infection on the gastrointestinal
tract will be held Mar. 5 to 7, 1993, at
the Palazzo della Cultura e dei Congressi, Bologna, Italy. The congress is
sponsored by the Association for the
Research in Gastroenterology and the
Italian Society for the Study of Infec
tious and Parasitic Diseases and is
patronized by the University of Bolo
gna. The scientific program will focus
on abnormalities of the gastrointestinal
tract in AIDS patients. Superimposed
opportunistic infections and tumours
will be considered with respect to epide
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B lunt Traumatic Avulsion
of an Intercostal Artery: an Unusual Case
of Thoracic Aortic Injury
Ciaran J. McNamee, MD, CM, MSc, FRCSC; John L. Knight, MB, BS, FRACS, FRCSC
The aortic isthmus is the most commonly injured part of the thoracic aorta in
patients who survive blunt deceleration injury to that vessel long enough to reach a
hospital. Occasionally, avulsion of the brachiocephalic arteries from the aortic arch
is seen. The authors describe an unusual form of intrathoracic vascular injury in
which mediastinal hemorrhage occurred secondary to avulsion of an intercostal
artery from the descending thoracic aorta as a result of a vertical deceleration injury.

L’isthme aortique est le segment de l’aorte thoracique qui est le plus frequemment
atteint chez les patients qui survivent suffisamment longtemps a une blessure
vasculaire fermee de deceleration, pour atteindre l’hopital. On peut observer,
occasionnellement, une avulsion du tronc arteriel brachiocephalique a partir de la
crosse de l’aorte. Les auteurs decrivent une forme inhabituelle de blessure
vasculaire intrathoracique, une hemorragie mediastinale etant apparue, suite a une
avulsion de l’artere intercostale a partir de l’aorte thoracique descendante, resultat
d’une blessure de deceleration verticale.

to the thoracic aorta is
I njury
common and well recognized in
blunt trauma.1 The proportion of
patients with injuries to the thorac
ic aorta who survive to reach the
hospital is 15%.2’3 Most patients
who survive the trauma long
enough to reach hospital and are
stable enough to undergo aortogra
phy suffer aortic disruptions involv
ing the aortic isthmus.4 The serious
nature of this injury tends to over
shadow the fact that a minority of
patients suffer disruption of the
brachiocephalic vessels from the
aortic arch.4 We report a rare exam
ple of blunt traumatic injury of the
thoracic aorta — a case of avulsion
of an intercostal artery from the

descending thoracic aorta as a re
sult of a vertical deceleration injury.

Case Report
A 52-year-old man was brought
to the emergency room 20 minutes
after falling off a 13-m scaffold. His
vital signs were stable on arrival.
Radiologic investigations revealed a
basilar skull fracture, a right shoul
der dislocation, a left acetabular
fracture, a Le Fort II facial fracture,
bilateral scapular fractures and mul
tiple bilateral rib fractures. There
were no fractures of the thoracic or
lumbar spine, and an initial chest
x-ray film was thought not to dem

onstrate a widened mediastinum. A
peritoneal tap was positive for
blood. Laparotomy revealed a mes
enteric tear of the mid-small bowel
accompanied by three proximal je
junal blow-out perforations. The devascularized segment of small
bowel was resected with primary
anastomosis, and the perforations
were repaired. A retroperitoneal he
matoma secondary to a traumatic
pancreatitis without duodenal inju
ry was found. This responded to
conservative treatment. A chest
x-ray film postoperatively in the
intensive care unit revealed a signif
icantly widened mediastinum with
loss of the aortic arch silhouette
and inferior depression of the left
main bronchus (Fig. 1). A subtrac
tion angiogram of the thoracic
aorta revealed an intimal tear 4 to 5
cm distal to the aortic isthmus (Fig.
2). At left thoracotomy, after vascu
lar control was obtained, a large
periaortic hematoma was opened to
reveal an intercostal artery avulsed
from the medial wall of the aorta.
This was treated by primary repair
of the aorta and suture ligation of
the retracted arterial stump. Recov
ery was prolonged because of the
patient’s associated injuries, but the
patient was discharged home well 6
weeks postoperatively.
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The second most common vascu
lar injury to the thoracic aorta in

THORACIC AORTIC INJURY

blunt trauma is avulsion of the
innominate artery followed by avul
sion of the subclavian artery from
the arch of the aorta .3"6 Avulsion of
the common carotid artery is in
frequently reported,3’5 but in one
series4 it occurred with equal fre
quency to subclavian artery disrup
tions. The pathophysiology of this
injury involves intimal disruption at
the injury site with extension into
the media but adventitial contain
ment of the hematoma.5 Thus, the
presentation of these injuries is
usually not exsanguination but de
creased or absent pulses with a
widened mediastinum on the chest
x-ray film.45 Owing to heightened
awareness of thoracic aortic injuries
this leads to suspicion of an aortic
tear, and the diagnosis is confirmed
preferably by aortography rather
than computed tomography.78
The mechanism of injury is
thought to be a movement of the
heart and the ascending aorta pos
teriorly and to the left, combined

with hyperextension of the head,
neck or shoulder.5-9 Another hy
pothesis is that brachiocephalic ves
sel avulsion with sternal fractures is
due to inward movement of the
fracture segment, sweeping the ves
sel off the aortic arch . 10 In our case
the intercostal artery avulsion with
intimal disruption might be ac
counted for by the vertical decelera
tion injury combined with distrac
tion forces from an extension injury
to the right shoulder.
The severity of vertical decelera
tion injuries depends upon impact
velocity, which is determined by the
distance fallen, impact duration, po
sition on impact and previous physi
cal condition of the patient. 11 These
factors are associated with a certain
constellation of injuries that in
cludes extremity and spinal frac
tures, head injury, pulmonary and
myocardial contusions, vascular in
jury and hollow visceral intra
abdominal injury. 12-13 Specific vas
cular injuries associated with falls

from heights are thoracic aortic
rupture, extremity vascular injury
and retroperitoneal hemorrhage
from rupture of hypogastric or lum
bar arteries in association with a
pelvic fracture or burst fracture of
the spine. 13 In our patient there
were no spinal fractures, but it is
possible that a vertical deceleration
injury combined with extension
forces to the right shoulder could
lever the intercostal artery over the
vertebral body to cause its avulsion
from the aorta. Despite the rarity of
these vascular injuries we should
remain aware of their potential to
occur as there is a significant in
crease in vascular injuries for pa
tients involved in multiple trauma . 1
We report this case to emphasize
the unusual manifestations of this
type of thoracic aortic injury in the
setting of blunt trauma from verti
cal deceleration.

References
G, B ecker NM, D ittmer N et
al: Vascular injuries in polytrauma.
World JSurg 1983; 7: 68-79

1. H eberer

FIG. 1. Chest x-ray film shows wide mediastinum with loss of aortic silhouette and
inferior depression of left main bronchus.

FIG. 2. Subtraction aortogram demon
strates intimal tear (arrow) 4 to 5 cm
distal to aortic isthmus.
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pressive treatments in high-risk patients
and provides a good review of the
recent clinical use of FX506 and deoxyspergualin.
There are comprehensive chapters on
specific organs, including kidney, liver,
lung, heart-lung and pancreas trans
plantation. Newer aspects of bonemarrow transplantation, especially its
application in certain forms of leuke
mia, are described as well as recent
experience with islet-cell transplanta
tion. Particular attention has been given
to the use of a genetically unrelated
living donor, of ABO-incompatible do
nors and of double and single pediatric
cadaver kidney in adult renal-transplant
recipients. The section dealing with
liver transplantation focuses on current
clinical experience and describes the
latest techniques and results of split-liv
er transplantation and liver-segment
transplantation from living related do
nors. Xenotransplantation is also dis
cussed. In the section on complications
of organ transplantation, the authors
focus on the development of spontane
ous malignant disease, especially lymphoproliferative disease.
One of the most interesting aspects
of this book is the section dealing with
the ethical, legal and religious aspects
of clinical organ transplantation and
organ donation among different cul
tures of the world, including the Middle
Eastern (Islamic), Far Eastern and Indi
an subcontinent.
Overall, the authors have succeeded

in addressing the medical advances and
future trends in transplantation, dealing
with the controversial issues of organ
transplantation in a comprehensive
fashion and well-written style, making
this book a good reference for physi
cians and fellows interested in organ
transplantation.
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ORGAN TRANSPLANTATION. Edit
ed by G.M. Abouna, N.S.A. Kumar and
A.G. White. 582 pp. Illust. Kluwer
Academic Publishers, Dordrecht, The
Netherlands. 1991. ISBN 0 -7 9 2 3 1191-4

During the past decade, the field of
organ transplantation has evolved con
tinuously as principles have been modi
fied by new concepts and extensive
research. Better understanding of graft
rejection immunobiology, advances in
surgical techniques, better patient man
agement and more effective im
munosuppressive therapy have made
organ transplantation a successful ther
apy for failure of many irreversible vital
organs.
This book, written by 218 contribu
tors who are well known experts in
their fields, is based on a meeting on
organ transplantation that was held in
Kuwait in 1990. It contains 79 chapters
in 14 major sections and represents a
recent update on many general and
specific issues in organ transplantation.
The first chapters are a recent review
of immunobiology and organ allograft
rejection with special emphasis on the
mechanisms and diagnosis of rejection,
the role of HLA matching in organ
transplantation and the potential for
tolerance induction. The section on im
munosuppression deals with the role of
blood transfusion in organ transplanta
tion, describes different immunosup
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ATLAS OF ABDOMINAL SURGERY.
Edited by J.W. Braasch, C.E. Sedg
wick, M.C. Veidenheimer and F.H.
Ellis Jr. 446 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. $123. ISBN
0 -7 2 1 6 -5 6 0 1 -3

This book was produced by surgeons at
the Lahey Clinic with the help of multi
ple contributors. The preface indicates
that it is intended for the practising
surgeon. The illustrations produced by
the Art Department of the Lahey Clinic
are outstanding. Many of the common

continued on page 666
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Treatment for Nonunion of the Shaft
of the Humerus: Comparison of Plates
and Seidel Interlocking Nails
Chi-Chuan Wu, MD; Chun-Hsiung Shih, MD

De juillet 1986 a novembre 1989, 35 adultes qui avaient subi une fracture du corps
de l'humerus et chez qui il n’y avait pas eu soudure osseuse ont ete traites par
osteosynthese a l’aide de plaques (19 patients) ou par enclouage enterograde des
fragments osseux a l’aide de clou imbrique Seidel (16 patients) avec greffe d’os
spongieux. La periode de suivi variait de 12 a 52 mois. Parmi les patients qui ont eu
une osteosynthese par plaque, 89,5 % ont eu une soudure osseuse en 4,5 ± 1 ,7
mois; chez les patients qui ont vu leurs fractures traitees par clou imbrique de
Seidel, 87,5 % ont eu une fusion osseuse en 4,4 ± 1 ,8 mois. L’amplitude des
mouvements de l’epaule a ete amelioree par les deux techniques. II y a eu davantage
de complications chez les patients a qui on a pose des plaques, que chez ceux qui
ont eu un enclouage (21 % contre 12 %).
Les auteurs preferent le clou imbrique car il s’agit la d’une technique plus simple
qui occasionne moins de complications. Celle-ci pourrait remplacer l'osteosynthese
par plaque dans le traitement des fractures non soudees du corps de l’humerus. On
ne peut toutefois oublier l’instabilite rotatoire associee a l’utilisation des clous
imbriques et, quand celle-ci est apparente, il y a lieu de recourir a l’osteosynthese
par plaque.

From the Department o f Orthopedic Surgery, Chang Gung Memorial Hospital, Chang Gung
Medical College, Taiwan, ROC
Accepted for publication July 10, 1992
Reprint requests to: Dr. Chi-Chuan Wu, Department o f Orthopedic Surgery, Chang Gung
Memorial Hospital, No. 5, Fu-Hsin St. 33333, Kweishan, Taoyuan, Taiwan, ROC

ractures of the humeral shaft
are uncommon 1 and are usually
caused by high-energy trauma. Tra
ditionally, conservative treatment is
satisfactory, and surgical treatment
is generally not indicated . 2-4 The
invention of the humeral functional
brace further improves the results
of conservative treatment ,5-7 so
that, theoretically, nonunion of hu
meral shaft fractures should be very
rare.8 However, nonunion still oc
curs sporadically because of inade
quate initial treatment by either
conservative or surgical modali
ties .9-11
The anatomic disadvantage of the
pathway of the radial nerve, which
passes along with the posterior and
lateral aspects of the mid-distal
shaft, greatly increases the risk of
nerve injury with the operative
treatment. In the past, the favoured
surgical technique for treating non
union of humeral shaft fracture was
plating with cancellous bone graft
ing . 12-14 However, disuse osteoporo
sis combined with the unfavourable
radial nerve pathway often endan
gers the treatment.
A traditional intramedullary nail
cannot adequately maintain me
chanical stability .814 The invention
of interlocking nails widens the in
dications for intramedullary nailing,
allowing stabilization of fractures
outside the isthmic area without the
use of supplementary devices . 1516 In
this retrospective study we compare

F

From July 1986 to November 1989, fractures of the humeral shaft in 35 adults who
had nonunion of the fracture were managed by plate fixation (19 patients) or
antegrade nailing of the fracture fragments with the Seidel interlocking nail (16
patients) together with cancellous bone grafting. The follow-up period ranged from
12 to 52 months. Of the patients who had plate fixation, 89.5% had fracture union
within 4.5 ± 1 .7 months; of the patients whose fracture was managed with the
Seidel interlocking nail, 87.5% had fracture union within 4.4 ± 1 .8 months. The
range of shoulder motion was improved with both techniques. Patients who had
plate fixation had more complications than those whose fracture was managed by
interlocking nailing (21% v. 12%).
The authors prefer interlocking nailing because it is a relatively simpler
technique, resulting in fewer complications. It may replace plating in the treatment
of nonunion of humeral shaft fractures. However, rotatory instability with
interlocking nailing cannot be disregarded, and if this is evident plate fixation
should be done.
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the technique of nailing with the
Seidel humeral interlocking nail and
that of plating to identify the best
technique for treating complicated
nonunited fractures of the humeral
shaft.

Patients and Methods
From July 1986 to November
1989, 41 consecutive adults with
nonunion of the humeral shaft were
treated with either plating (23 pa
tients) or Seidel interlocking nailing
(18 patients) at our institution.
There were no cases of bilateral
fracture. Nonunion was defined as
the persistence of a radiolucent gap
between sclerosing ends of both
fracture fragments after 6 months
of treatment17 or nonunion of frac
tures after 1 year of treatment.18
The Seidel humeral interlocking
nail was first used in November
1987. Previously, plating was the
treatment of choice. Gradually, in
terlocking nailing replaced the
plating technique. However, if the
narrow space of the distal fragment
was enlarged by previous in
tramedullary nailing or the distal
fragment was too short, plating was
chosen. The patients who had plat
ing ranged in age from 19 to 64
years (average, 38 years) with a
male-to-female ratio of 5:1, and
those who had nailing ranged in
age from 17 to 56 years (average,
34 years) with a male-to-female
ratio of 3:1. The intervals from
injury to treatment ranged from 8
months to 3 years (average, 14
months) in the plating group and
from 1 to 4 years (average, 20
months) in the nailing group.
Twenty-nine (71%) patients had un
dergone as many as three previous
operations for implant fixation (17
plates and 12 Rush pins). In the
other 12 patients (29%) conserva
tive treatment had failed. The radiographic appearance, the condition
662

of the bone stock and the location
of the radial nerve were similar in
both groups.
The steps in the surgical treat
ment of nonunion were as follows:
removal of the previous implant;
plate fixation or antegrade inter
locking nailing of the fracture frag
ments; and decortication with can
cellous bone grafting at the site of
nonunion. When the mechnical sta
bility of plate fixation was doubtful
because of severe osteoporosis, the
plating was supplemented by wiring
or a functional brace. When the
mechanical stability of interlocking
nail fixation was insufficient, the
nailing was supplemented by a
functional brace. Intraoperatively,
stability was obtained by immobiliz
ing the proximal fragment with one
hand and rotating the distal frag
ment with another. Two of the 18
patients who had interlocking nail
ing required a functional brace. If
rotatory instability of nailing was
evident grossly, plating was carried
out immediately. Postoperatively,
range of motion exercises of the
shoulder and elbow were encour
aged as early as posssible. To mini
mize the complication rate, elbow
stiffness was not usually corrected
during surgery but rather after the
ununited fracture had healed.
Patients were followed up in the
Outpatient Department at 4-to
6-week intervals. Bony union was
considered to have occurred when
clinically there was no pain, tender
ness or movement of the humerus
at the fracture site, and when the
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x-ray film showed solid bridging
callus connecting the bone frag
ments.101519 Delayed union was not
defined to avoid misrepresenting
the union rate.
Differences in the findings were
analysed by Fisher’s exact test and
Student’s t-test.

<

Findings
In the group of patients who had
plating, 19 were followed up and in
the group of patients who had
nailing, 16 were followed up. The
period of follow-up was at least 1
year (range from 12 to 52 months,
average 34 months) (Table 1). In the
group who had plating (Fig. 1), the
union rate was 89.5% (17 of 19),
and the time required for healing
was 4.5 ± 1 .7 months, and in those
who had nailing (Fig. 2), the union
rate was 87.5% (14 of 16, p > 0.05,
Fisher’s exact test), and the time
required for healing was 4.4 ± 1 .8
months (p > 0.05, Student’s t-test).
The range of motion of the
shoulder improved in both groups:
abduction improved from an aver
age of 90° preoperatively to 160°
postoperatively in the plating group
and from 80° preoperatively to
160° postoperatively in the nailing
group. Adduction, flexion, exten
sion and internal or external rota
tion were satisfactory in both
groups. Range of motion of the
elbow showed mild deterioration:
flexion on average ranged from
120° preoperatively to 90° postop-

T a b le 1. C o m p a ris o n o f P la tin g and S eidel N a ilin g U sed in T re a tm e n t o f N o n u n io n o f F ra c tu re s o f
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eratively in the plating group and
from 120° to 100° in the nailing
group. Extension, supination and
pronation were not affected.
Complications
Complications occurred in both
groups (21% in the plating group

and 12% in the nailing group,
p > 0.05, Fisher’s exact test).
Nonunion was noted in two cases
in each group (10.5% and 12.5%
respectively in the plating and nail
ing groups). In the plating group
the patients were treated with can
cellous bone grafting only, but in
the nailing group the patients un

derwent plating with supplementary
cancellous bone grafting to fill the
enlarged intramedullary space.
Bony union ensued without further
complication.
A new fracture was noted in one
man (5.3%) in the plating group, so
an interlocking nail was used for
fixation. This resulted in bony
union at 4 months (Fig. 3).
Iatrogenic radial nerve palsy was
noted in one patient (5.3%) in the
plating group; rehabilitation thera
py resulted in a complete cure with
in 4 months.
No deep infection or malposition
of fracture fragments was noted.

Discussion

FIG. 1. Type Ilia open fracture of left humeral shaft. Initially, Hoffmann external
fixator was inserted. After soft-tissue healing, functional brace was applied.
Avascular nonunion was noted at 10 months. Open reduction with plating, wiring
and cancellous bone grafting was performed. There was bony union 5 months later.

FIG. 2. Fixation of fracture of right humeral shaft with Rush pin failed after 3
years, resulting in hypervascular nonunion. Open interlocking nailing with
cancellous bone grafting was performed. There was bony union 4 months later.

A fracture nonunion should be
classifed as hypervascular or avas
cular because the treatment for
each is different. The former can be
treated with stable fixation only,
but the latter should be supple
mented with cancellous bone graft
ing.20 Electrical stimulation, al
though associated with an 80% to
85% success rate,21 is usually inef
fective in the presence of synovial
pseudarthrosis.2223 A 42% incidence
of synovial pseudarthrosis in non
union of humeral shaft fractures
was reported by Esterhai, Brighton
and Heppenstall.24 Therefore, surgi
cal treatment of nonunion is the
reasonable choice.
For the treatment of aseptic non
union, internal fixation with cancel
lous bone grafting is usually suc
cessful. However, the success rate
will decrease in proportion to the
number of repeat operations.25 Tra
ditionally, all internal fixators have
specific advantages and disadvan
tages, and the favoured technique is
plating.12-14
Conservative treatm ent with
casts, splints, functional braces or
traction, which cannot maintain
sufficient stability and requires joint
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immobilization, is not appropriate
to treat humeral shaft nonunion.
Traditional nonreamed intramedul
lary nails such as Ender’s nails,26
Rush pins2728 and Hackethal
stacked nails,29 or reamed Kuntscher nails8 also do not provide suffi
cient stability.
Fixation with the Huckstep nail
is technically demanding and timeconsuming, particularly during in
sertion of the transfixion screw.30 In
the past, a plate was considered the
best instrument to treat such non
union. Nevertheless, osteoporotic
bone stock and the location of the
radial nerve make the plating tech
nique difficult and risky. Iatrogenic
radial nerve palsy in plating of the
humeral shaft is not unusual, the
reported incidence being 0% to
5.6%.1112-31 Although the tensionband principle should be utilized in
plating, the placement of the plate
on the posterior aspect of the shaft
is prevented by the radial nerve.
The potential for mechanical failure
of plate fixation exists. Besides,
with the stress riser effect over the
end of the plate there is the possi

bility of a new fracture (Fig. 3).32
Distal fixation of a Seidel nail is
by an intramedullary spreading
screw.3334 It does not require dissec
tion of the distal fragment to identi
fy the radial nerve, and the an
terolateral approach to the non
union site diminishes the risk of
nerve injury. For a nonunion site,
the rugged bony surface caused by
callus formation makes the place
ment of a plate difficult but pres
ents no problem for intramedullary
nails. The disadvantage of spread
ing screw fixation is its inability to
control rotation from inside, espe
cially when the intramedullary
space is enlarged. Therefore, if non
union is caused by a previous in
tramedullary nail, a plate should be
considered.
When nonunion occurs in a hu
meral shaft, the elbow joint may
become stiff, and the centre of
elbow movement is at the nonunion
site. Once the nonunion site is
stabilized with an implant, the
elbow immediately loses its motion
function. Thus, release of elbow
joint contracture may be neces

sary.35-38 We believe it is better to
do this after the humeral fracture
has united because extensive dissec
tion may increase the infection and
nonunion rates.
Although the healing processes
of a plate and an interlocking nail
are similar in the present series
(Fig. 4), theoretically and clinically
the latter is associated with fewer
complications and simpler surgical
technique. Therefore, whenever
possible, interlocking nailing with
cancellous bone grafting should be
chosen for the treatment of most
cases of nonunion of humeral shaft
fractures. Nevertheless, if rotation
cannot be controlled by a Seidel
interlocking nail, a plate should be
used.
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BOOK REVIEWS
continued from page 660

operations in abdominal surgery are
reviewed, and descriptions of inguinal
hernia repair, surgery of the anus and
rectum, and surgery for the adrenals
are included. Descriptions of the proce
dures are brief. As noted in the preface
the emphasis is on the illustrations.
Although the illustrations are out
standing, only one procedure is usually
presented for each condition. A few
details might be criticized. A free omen
tal graft for closing a perforated ulcer is
rarely used. Only a distal clip is applied
to the vagus nerves during vagotomy.
Use of the TA-55 stapler for bowel
anastomosis is illustrated, but this pro
cedure is rarely performed any longer.
Illustrations for abdominal surgery for
obesity show an incision well below the
umbilicus, which is unnecessary. Gas
tric pouches are made very large, and
this could lead to poor results. A trans
verse gastroplasty is demonstrated with
removal of staples. This procedure is
ineffective and should not be used. The
vertical banded gastroplasty illustrated
uses a Marlex band 5.5 cm in circumfer
ence, which is too large by modern
standards.
The illustrations of appendectomy
are very clear. This would be useful for
the medical student who may be more
inclined to see exotic problems than the
common appendectomy. Illustrations
for the anus and rectum are quite good.
The description of liver abscess drain
age at operation includes no mention of
percutaneous drainage which is the
most common modern operation. Sur
prisingly 20 pages are devoted to liver
transplantation. The pictures are clear,
but the procedure would not be at
tempted by the occasional surgeon and
the liver transplant surgeon would need
more detail. However, the description
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may be helpful for residents or students
who might assist with such a proce
dure. The brief description of laparo
scopic cholecystectomy is quite clear.
Transduodenal sphincteroplasty is illus
trated but rarely performed now. There
is no mention of endoscopic retrograde
cholangiopancreatography, which is the
favoured procedure.
Because of the outstanding illustra
tions this is an excellent book for
residents and students and would be a
good teaching aid. The clear illustra
tions would help the practising surgeon
review procedures quickly and easily.
However, there is not enough detail on
most common surgical procedures and
too much detail on specialized proce
dures. The book would be useful for
hospital or medical school libraries, and
general surgeons involved in teaching
medical students. The illustrations of
common operations are among the best
available in any text or atlas.

INTRA-ABDOMINAL INFECTIONS.
Dietmar H. Wittman. 84 pp. Illust.
Marcel Dekker, Inc., New York. 1991.
$79.75 (US). ISBN 0-8247-84974-9

local and systemic factors in the patho
physiology of peritonitis is provided,
but cytokines are not mentioned, and
there is little discussion of the patho
genesis of multiple organ failure. A
practical classification is presented, and
mortality, risk factors and scoring sys
tems are discussed and illustrated in
detail.
Surgery, critical care support and
antibiotic therapy are well discussed as
“pillars” of therapy. Emphasis is placed
on etappenlavage or scheduled relaparo
tomy in selected patients with recur
rent, residual or severe disease. The
data provided suggest, but do not
prove, an advantage for this method.
Curiously, the treatment by interven
tional radiologists of intra-abdominal
abscesses by percutaneous drainage is
only briefly mentioned. This is a glaring
omission in an otherwise well-rounded
monograph. Further, visceral abscesses
in the abdomen are noted in the classifi
cation but are not discussed elsewhere.
The section on critical care therapy
includes cardiopulmonary and renal
support, but there is no discussion of
immunologic therapy, which is admit
tedly in its infancy.
Residents in surgery and practising
surgeons will find this a handy and
clear account of the up-to-date manage
ment of diffuse intra-abdominal infec
tion. They will have to look elsewhere,
however, for a summary of the current
treatment of intra-abdominal abscesses.

This is a brief review of the pathophysi
ology and treatment of diffuse intra
abdominal infections. The text is superb
and is supported by good illustrations.
The etiology and pathogenesis of intra
abdominal infections are described
clearly. An excellent summary of basic

Ronald T. Lewis, MB, BS, MSc, FRCSC,
FACS
Surgeon-in-chief
Queen Elizabeth Hospital
2100 Marlowe Ave.
Montreal, PQ
H4A 3L6

D. Michael Grace, MD, PhD, FRCSC, FACS
Department of Surgery
University Hospital
London, ON
N6A 5A5
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GENERAL SURGEON: ON - National De
fence Medical Centre, a 244-bed fully accred
ited military teaching hospital affiliated with
the University of Ottawa, requires a third
general surgeon for a full-time, hospital-based
practice. Located in Ottawa, National Defence
Medical Centre has a fully staffed emergency
eight-bed ICU, excellent operating room/outpatient facilities, laparoscopic surgery equip
ment and anesthetic/diagnostic imaging/ lab
oratory services. Contact: Colonel Claude
Auger, MD, FRCSC, FMSPQ, Chief of Sur
gery, National Defence Medical Centre,
1 745 Alta Vista Dr., Ottawa, ON K1A
0K6; tel (613) 7 3 8 -5 2 0 6 , fax (613)
9 9 1 -1 5 4 3 .
CHIRURGIEN DEMANDE: ON - Le Centre
mddical de la Defense nationale, une institu
tion d'enseignement militaire, accrdditee, de
244 lits, affiliee a I'Universitd d'Ottawa, requiert les services d'un spdcialiste en chirurgie
gdndrale a temps plein. Situd a Ottawa, le
Centre medical de la Defense nationale offre
les services d'urgences, une unite des soins
intensifs de huit lits, soins ambulatoires, ser
vices d'imagerie diagnostique et laboratoires,
services d'anesthbsie ainsi que I'equipment
de chirurgie moderne incluant laparoscopie.
Veuillez contacter le Colonel Claude Auger,
MD, FRCSC, FMSPQ, chef du departement de Chirurgie, Centre medical de la
Defense national, 1745, prom. Alta Vista,
O ttaw a (ON) K1A 0K6: tel (613)
7 3 8 -5 2 0 6 , fax (613) 9 9 1 -1 5 4 3 . -S92-132
GENERAL SURGEON: ON - Well-estab
lished group practice is looking to replace a
retiring partner/surgeon to serve a communi
ty of 30 OOO + located 25 minutes west of
London. Town population 10 0 0 0 + . Fully
computerized, modern clinic adjacent to a
fully accredited, well-equipped hospital using
116 acute care beds. Busy emergency de
partment. Preference will be given to orthopedics/gynecology. Essentials include la
paroscopy skills and fellowship status. Onein-three on-call schedule for this pleasant
community. Large referral base guaranteed.
Associate to full partnership attainable.
Please contact or send CV to: Steven Wong,
c/o Strathroy Medical Clinic, 376 Carrie
St., Strathroy, ON N7G 3E3; tel: (519)
2 4 5 -0 4 3 0 .
-S92-128

BETHESDA HOSPITAL
STEINBACH, MANITOBA

FELLOWSHIP IN
ENDOUROLOGY AND ESWL

requires a

GENERAL SURGEON
The medical staff of the Bethesda Hospital,
a fully accredited 80-bed acute care hospi
tal, located 48 km southeast of Winnipeg in
one of Manitoba's fastest growing commu
nities, is seeking a full-time surgeon.
The facility offers a full range of services to
a regional population of approximately
40 OOO people. The surgical program offers
extensive flexibility and input to the candi
date. Deadline: Nov. 30, 1992.
Interesting candidates should submit a cur
riculum vitae or contact:
Dr. Curtis Krahn, Bethesda Hospital
PO Box 939
Steinbach, MB R0A 2A0
Tel: (204) 326-3401 -S92-129

This 1-year postgraduate fellowship offers a
wide range of clinical experience in endourology including percutaneous surgery,
ureteroscopy, ESWL and laparoscopic sur
gery in urology. Aproximately 50% o f the
fellow 's time will be spent in the laboratory
participating in projects related to endourologic and shock wave lithotripsy re
search. Salary will commensurate w ith the
level of training.
Please reply with curriculum vitae to:
Dr. John Denstedt
Chief of Urology
St. Joseph's Health Centre
2 6 8 Grosvenor St.
London, ON
N6A 4V2
—S92-130

Director of Lithotripsy/Urolithiasis
Division of Urology
University of Toronto
The University of Toronto and the Wellesley Hospital, a 400-bed teaching hospital, are seeking a
full-time director with the necessary clinical and academic credentials to lead a university-wide
program in lithotripsy and urolithiasis. This will involve administering and directing the lithotripsy unit,
which treats in excess of 2500 patients per year and is one of two serving a population of 9 million
plus. A large endourology program complements a state-of-the-art facility with a dedicated interven
tional room, cystoscopy rooms, a recovery room, anesthesia, etc. An undergraduate and postgraduate
educational program and research program is incorporated as well. Candidates for this position should
have Royal College of Physicians and Surgeons of Canada certification or the equivalent, and be
eligible for licensure in Ontario. Academic rank will be commensurate with qualifications and
experience.
In addition, there are openings for the Chief of Urology at the Wellesley Hospital and St. Michael’s
Hospital. An academic and clinical relationship between the two hospitals is under consideration.
In accordance with Canadian immigration requirements, this advertisment is directed to Canadian
citizens and permanent residents. The closing date for receipt of applications is Jan. 31, 1993.
Applications should be sent to the attention of:

Dr. D. Hastings,
Surgeon-in-Chief
The Wellesley Hospital
Room 217, E.K. Jones Building,
160 Wellesley Street East
Toronto, Ontario M4Y 1J3
Please include your complete CV and the names of three individuals who may be contacted to supply
a reference.
_ S92-135
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ORTHOPEDIC SURGEON: SK - The De
partment of Surgery at the University of
Saskatchewan requests applications for an
appointment to the Division of Orthopedic
Surgery with an associated full time appoint
ment to the staff of the Department of Ortho
pedics at Royal University Hospital and an
academic appointment in the College of Medi
cine. The candidate must hold certification in
orthopedic surgery from the Royal College of
Physicians and Surgeons of Canada, and be
eligible for licensure by the College of Physi
cians and Surgeons of Saskatchewan. The
position will be full-time faculty appointment
on tenure track in the Department of Surgery
at the University of Saskatchewan. Salary and
rank will be commensurate with candidate
qualifications and experience. The successful
candidate will have established expertise in
pediatric orthopedic surgery and diseases of
the back. A documented reputation in under
graduate education is required, with expecta
tion the candidate will assume primary re
sponsibility for this discipline in orthopedic
surgery. A previous record of satisfactory
academic activity is recommended. The Uni
versity of Saskatchewan is committed to the
principles of employment equity. This posi
tion has been cleared for advertising at the
two-tier level. Accordingly, applications are
invited from qualified individuals regardless of
their immigration status in Canada. Interested
candidates should submit a current curriculum
vitae and names of three referees, to: Dr.
Roger G. Keith, Professor and Chairman,
Department of Surgery, University o f Sas
katchewan, Royal University Hospital.
Saskatoon, SK S7N 0X0. Deadline for ap
plications is Jan. 3 1 ,1 9 9 3 .
-S92-133

E j If you are interested in pursuing =
EE th is opportunity, please con- =
EE tact:
EE

§E Dr. George Miller, FRCSC
E Chief of Surgery
- Moose Jaw Union Hospital
455 Fairford Street East
Moose Jaw, Saskatchewan
| S6H 1H3
Tel
(306) 694-0300
Fax
| (306) 692-5596
— S92-134

Vascutech, Inc.
Valvulotome 579

SURGICAL ONCOLOGY FELLOWSHIP:
ON - The Division of General Surgery at the
University of Toronto is offering a 1-year
clinical fellowship available July 1, 1993.
The fellowship is intended for individuals
who have completed an accredited North
American university general surgical resi
dency and are eligible for certification. Pref
erence will be given to applicants eligible for
Canadian licensure. Applicants should sub
mit a current curriculum vitae with the
names of three referees to: Lome E. Rotstein, MD, Director, General Surgical On
cology Postgraduate Education. Toronto
General Hospital, Eaton W ing, 7 th Floor,
2 00 Elizabeth St., Toronto, ON Canada
M5G 2C4.
-S92-131

ee

G E N E R A L /V A S C U L A R SUR G EO NS:
NORTH DAKOTA, US — Busy, w e ll-e st
ablished department of six surgeons is
seeking to add additional BC/BE general and
vascular surgeons. Physicians will join large
multispecialty group practice with main clinic
located in metropolitan community of 130 000.
Affiliated 400-bed hospital is a regional tertiary
and trauma centre. Regional network of over
25 primary care clinics offers a substantial
referral population base. Excellent public and
parochial school education plus the addition of
two universities and a private liberal arts col
lege offer many amenities. Affiliation with medi
cal school and surgery residency program
available. Please respond with full curriculum
vitae to: Kathleen McKittrick Toft, 737 Broad
way, Fargo, ND, US 58123; or call: (701)
234-2151.
_________________ — S 9 2 -1 17

